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The studies incorporated in this thesis examined ways to develop ex situ normothermic machine 
perfusion (NMP) of the liver as a tool to enhance the reconditioning of high-risk extended 
criteria donor (ECD) organs. Two possible alternatives were investigated: (1) The use of 
hypothermic oxygenated machine perfusion as a therapeutic intervention preceding NMP; and 
(2) the delivery of a pharmacological combination of drugs targeting hepatic lipid metabolism 
during NMP. Using human donor livers discarded for transplantation, the feasibility of a 
combined protocol of hypothermic oxygenated perfusion (HOPE) and NMP was shown. HOPE 
optimised hepatic mitochondrial bioenergetic and oxidative status as well as mitigated 
ischaemia-reperfusion injury, while NMP maintained the organs’ metabolism thus allowing the 
assessment of its metabolic functions. This combined protocol was facilitated with the use of 
a single acellular haemoglobin-based oxygen carrier (HBOC)-based perfusate throughout the 
entire perfusion, using a cold-to-warm machine perfusion protocol. These combined protocols 
enabled superior recovery of metabolic functions of ECD livers compared to NMP alone. The 
delivery of a combination of drugs targeting the hepatic lipid metabolism during NMP was also 
investigated. This approach reduced the intracellular lipid content of discarded human donor 
livers via enhancement of fatty-acids β-oxidation and solubilisation of lipids in the perfusate. 
The boosted lipid metabolism improved the metabolic status of the organs optimising their 
functional recovery and halted oxidative stress-related hepatobiliary injury. These findings are 
promising and guarantee future clinical investigation, opening a window of opportunity to 
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GENERAL INTRODUCTION: THE CURRENT CHANGE IN 
DONOR CHARACTERISTICS AND THE NEED TO INCREASE 
UTILISATION OF EXTENDED CRITERIA DONOR ORGANS. 












1.1 Historical perspective of liver transplantation 
The first clinical series of liver transplantations (LT) was described by Starzl et al. in 1963 (1). 
Of the three reported cases, the first died during the operation due to bleeding and the other two 
lived for 22 and 7 days, respectively. In 1968, Starzl et al. reported another seven cases of LT: 
Four of the patients died between two and six months post-procedure, while the other three 
remained alive, one of whom completed a 12-month follow-up post-transplantation at the time 
of the report (2). Initial technical challenges of the procedure, such as preservation of the donor 
liver and surgical technique, have been discussed by Roy Calne and Roger Williams when 
reporting five cases in the United Kingdom (UK) (3). 
Further advances were achieved with the definition of irreversible coma as a criterion for death 
in 1968 (4), and advances in immunosuppressive regimen in following decades. Cyclosporine 
was introduced in the seventies, and revolutionised post-transplant survival rates (5). In 1989, 
5-year survival rates post-procedure reached 64% with the use of cyclosporine (6). In the late 
eighties and early nineties, tacrolimus was introduced by Starzl (7, 8). Tacrolimus was shown 
to be more effective than cyclosporine in reducing the occurrence of acute cellular rejection, as 
well as improving graft and patient survival after the procedure. Thus, the use of tacrolimus has 
become the gold standard immunosuppressive regime (9).  
Since the nineties, LT has spread to many parts of the world. It is the only definitive therapeutic 
option for end-stage liver diseases and a curative treatment for early-stage hepatocellular 
carcinoma (10). The currently 1-year and 5-year patient survival rates in the UK for donation 
after brainstem death (DBD) LT are as high as 93% and 81%, respectively (11). In the United 
States of America (USA), 5-year survival rates are 81.2% (12). 
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However, LT has become a victim of its own success. With an ever-growing number of patients 
on waiting lists for LT, the supply of donor organs has largely exceeded the demand and many 
countries have been observing high waiting-list mortality rates (13). It is estimated that over the 
past decade, the number of patients on the transplant waiting list in the UK has almost doubled 
(14). This continuously increasing demand for LT is contemporarily driven mainly by a global 
climbing prevalence of non-alcoholic fatty liver disease (NAFLD). Indeed, NAFLD is one of 
the leading reasons for LT (15). It is considered the hepatic manifestation of metabolic 
syndrome and its compounds, such as obesity, diabetes and hypertension (15).  
1.2 Change in donor characteristics and the Extended Criteria Donors 
In the UK, between April 2017 and March 2018, the total number of organ donors increased 
approximately 10%, while the number of patients on the LT waiting list decreased by 32% (11). 
Despite these advances in absolute numbers, there is still a discrepancy between the availability 
of donor organs for transplantation and patients on the waiting list. Consequently, 11% of 
patients listed for LT between 2015 and 2016 died while waiting for an organ for the procedure 
(11).  
This discrepancy is mainly associated with a significant change in donor characteristics. The 
Transplant Activity Report 2017-2018, from the National Health Service Blood and Transplant 
(NHSBT), states that donors are becoming older, more obese and are more frequently dying 
from non-traumatic causes (11). This report indicates that, between 2008 and 2018, there was 
an 8% increase (20–28%) in the proportion of donors with a body mass index (BMI) > 30 kg/m2, 
and a 9% (5–14%) increase in donors older than 69 years (11). These changes negatively impact 
the quality of donor organs. Therefore, the percentage of donor livers discarded for 
transplantation after retrieval has consequently increased from 12% to 15% over the same 
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period. Stratifying this discard rate by donor type, between April 2017 and March 2018, the 
discard rate reached 9% for donation after brain stem death (DBD) and 33% for donation after 
circulatory death (DCD). Moreover, clinical unsuitability was the most common reason for 
discard donor organs. Clinical unsuitability was defined in the document as poor perfusion, 
prolonged preservation times and donor history (11). In a previous and more detailed version 
of the report (2016), steatosis was the most frequent reason within this wide category of clinical 
unsuitability (16). In the USA, the last annual report on LT noted a discard rate of 9% for donor 
livers following retrieval (12). However, these rates were higher for older donors and DCD 
organs (12). 
In the UK, 26% of deceased donor livers transplanted between April 2017 and March 2018 
were from DCD donors (11). Donation after circulatory death transplantation is associated with 
high-rates of ischaemic-type biliary lesions (ITBL) and shorter patient and graft survival (17–
19). Donor organs with steatosis, organs that have been exposed to prolonged preservation 
times or organs from elderly donors are all more vulnerable to ischaemia-reperfusion injury 
(IRI), and therefore, are referred to as marginal or extended criteria donor (ECD) organs (20). 
However, the defining parameters of ECD are not definitive, and can vary slightly between 
centres (21), although donor age greater than 60, steatosis rates more than 15% and cold 
ischaemia times longer than 10 hours are frequently quoted as possible thresholds (22). 
Moreover, ECD liver transplantation is associated with high rates of primary non-function 
(PNF) and/or delayed graft function (DGF), as well as higher morbidity and mortality rates (23–
25). In a recent publication, which reported on the outcomes of 611 LT recipients, age > 65 
years, macrovesicular steatosis on biopsy > 40% and cold ischaemia time > 14 hours were 
identified as major risk factors of inferior patient and graft survival (26). Despite these 
unfavourable outcomes, the utilisation of ECD livers is necessary due to contemporary changes 
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in donor characteristics and the ever-growing discrepancy between supply and demand for 
donor organs.  
1.3 Strategies to improve utilisation of Extended Criteria Donor Livers 
1.3.1 On the recipient side 
To increase utilisation rates of ECD livers, many centres have begun allocating these high-risk 
organs to less sick patients on the waiting list (25, 27, 28). Whilst donor risk factors associated 
with inferior outcomes post-transplantation have previously been described, their interaction 
with recipient characteristics has not yet been investigated in-depth. As a result, researchers 
have begun to develop clinical prognostic models in an attempt to balance donor and recipient 
risks. The D-MELD, the product of donor age versus the Model for End-Stage Liver Disease 
(MELD) score of the recipient, was created as an attempt to enable a safer donor/recipient match 
(29). A result greater than 1,600 is associated with poor post-transplant outcomes, such as 
shorter patient survival and prolonged length of stay (29). Later, the Zurich group developed 
the Balance of Risk (BAR) score (30) utilising  The United Network for Organ Sharing (UNOS) 
database (37,255 patients). In their study, six risk factors were associated with inferior post-
operative outcomes, namely the recipient’s MELD score, cold ischaemia time, recipient age, 
donor age, re-transplantation, and life support dependence prior to LT (30). The authors 
concluded calculating the BAR score optimises the recipient’s survival/resource utilisation 
ratio. 
More recently, a new predictive clinical score was developed for DCD livers specifically. The 
UK DCD Risk Score aims to assess the risk of DCD LT based on donor and recipients features 
(31). A large cohort of 1,153 recipients was used to develop the score, which was then validated 
using the UNOS database. The authors identified the following seven independent predictors 
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of poor graft survival: functional donor warm ischaemia time, cold ischaemia time, recipient 
MELD score, recipient age, donor age, previous LT and donor BMI. A score greater than 10 
predicted, with good accuracy, graft loss for PNF and ITBL (31). Interestingly, this risk score 
not only predicts the risk of donor/recipient matchings, but also determines whether an organ 
requires optimisation before transplantation through the machine perfusion of donor livers. 
Whereas risk-assessment predictive tools are important to optimise donor/recipient matching, 
the capacity of the sickest recipients to wait for a standard donor organ should be taken into 
consideration. For example, Jennifer Lai (2017) proposed an interesting framework that 
considers pre-transplant patient vulnerability in the decision-making process of accepting an 
ECD liver (32). Transplantation of a high-risk ECD liver into a highly-vulnerable patient would 
make transplantation futile. This is due to the fact that the patient, most likely, does not have 
enough metabolic reserve to cope with a complicated postoperative period (32).  
Altogether, these proposals reveal the complexity of optimising ECD liver utilisation. In 
addition, the transplant community should be careful to not penalise less sick patients by 
transplanting them with high-risk ECD organs. Therefore, to solve this conundrum, strategies 
to alleviate the risks associated with ECD LT are required. One option is to consider better 
techniques of organ preservation, thereby preventing further damage to such highly vulnerable 
organs. Moreover, the possibility of reconditioning the organs prior to LT should be considered. 
1.3.2 On the donor organ side 
Current changes in donor characteristics, as previously described, are likely to persist over time, 
or even worsen with an upward trend of elderly and obese donors. Whilst transplant surgeons 
do not have control over these donor features, they can consider alternatives to better preserve 
or even recondition ECD livers. Traditionally, donor livers are stored on ice and immersed in 
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preservation solutions after retrieval. This method has proven to be highly effective at 
successfully preserving donor organs thus far (33). Nevertheless, the wider utilisation of ECD 
livers has exceeded the preservation capacities of traditional static cold storage (SCS). 
Consequently, as mentioned previously, ECD LT using SCS is associated with inferior 
outcomes (23, 24, 26, 34). 
Attempting to overcome the risks associated with ECD LT, the transplant community has thus 
far attempted to minimise recipient risk factors. This strategy centres around a more appropriate 
donor/recipient matching. On the donor organ side specifically, transplant surgeons balance 
donor risk factors when making utilisation decisions about poor-quality organs. For example, 
combinations of steatosis and DCD status, or advanced age and DCD status, are avoided when 
considering the transplantability of an organ (35). Consequently, 17% of donor livers retrieved 
in the UK are not transplanted (11). While these organs are being discarded, patients are dying 
on the waiting list or their condition is worsening to the point that transplantation is no longer 
a viable option. Therefore, new strategies for organ preservation, or even organ reconditioning, 
are urgently needed. Figure 1.1 presents a diagrammatic summary of strategies to increase 












1.3.2.1 Machine perfusion of the liver 
Lindbergh and Carrel (1935) first reported the use of an ex situ device to sustain prolonged 
organ functioning via perfusion with oxygenated serum at normothermia (36). While this 
concept of dynamic organ preservation was investigated later in canine models by Starzl et al. 
(37), the development of effective cold preservation solutions dampened interest in this 
approach. Since cold preservation solutions allowed for the safe static storage of organs, thus 
facilitating the process of organ preservation and transportation, SCS became the gold standard 
for organ preservation and dynamic techniques, such as the device recommended by Lindbergh 
and Carrel, were abandoned (38–40).  
Dynamic preservation techniques resurged, however, due to the increase in utilisation of high-
risk livers, such as ECD and DCD organs. Due to their high vulnerability to ischaemia and poor 
post-transplant outcomes following SCS, machine perfusion (MP) of the liver is considered to 
be a possible alternative preservation method. The use of this device may offer several 
advantages compared to SCS, including superior organ preservation limiting ischaemia, 
assessment of organ function before transplantation and the possibility to improve or repair 
these highly vulnerable organs. Nevertheless, benefits may vary between different modalities 
of MP depending on the characteristics of the perfusion; for example, timing, temperature, level 
of oxygenation, and constitution of the perfusate.  
First, it is worth noting that an MP can be performed in situ during donor organ procurement, 
as well as ex situ after the organs have been harvested. Second, the temperature of the perfusate 
pumped through the liver can vary from hypothermic temperatures (10 C) to normothermic 
(37 C). In addition, the perfusate has been actively oxygenated in some studies, but not in 
others. Finally, regarding the timing for the use of the device, MP can be performed: (1) as a 
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preservation method, fully replacing SCS during organ transportation from the retrieval to the 
transplant centre; or (2) in the end-ischaemic method, wherein the organ is transported to the 
transplant centre in SCS and then undergo MP before transplantation. Figure 1.2 represents the 
possible timings for performing MP of the liver, from organ donation to liver transplantation. 
The most studied modalities of MP of the liver will hereafter be discussed. Technical aspects 
and overall comments about each technique are initially presented, and then their 














Figure 1.2: Possible timings for performing machine perfusion of the liver from the organ donation until transplantation and possible 




1.3.2.1.1 In situ machine perfusion of the liver 
This modality of MP is performed during the organ retrieval operation, or even before, via 
cannulation of the aorta/iliac arteries or cava/iliac veins. A balloon, or a clamp, is positioned on 
the descending thoracic aorta to prevent perfusion of the heart and brain. The donor blood, or a 
preservation solution, is used as a perfusion fluid. Thus far, in situ liver perfusion has only been 
performed at 37 C and is therefore known as oxygenated normothermic regional perfusion 
(NRP) (41). Normothermic regional perfusion is considered crucial for the recovery of 
uncontrolled DCD organs (witnessed cardiac arrest without response to resuscitative measures), 
since donors would otherwise experience a prohibitively long warm ischaemic time, from 
asystole to the cannulation of the vessels and could flush (42). Furthermore, NRP is also 
considered to be beneficial within the context of controlled DCD (withdrawal of life support in 
patients with irreversible clinical conditions), when the warm ischaemic time is carefully 
assessed (43).  
Benefits: Normothermic regional perfusion re-establishes the delivery of oxygen to the organs 
following asystole in the donor and thus, limits the injury associated with a longer warm 
ischaemia period (42, 43). Full metabolism recovery of the organs allows for an assessment of 
the markers of cellular injury and/or function prior even to SCS (41). Assessment of organ 
function is the cornerstone of safe utilisation of ECD organs. Until now, NRP studies have 
evaluated the release of transaminases in the perfusate, macroscopic appearance of the organ, 
bile production and some other parameters of the blood-gas analysis (such as lactate clearance, 
base excess and bicarbonate levels), together with donor characteristics, to predict the function 
of a liver post-transplantation (44). In addition, the presence of flow through the vessels 
facilitates organ retrieval and may deter organ injury (44).  
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Limitations: No published study has performed yet an in-depth analysis of the mechanistic 
effect of the procedure on the metabolism of donor organs. Thus, further investigation is needed 
in terms of the impact of NRP on mitochondrial injury and function, oxidative injury and 
downstream activation of the inflammatory cascade. Additionally, the criteria for 
transplantability of the organs are not clear, and many organs are refused during perfusion (45). 
Therefore, it is necessary to determine whether this technique can improve the organs, or if the 
beneficial effects seen are just the result of organ selection. 
1.3.2.1.2 Ex situ machine perfusion of the liver 
The majority of MP protocols are performed once organ retrieval is finished, therefore, are 
classified as ex situ MP. These protocols may vary in terms of temperature and extent of 
oxygenation of the perfusion fluid. The details of the different protocols, as well as the benefits 
and limitations are discussed in this section. 
1.3.2.1.2.1 Hypothermic machine perfusion of the liver 
For hypothermic machine perfusion (HMP), the temperature of the perfusate is generally 
around 10 C (46–50). Guarrera et al. (2010) first published a series of 20 cases of standard 
DBD livers transplanted following a period of HMP (46). The perfusion was done via hepatic 
artery and portal vein without active oxygenation of the perfusate in an end-ischaemic model. 
Postoperatively, the recipients of the perfused livers experienced less early graft dysfunction 
and lower levels of transaminases within the first seven postoperative days, as well as a shorter 
hospital stay compared to the recipients of non-perfused donor organs (46). More recently, the 
authors applied the same protocol to high-risk DBD livers and reported lower rates of biliary 
complications post-transplantation (47). Subsequently, the Zurich group developed the 
hypothermic oxygenated perfusion (HOPE) technique, which differs from the previous 
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technique in that the perfusate is actively oxygenated and perfusion solely occur via the portal 
vein. Clinical studies have only employed HOPE to investigate DCD organs thus far, and they 
have confirmed the positive impact of HMP on intrahepatic biliary complications (48, 49). The 
Groningen group has been working on dual vessel (hepatic artery and portal vein) hypothermic 
oxygenated perfusion (D-HOPE) (51). In 2017, the first clinical study to use D-HOPE for 10 
DCD livers transplanted found a reduction in intrahepatic biliary complications (50). 
The majority of mechanistic studies on HMP that have been published thus far were undertaken 
by the HOPE group (52–54). During ischaemia, succinate will accumulate in the mitochondria, 
as in the absence of oxygen, succinate will function as an acceptor of electrons in the electron 
transport chain (ETC). During reperfusion, the metabolism of the accumulated succinate 
momentarily blocks the ETC, causing the reverse flow of electrons, which will then leak and 
result in the production of reactive oxygen species (ROS). Exaggerated ROS production causes 
oxidative tissue injury and activation of the inflammatory cascade, which in turn perpetuates 
tissue injury. It has been proposed that the delivery of oxygen at hypothermic temperatures 
leads to consumption of the accumulated succinate, enhancing mitochondrial oxidative function 
prior to reperfusion (55). This hypothesis is sustained by experimental studies that have found 
a decrease in the expression of markers indicating oxidative tissue damage, and an activation 
of Kupffer cells and leukocytes; In addition, these studies have found a lower release in the 
perfusate of markers of mitochondrial injury, damage-associated molecular pattern (DAMPs) 
and cytokines in livers after reperfusion following the HOPE procedure (22, 54, 55). These 
changes occur concomitantly with signs of down-regulation in mitochondrial respiration and 
enhanced ATP synthesis (22, 54, 56).  
Benefits: Patients enrolled in clinical studies employing HMP, mainly the oxygenated 
modalities (HOPE and D-HOPE), exhibit significantly lower rates of intrahepatic biliary 
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complication post-transplantation (48–50). Moreover, HMP does not require the use of oxygen 
carriers in the perfusate, since the oxygen supplied to the cells through diffusion is adequate to 
supply the diminished metabolic demand of the organ at a low temperature. Failure of the 
perfusion device can be safely managed by returning the organ to SCS without risk to the organ. 
Limitations: The diminished metabolic rate of the organs at 10 C limits their functional 
assessment during HMP. One promising approach that may guarantee future studies is the 
investigation of dynamic changes in the mitochondrial bioenergetic status. Without any readily 
available parameter thus far, the threshold to stop HMP or the response of individual organs to 
the treatment is not so clear. The minimum perfusion period recommended is one hour, as it is 
advocated that 1–2 hours of oxygenated HMP is enough to replenish the ATP content of the 
mitochondria (22). However, despite a general orientation, a definition of the biomarkers to 
individualise perfusion times and assess responses to treatment in real-time is still pending. This 
real-time assessment of the effects of HMP on the organs is highly relevant in a context where 
a previous experimental model using intravital microscopy has shown that prolonged HMP may 
impair parenchymal perfusion (57).  
1.3.2.1.2.2 Subnormothermic machine perfusion of the liver 
Subnormothermic machine perfusion (SMP) is performed usually at around 20 C with active 
oxygenation of the perfusion fluid via the portal vein and hepatic artery. The requirement of an 
oxygen carrier in the perfusate at this temperature, however, is unclear and it has not been 
always used (58–60). Defenders of this technique advocate that the increase in the organ’s 
metabolic rate, as a result of the increase in temperature (from 10 C to 20 C), is sufficient for 
viability testing (58). In addition, it has been suggested in transplant animal models that SMP 
can positively impact mitochondrial function, increase organs’ ATP stores, decrease the release 
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of markers of tissue injury (such as transaminases and cytokines) and improve graft function 
postoperatively (58, 60). 
Despite the promising conjectures, no clinical studies have yet transplanted human livers 
following SMP. Bruinsma et al. (2014) performed SMP on seven discarded donor human livers; 
Interestingly, the authors have found that the organs metabolised lactate effectively, increased 
ATP stores along the perfusion and exhibited other parameters of appropriate liver metabolism 
(evidence of urea, albumin and bile production) without evidence of tissue injury, as assessed 
histologically and by the lower release of ALT and lactate dehydrogenase (LDH) in the 
perfusate (61). This study reinforces the hypothesis that it is feasible to assess the metabolism 
of human livers during SMP.  
Minor et al. (2013) proposed a variant of the SMP technique, the controlled oxygenated 
rewarming (COR) (62). This method involves dual perfusion (hepatic artery and portal vein) of 
organs in a highly oxygenated perfusion fluid without any oxygen carrier. Total perfusion time 
is 90 minutes; The perfusion starts at 8 °C, and gradually increases to 20 C within 60 minutes. 
In a reperfusion porcine model using ex situ NMP, compared to HMP or SMP alone, COR was 
found to increase cellular ATP stores and decrease the release of lipid peroxides and markers 
of hepatocellular injury (AST and ALT) in the perfusate after reperfusion. During NMP, organs 
that had undergone COR exhibited increased bile production, lower vascular resistance and 
decreased expression of proinflammatory genes (intercellular adhesion molecule 1, toll-like 
receptor 4 and tumour necrosis factor alpha) (62). In 2016, a clinical series of 6 DBD livers 
transplanted following the application of COR reported a 50% reduction in peak serum AST 




Benefits: In a study on discarded human livers, SMP was shown to be able to sustain liver 
metabolic rates to a high enough level to enable viability assessment; SMP also enhanced ATP 
production without any evidence of tissue injury during the procedure (61). The COR protocol 
was suggested to yield even better results than SMP alone on an experimental model. Moreover, 
it was shown to be safe and significantly decrease the release of tissue injury markers after 
transplantation (62, 63).  
Limitations: Only experimental studies have been published on SMP so far (60, 61), thus 
limiting further consideration for this technique, since the final testing for safety and 
effectiveness in this context is transplantation. While it has been suggested that COR can better 
preserve donor organs, the studies reported minimal changes in the metabolic parameters, such 
as bile production and lactate metabolism, of the organs during perfusion (62, 63). 
Consequently, COR may prevent the possibility of a functional assessment of an organ achieved 
during SMP.  
1.3.2.1.2.3 Normothermic machine perfusion of the liver 
Ex situ normothermic machine perfusion (NMP) is performed at 37 C, and requires active 
oxygenation of the perfusate and cannulation of both the hepatic artery and portal vein. At a 
physiological temperature, the organs will be fully functional, allowing for an assessment of 
their metabolic parameters prior to transplantation (64, 65). This is vital to safely increase the 
utilisation of ECD livers, even if the ideal criteria of organ viability are still under investigation 
(64).  
According to the Birmingham viability criteria, lactate clearance to levels of less than 2.5 
mmol/L within 4 hours is a major criterion for considering an organ transplantable. This should 
be accompanied by two of the minor criteria: perfusate pH > 7.3, evidence of bile production, 
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metabolism of glucose, homogeneous perfusion with a soft parenchyma, arterial flow > 150 
mL/min and portal vein flow > 500 mL/min. These criteria were validated in a clinical study 
wherein 5 discarded donor livers were successfully transplanted following an objective 
assessment of organ function during NMP (65). In addition, they were used in the Viability 
Testing and Transplantation of Marginal Livers (VITTAL) study (ClinicalTrials.gov Identifier: 
NCT02740608), which finished recruitment in early 2018 and are still awaiting results (66). 
More recently, Watson et al., in a clinical series of 22 livers transplanted following NMP, 
proposed a comprehensive viability criteria that take into consideration markers of 
hepatocellular metabolism (as assessed by peak lactate fall ≥ 4.4 mmol/L/Kg/h; stable perfusate 
pH > 7.2 without sodium bicarbonate supplementation greater than 30 mmol; falling glucose 
beyond 2 hours, or < 10 mmol falling after 2.5 g challenge), hepatocellular injury (Alanine 
aminotransferase [ALT] perfusate levels < 6,000 UI at 2 hours of perfusion) and biliary 
function/injury (bile pH > 7.5; bile glucose < 3 mmol/L or > 10 mmol/L less than the perfusate) 
(67).  
After a period of SCS, NMP was performed in the two clinical series described above using an 
end-ischaemic approach. In this method, the organs are cold flushed in situ, preserved in SCS 
during the transport to the transplant centre as routine, and then placed on an NMP. Whilst end-
ischaemic NMP facilitates logistical aspects of the perfusion, such as avoiding device and 
perfusion team mobilisation to the retrieval centre, it does not prevent injury associated with 
SCS. Alternatively, NMP can be used in a preservation approach, fully replacing SCS. In this 
method, after the donor retrieval operation finishes, the organ is prepared for transplantation by 
being placed in a basin of cold fluid and smashed ice, following standard protocol (68). The 
common hepatic artery, portal vein, vena cava and common hepatic duct are cannulated, and 
the perfusion begins. The donor organ will then be transported on the device and remain there 
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until transplantation (69). Nasralla et al. (70) recently published a clinical trial reporting the 
results of transplantation of 121 donor livers following preservation NMP. The authors found 
a 50% decrease in the release of aspartate transaminase (AST) in the recipient within the first 7 
postoperative days in comparison with grafts that had SCS (70). 
Benefits: Independent of the NMP approach used, assessment of organ functioning prior to 
transplantation is the cornerstone of NMP utilisation. Identification of ECD livers at a high risk 
of graft dysfunction postoperatively may prevent recipient morbidity and mortality. However, 
the benefits of having an organ at full metabolism are not limited to viability assessment. 
Indeed, NMP allows for the administration of pharmacological therapies to donor organs (71). 
Such therapies may include agents that target the mitigation of IRI or the provision of drugs to 
accelerate the intracellular lipid metabolism leading to steatosis reversal or defatting (72). 
Another potential advantage of NMP is the possibility of prolonged organ preservation, which 
may help improve logistics in busy transplant centres (70, 73).  
Limitations: Recovery of the organ’s full metabolism imposes some requirements on this 
technique. First and foremost, it requires the use of an oxygen carrier in the perfusate to deliver 
adequate oxygen levels to supply the high metabolic demand of the organs. Human red blood 
cells have been traditionally used for this purpose. However, human red blood cells are a 
precious resource with limited availability, which also carries a low, but not insignificant risk 
of microbiological contamination of the organ as well as requires well-controlled storage 
conditions with a relatively short shelf half-life (60). For this reason, acellular haemoglobin-
based oxygen carrier (HBOC)-based perfusate have been investigated as an alternative to 
replace human red blood cells during NMP (74). Moreover, failures to identify problems with 
the cannulation of vessels may induce a new period of warm ischaemia, which can ultimately 
result in the loss of the donor organ (75). In addition, experimental models have shown that 
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even without the presence of leukocytes and platelets in the circuit, NMP mimics IRI to some 
extent, causing oxidative tissue injury and activation of the inflammatory cascade (54, 55). 
1.4 Thesis plan and aims 
Despite hypothetical advantages of preservation NMP over an end-ischaemic approach, as it 
shortens the ischaemic injury to the organs, published studies have not yet proven its superiority 
(51). End-ischaemic NMP facilitates the logistics of organ perfusion while avoiding the 
mobilisation of the perfusion team and the device, and it has the potential to assess organ 
function prior to transplantation (64, 65, 67). Despite ongoing discussions about the need for 
more appropriate viability criteria during NMP (64), the Birmingham criteria have been shown 
to be in a pilot clinical series, at minimum, safe for assessing the transplantability of discarded 
marginal livers (65). However, approximately 40% of the high-risk ECD donor livers 
undergoing end-ischaemic NMP are deemed non-viable according to these criteria. This data 
may suggest that: (1) In the interest of patient safety, the criteria are highly selective; or (2) 
While NMP, which re-establishes the organ’s full metabolism, allows for a viability assessment, 
its ‘resuscitative’ capacity is potentially limited. Therefore, an additional therapeutic 
intervention may be required. 
While patient safety is central, additional therapeutic interventions during NMP may enhance 
organ reconditioning. In accordance, this thesis investigates opportunities for the further 
development of NMP to improve donor organ quality.  
The aims of this thesis are: 
• To investigate whether a combined protocol of ex situ hypothermic and normothermic 
perfusions of the liver derive the benefits of each individual technique and, more 
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importantly, whether this combined protocol positively impacts the reconditioning of 
discarded human donor organs. 
• To test, in vitro, the cytotoxicity and effectiveness of a combination of defatting drugs 
on the primary human cells of the liver, including primary human hepatocytes, 
intrahepatic endothelial cells and cholangiocytes. 
• To investigate the feasibility of the delivery of this combination of defatting drugs to 
steatotic human donor livers undergoing end-ischaemic normothermic machine 
perfusion; To also determine whether this intervention: (1) promotes the mobilization 
and metabolization of intracellular lipid stores leading to defatting; (2) positively 
impacts the recovery of the organs’ metabolic activity.  
The study framework is presented in Figure 1.3. A brief summary of the studies undertaken for 
















Chapter 2: This chapter reviews the clinical studies on MP of the liver published so far, and 
discusses how MP can be a tool to recondition high-risk grafts. After an initial overview of MP 
in Chapter 1, Chapter 2 describes where we stand with clinical studies. Vital targets of MP to 
increase the utilisation of high-risk organs are discussed, including promising future 
interventions. 
 
Chapter 3: This chapter presents the results of a newly developed protocol of MP that 
combines HOPE and NMP. Whilst individual characteristics of each MP technique (including 
temperature, levels of oxygenation, requirement of an oxygen carrier in the perfusate) result in 
the specific benefits associated with that protocol, they also impose limitations. For example, 
although HOPE has been shown to enhance the bioenergetic status and oxidative function of 
organs, the lower metabolic rate limits the viability assessment of the organs thus far. 
Conversely, NMP allows for an assessment of the metabolic functions of an organ at full 
metabolism, though it inevitably results in reperfusion injury to some extent. Combining these 
protocols, seen as divergent so far, was shown to derive individual benefits that improve the 
functional recovery of ECD livers. 
 
Chapter 4: Following Chapter 3, which suggests that a combined protocol of hypothermic and 
normothermic perfusions is superior to NMP alone in the reconditioning of high-risk ECD 
livers, Chapter 4 proposes a refinement of the combined MP protocol. The requirement for an 
oxygen carrier during NMP, and the impossibility of using red blood cells during HMP, made 
the exchange of perfusates in the combined perfusion mandatory. To prevent entirely any 
concerns of exposing the organs to additional unnecessary ischemia time to switch the 
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perfusate, Chapter 4 investigates the feasibility of using an acellular haemoglobin-based oxygen 
carrier (HBOC)-based perfusate during HMP, and then rewarming it until normothermia. This 
approach allows for an uninterrupted combination of HMP and NMP, the Cold-to-Warm MP 
of the liver, which may increase its clinical applicability. 
 
Chapter 5: This chapter initially discusses fatty liver disease within the context of organ 
donation and transplantation. Steatosis is one of the leading reasons to discard donor organs 
globally due to their inferior postoperative outcomes, as reported in clinical series. Following 
the introduction to this topic, and its relevance when considering strategies to increase donor 
organ utilisation, the role of MP of the liver as a tool to recondition steatotic livers is discussed. 
A special focus is given to the possibility of using NMP as a platform for the delivery of drugs 
that target intracellular lipid metabolism. The pharmacodynamics of the drugs are reviewed, 
and the benefits of this approach to human donor livers are discussed. 
 
Chapter 6: This chapter reports an in vitro study that tests the cytotoxicity of a defatting 
combination of drugs to primary human cells of the liver. After thoughtful examination of the 
pharmacodynamics of a combination of defatting drugs presented in Chapter 5, primary human 
cells of the liver are isolated and exposed to these defatting drugs. This preliminary study 
indicates that the agents are not toxic to primary human hepatocytes, human intrahepatic 
endothelial cells and cholangiocytes in culture. In addition, steatosis is induced in primary 
human hepatocytes by supplementation of the perfusate with a combination of saturated and 
unsaturated free fatty acids. Thereafter, the effectiveness of the drugs in enhancing the 
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metabolism of intracellular lipid stores, and thus promoting steatosis reversal, is assessed in the 
fat-laden hepatocytes. 
 
Chapter 7: Following investigation of alternatives of pharmacological interventions to rescue 
steatotic donor organs in Chapter 5; and testing in vitro the toxicity of the drugs to primary 
human cells of the liver in Chapter 6; Chapter 7 describes the results of the delivery of defatting 
drugs to whole human livers discarded for transplantation undergoing NMP. This first proof of 
concept study reveals that ex situ manipulation of the hepatic lipid metabolism during NMP is 
feasible. It not only decreases the intracellular lipid content of the cells, it also enhances 
metabolic support to other intracellular processes. An outstanding impact of this therapeutic 
can be seen in the biliary system: treated livers not only produced a higher volume of bile, but 
the quality of the bile also significantly improved (determined based on bile pH). Finally, all of 
the treated livers reached the Birmingham viability criteria, and therefore would be considered 
transplantable. 
 
Chapter 8: This chapter reviews the current clinical evidence of the effect of MP of the liver 
on post-transplant biliary complications. Ischaemic-type biliary lesions following LT increases 
postoperative patient morbidity, and it is frequently associated with graft loss and re-
transplantation. The mechanisms underlying the aetiology of this disease are investigated, and 
the potential protective role of MP is discussed. Subsequently, the studies performed during the 





Chapter 9: This final chapter comprises a general discussion and conclusion. The contributions 
of this thesis to the existing scientific knowledge are comprehensively interpreted, and the 
limitations of the present work are discussed. Finally, the implications of this thesis for future 
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Purpose of the Review:  
Machine perfusion is a novel technology recently introduced in liver transplantation, redefining 
the current practice of organ preservation and pushing the limits of high-risk liver utilisation. 
This review highlights the key benefits of machine perfusion over conventional static cold 
storage, demonstrated in human liver research and clinical transplants. 
Recent Findings:  
The first clinical trials have demonstrated both safety and feasibility of machine perfusion. The 
most recent transplant series and results from a randomised trial suggest the technology is 
superior to static cold storage. The key benefits include extended period of organ preservation, 
decreased incidence of early allograft dysfunction and reduction of biliary complications. 
Normothermic liver perfusion allows viability testing to guide transplantability of the highest-
risk organs. This technology also provides opportunities for therapeutic interventions to 
improve liver function and quality in organs that are currently declined for clinical use. 
Summary:  
Machine perfusion is likely to transform the liver preservation pathway and to improve 









A recent report from the British National Health Service identified that 13% of the 1769 
patients registered for liver transplantation in the United Kingdom (UK) between 2016 and 
2017 died or were removed from the waiting list after becoming too ill for transplantation (1). 
Similar data are reported from many other countries reflecting that organ shortage in the 
context of rising incidence of liver disease is a worldwide phenomenon (2). To address 
shortfalls in supply of standard criteria donors, transplant teams have progressively extended 
the criteria to accept marginal, high-risk organs (3). Such extended criteria donors (ECD) 
include donors after circulatory death (DCD), fatty livers, and organs from donors with higher 
risk behaviour or advanced age with multiple comorbidities (3). ECD grafts are more 
susceptible to ischaemic injury and detrimental effects caused by static cold storage (SCS) and 
are associated with an increased rate of early allograft dysfunction, post-transplant biliary 
complications and recipient mortality (4–6). Consequently, an increasing number of procured 
livers are being declined for transplantation (7). Steatosis is the leading cause worldwide of 
livers being discarded (40%), followed by prolonged donor warm ischaemia, poor organ 
flushing and logistical reasons (8, 9). Confronting the ongoing decline of standard criteria 
donors, the increased need for transplantation can be achieved only by more successful 
transplants from marginal grafts and increased utilisation of high-risk livers (10). 
The inferior outcomes of ECD grafts have exposed shortcomings of SCS and directed research 
towards finding superior means of liver preservation. Following encouraging data from pre-
clinical experiments and breakthroughs achieved in heart, lungs and kidney preservation, 
several teams around the world have reported successful transplantation of machine-perfused 
livers, and this promising technology has attracted the attention of the transplant community 
worldwide (3, 11–14). 
35 
 
Machine perfusion of the liver (MP) has become a rapidly progressing field. Whilst the initial 
case series demonstrated the technology is safe and feasible in standard criteria livers, 
subsequently conducted randomised trials have evaluated its efficacy on a whole spectrum of 
currently utilised organs (11, 15–19) Table 2.1. In keeping with promising experimental data, 


















Table 2.1: Evidence and benefits of machine perfusion over the static cold storage 
Study 
endpoint* 
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PCS, prospective cohort study; RCT, randomised controlled trial; DBD, donation after brain death; DCD, 
donation after circulatory death. *The table includes the key evidence published to date in each particular 
perfusion technique and the static cold storage used as a reference for comparison. §n number relates to 
the largest published series. &COPE WP2 trial (ISRCTN 39731134). @Multi-centres European 




Recently several teams have started programmes to recondition marginal grafts and to explore 
frontiers of high-risk organ utilisation. The predominantly used perfusion temperatures are 
hypothermic (8–12 °C) and normothermic (37 °C), although sub-normothermic and rewarming 
alternatives have been reported (20–23). 
The hypothermic perfusate is similar to conventional cold storage preservation fluid, and the 
perfusion technique simpler and cheaper than normothermic machine perfusion (NMP). It does 
not pose additional risks of graft loss compared to SCS and can reveal pre-existing organ 
damage; however, in a clinical setting, it does not generate the data necessary to assess liver 
function and transplantability (24, 25). 
Sub-normothermic perfusion encompasses the temperature range from 12 °C to 35 °C, 
although the majority of experiments were performed at temperatures close to 21 °C (21, 26, 
27). Whilst this perfusion modality delivered promising data in pre-clinical testing, to date, 
there have not been published data from clinical use. Several teams have investigated graft 
rewarming, gradually increasing the perfusion temperature from 4 °C to 21 °C with promising 
results (22, 28, 29). Both these perfusion approaches achieve a partial recovery of liver 
metabolic function with oxygen requirements that can be met without a dedicated oxygen 
carrier in the perfusion fluid. 
NMP requires a blood-based perfusate and preserves the liver in near-physiological, fully 
functioning condition, generating real-time data allowing assessment of its viability (15, 30, 
31). It can be used as an alternative to SCS and such application has been currently tested in 
prospective clinical trials across Europe and North America. NMP has arguably the most 
potential to minimise any deleterious effects of the cold ischaemia, but is less flexible, costlier 
and logistically more demanding (32). Liver reconditioning provides a more flexible 




have used this technique to resuscitate graft function prior to transplantation, including our 
team’s work on viability assessment of declined livers (15, 16). It can be applied selectively to 
grafts with suboptimal macroscopic appearance or livers deemed too high-risk for any other 
reason. 
2.3 Extending the Liver Preservation Times 
The progressive detrimental effect of cold ischaemia on graft quality is the fundamental 
limitation of SCS. Shortening cold ischaemia times (CIT) to the bare minimum has become a 
key aspect of successful utilisation of ECD organs and many more livers could have been used 
had the organ arrived at the transplanting centre earlier (33). The benefit of MP on removing 
the constraints due to CIT has previously been shown in the first-in-man NMP series where the 
longest preservation time was close to 19 hours (h) (11). 
Subsequently, the first randomised trial comparing NMP with SCS performed by the 
Consortium for Organ Preservation in Europe (COPE WP2 trial, ISRCTN 39731134) identified 
that clinicians started to exploit this logistic advantage, and livers in the NMP group were 
preserved for significantly longer compared to SCS (11 h 39 minutes [min] vs. 7 h 21 min, 
p < 0.01). Despite this, the organs suffered from less early allograft dysfunction (12.6% vs. 
29.9%; p = 0.002; Nasralla et al., data presented at the British Transplant Society Congress in 
2017). Recently, Watson et al. reported successful implantation of an ECD liver 26 h after 
procurement; in this example, NMP was used to assess the organ and the transplant was 
deferred until extra-hepatic malignancy in the recipient was excluded (34). This case report 
highlights the logistical advantages of NMP and the differences in specification of available 
devices in terms of the maximum liver preservation times (11, 15, 30, 35). Liberation from the 
CIT constraints might redefine multiple aspects of current liver transplant practice in the future, 




transformation of donor—recipient matching or streamlining operating theatre logistics and 
transplant teams’ workforce management. 
The limits of extending the NMP preservation are yet to be defined, though experimental work 
has demonstrated successful perfusions beyond 24 h (34–37). Whilst 24 h preservation would 
be sufficient to achieve significant improvements in organ sharing and transplant logistics, MP 
may preserve livers for significantly longer. Several research groups have reported experiments 
with 72-h canine and porcine liver perfusions (36, 38). The prolonged perfusion will 
undoubtedly impose new challenges to overcome. For example, red blood cells (RBCs) have 
clear biophysical limitations when exposed to sheer stress from the circuit tubing and abrasive 
mechanical insult from centrifugal or roller pumps, leading to an unavoidable degree of 
haemolysis (39). To address the problem, our team investigated the feasibility of replacing 
RBCs with an acellular haemoglobin-based oxygen carrier (HBOC), Hemopure®, in a human 
model of NMP. Our results demonstrated similar metabolic and flow parameters, whilst the 
HBOC-perfused livers extracted more oxygen than those perfused with RBCs (O2ER 13.75% 
vs. 9.43% × 105 per gram of tissue, p = 0.001) without increased apoptosis or necrosis, tested 
in vitro hepatic cell lines (32). Exploring strategies to maintain prolonged perfusion will clearly 
require intensive research to optimise the perfusate composition and device design, but 
achieving this goal will open new possibilities for using MP as a tool for therapeutic 
intervention and regeneration of the highest-risk liver grafts. 
2.4 Pushing the Limits of High-Risk Organ Utilisation 
While the initial series of machine perfused transplants included essentially standard criteria 
organs, the technology’s greatest benefit is preservation of marginal livers (40). Guarrera et al. 
applied hypothermic perfusion to 31 ECD livers donated after brainstem death (DBD) and, 




rate of biliary complications and hospital stay compared to matched SCS controls (19). 
Compelling data were reported by the Zurich group using hypothermic oxygenated perfusions 
(HOPE) of DBD livers (41). Consequently, Dutkowski and colleagues achieved nation-wide 
adoption of HOPE by the Swiss healthcare for all DCD livers, utilising these marginal organs 
with superior outcomes. Comparison of their results with matched controls from the 
Netherlands and UK demonstrated the incidence of non-anastomotic biliary strictures in 25 
HOPE-perfused livers compared to 50 SCS matched DCD transplants was significantly lower 
(0% vs. 22%, p = 0.015), together with superior 1-year graft survival (90% vs. 69%, p = 0.035) 
(17). Most recently, the data from the COPE WP2 multi-centre European study enrolling 272 
donors (consisting of 194 DBD and 78 DCD organs) showed significantly lower organ discard 
rate in the normothermic arm (NMP 16 vs. SCS 32 livers; p = 0.01; Nasralla et al., data 
presented at the British Transplant Society Congress in 2017). The data regarding biliary 
complications and survival at 6-months from this trial are not yet available (Table 2.1). 
The development of normothermic perfusion enabled objective assessment of the liver 
function, advancing the graft selection process, and several teams researched the development 
of criteria for viability assessment including perfusate pH, bile production, transaminase levels 
or lactate clearance. 
Through pre-clinical experiments, our team observed a close relationship between liver 
function and perfusate lactate metabolism. The organs able to achieve lactate clearance below 
2.5 mmol/L within 120 min of commencing perfusion retained physiological perfusate acid 
base milieu and did not require any interventions to maintain extended perfusion. Transforming 
the observations into clinical practice, we proposed composite criteria, based on the lactate 
clearance and bile production in combination with vascular flows and macroscopic appearance 
(16). These were applied on a pilot series of six livers declined for transplantation by all the 




and two DBD grafts, commencing perfusion after a period of CIT ranging from 387 to 474 min 
(15). The liver viability was assessed within a 2-h window, and five of the organs met the 
criteria and were successfully transplanted. In all recipients, we observed immediate graft 
function recovery with a short hospital stay, and normalised liver function tests within the first 
post-transplant month (15). We have consequently conducted the VITTAL clinical trial 
(VIability Testing and TrAnsplantation of discarded donor Livers; NCT02740608), further 
testing the boundaries of the highest-risk organ utilisation by criteria principally based on 
lactate metabolism, extending the assessment period up to 4 h. 
NMP provides the opportunity to explore multiple parameters relevant to liver function, and it 
is still to be determined which can best predict post-transplant outcomes. The Cambridge group 
advocated graft assessment based on the perfusate transaminases and bile pH (42). The authors 
observed a significant correlation between the alanine transaminase (ALT) in the perfusate 
measured after 2 h perfusion and the peak ALT post-transplant levels within the first week 
(42). In this report, Watson et al. also hypothesise that the liver capacity to produce an alkaline 
bile (pH > 7.4) might be a marker of good cholangiocyte function, possibly allowing selection 
of organs with a low risk of developing intrahepatic cholangiopathy. If validated, this 
observation might revolutionise DCD liver utilisation, preventing futile transplantation of 
grafts with a limited life span. We expect that future organ functional assessment will include 
more sophisticated methods and markers based on perfusate omics or microRNA analyses (43, 
44). 
Although the viability testing data have already shown benefits of NMP in high-risk graft 
utilisation and reduced risk of early graft failure, the evidence that MP improves long-term 
transplant outcomes is still elusive. A pertinent cohort in which to study this subject are DCD 
livers. To date, the only clinical evidence comes from retrospective observations published by 




The experimental evidence from normothermic perfusion suggests a protective effect of peri-
biliary glands (46–48). The evaluation of the biliary complication data from the randomised 
COPE trials is eagerly awaited. 
2.5 New Frontiers and Therapeutic Interventions during Machine Perfusion 
Designing a MP clinical trial powered to demonstrate differences in post-transplant graft or 
patient survival is very challenging and researchers often use a validated surrogate endpoint as 
a substitute. A difference in the post-transplant transaminase levels, incidence of delayed graft 
function, and markers proving less ischaemia-reperfusion injury have been a frequent reported 
endpoint with many MP series (11, 15, 17, 28, 40, 49). The circulating perfusate in the liver 
itself prevents accumulation of succinate and other metabolic products and removes the debris 
and necrotic or apoptotic cells, likely decreasing the post-reperfusion transaminases and having 
a beneficial effect on the graft (19, 50). The major benefit is, however, the oxygenation 
preventing the damage caused by ischaemia and anaerobic metabolism (50). The pre-clinical 
research gathered mechanistic evidence of multiple aspects of cellular metabolism pathways 
influenced by MP with several teams focused in particular on energy metabolism and 
mitochondrial function (51). The HOPE perfusion was shown to induce mitochondrial function 
with down-regulation of the respiratory rate, associated with adenosine tri-phosphate synthesis. 
Such 60 to 120-min duration perfusion achieves recovery of the liver energy resources together 
with prevention of mitochondrial reversal flow of electrons during the organ re-warming, 
decreasing production of reactive oxygen species mitigating activation of the inflammatory 
processes involved in the reperfusion injury (52, 53). 
Despite an extensive knowledge on a cellular level of the mechanisms of hepatic function 
protection during HOPE, NMP has the advantage of allowing the exploration of targeted 




combat the anticipated risks of bacterial contamination and overgrowth, antibiotics are 
universally added to the normothermic perfusate fluid composition (30, 32). Targeted 
antibiotics added to the perfusate for livers from positive culture donors might be an easy 
intervention to improve transplantability of organs from donors with infections. A proof of 
concept with NMP antiviral pre-treatment during MP in a porcine model was recently reported 
by the Toronto group (54). The same group also explored strategies to further enhance the 
protective MP mechanisms in a sub-normothermic porcine DCD liver model, enriching the 
perfusate with anti-inflammatory drugs (alprostadil, n-acetylcysteine, carbon monoxide and 
sevoflurane). This intervention significantly lowered the perfusate levels of aspartate 
aminotransferase, interleukin 6, tumour necrosis factor alpha and galactosidase, and increased 
interleukin 10 levels compared to the untreated controls. MP itself reduces activation of the 
post-reperfusion inflammation cascade, and despite the improvements in reperfusion injury 
markers not achieving statistical significance, this concept to enhance the protective 
mechanisms merits further research (52, 53). 
Another frequent reason for discarding donor livers is a suboptimal flushing. Addition of a 
thrombolytic agent together with the standardly included heparin might improve graft 
circulation without increasing the bleeding risks for the organ recipient (31, 55). 
Steatotic livers are the largest group of poorly utilised organs, and resuscitation of fatty livers 
is an important goal whilst combating the growing obesity epidemic (56). The concept of 
pharmacological intervention to reverse steatosis during NMP has been explored by several 
teams including our own. We performed NMP on severely steatotic donor human livers, 
exposing the organs to a combination of defatting drugs. We observed solubilisation of the 
liver fat, commencing within 3 h, and continuing until the end of 24-h perfusions. Although it 
is unclear whether removal of fat from a viable liver during NMP would be relevant in 




better metabolic parameters compared to matched controls, and the histological improvement 
became apparent after only 6 h. A potential shortfall of MP with metabolically active livers 
might be re-circulation of harmful or toxic metabolites (57). In the described experiment the 
mitochondria fatty acids β-oxidation increased ketone production and continuously increased 
the perfusate apolipoprotein and cholesterol levels. Removal of the metabolism by-products 
from the device circuit is an interesting issue requiring more research. 
The perfusion model of steatotic livers also demonstrates that different graft categories may 
benefit from different MP modalities. Cooling the hepatic fat leads to changed lipid 
consistency, increasing its droplet volume which ultimately compromises the liver 
microcirculation. The optimal strategy to minimise any post-procurement damage might be 
minimising exposure to the cold by normothermic preservation. Following a period of SCS, 
however, the disturbed hepatic microcirculation makes subsequent machine resuscitation and 
perfusion processes challenging and the optimal temperature and combination of different 
approaches is yet to be determined. 
The feasibility of the therapeutic interventions discussed has been demonstrated by animal or 
proof of concept human research. In the near future, MP will be studied as a method to deliver 
cell-based and small molecule therapies, aimed at improving the condition of high-risk liver 
grafts, following the emerging evidence showing efficacy of these novel concepts in promoting 
organ regeneration (58–61). 
2.6 Conclusion 
MP is a rapidly progressing field which is likely to change multiple aspects of liver preservation 
and transplantation practice in the future. This superior organ preservation mode has already 
shown benefits by enabling functional liver assessment with normothermic perfusion or 




set new limits for organ preservation times, increase utilisation of the highest-risk DBD grafts 
and improve long-terms outcomes in DCD livers. The perfusion procedure will provide an 
opportunity for liver regeneration and therapeutic intervention. Different type of livers may 
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Background: Hypothermic oxygenated perfusion and normothermic perfusion are seen as 
distinct techniques of ex situ machine perfusion of the liver. We aimed to demonstrate the 
feasibility of combining both techniques and whether it would improve functional parameters 
of donor livers into transplant standards.  
Methods: Ten discarded human donor livers had either 6 hours of normothermic perfusion (n 
= 5) or 2 hours of hypothermic oxygenated perfusion followed by 4 hours of normothermic 
perfusion (n = 5). Liver function was assessed according to our viability criteria; markers of 
tissue injury and hepatic metabolic activity were compared between groups.  
Results: Donor characteristics were comparable. During the hypothermic perfusion phase, 
livers down-regulated mitochondrial respiration (oxygen uptake, p = 0.04; pCO2 perfusate, p = 
0.04) and increased ATP levels 1.77-fold. Following normothermic perfusion those organs 
achieved lower tissue expression of markers of oxidative injury (4-hydroxynonenal, p = 0.008; 
CD14 expression, p = 0.008) and inflammation (CD11b, p = 0.02; vascular cell adhesion 
molecule 1, p = 0.05) compared with livers that had normothermic perfusion alone. All livers 
in the combined group achieved viability criteria, whereas 40% (2/5) in the normothermic group 
failed (p = 0.22).  
Conclusion: This study suggests that a combined protocol of hypothermic oxygenated and 
normothermic perfusions might attenuate oxidative stress, tissue inflammation and improve 








The rising incidence of liver disease, in combination with changes in organ donor 
demographics, has increased reliance on extended criteria donor (ECD) livers for 
transplantation globally (1, 2). Although these organs have inferior outcomes compared to 
standard criteria livers, their use is deemed necessary to control the waiting list mortality (3–5). 
Current utilisation of ECD livers remains relatively low mainly when risk factors concur. For 
example, in the United Kingdom 17% of the procured livers are currently not transplanted (6).  
Ex situ machine perfusion is a novel preservation method developed to protect organs from the 
detrimental effects of ischaemia during static cold storage (SCS). Potential beneficial protective 
mechanisms of machine perfusion have been demonstrated for both hypothermic and 
normothermic perfusion techniques during pre-clinical experiments and pilot clinical studies 
(7–9).  
Hypothermic oxygenated perfusion (HOPE) may permit mitochondrial functional recovery, 
increasing cellular adenosine trisphosphate (ATP) levels, and mitigate the injury to the tissue 
that occurs during rewarming (9). Whilst there is a mounting evidence of the protective effect 
of HOPE on the liver graft quality, evidence regarding its value in viability testing still under 
investigation. Hoyer at al. reported a correlation between perfusate transaminases content and 
its post-transplant levels suggesting that hepatocellular injury could potentially be assessed also 
outside of normothermia (10, 11). Normothermic machine perfusion (NMP) of the liver enables 
metabolism at physiological temperature and therefore facilitates functional assessment (12).  
Several groups including our own have demonstrated that viability assessment by NMP can be 
used to select transplantable livers from the pool of currently discarded organs (12, 13). There 
is no convincing data, however, to show that NMP improves the quality of ECD organs injured 




liver quality from the time of commencing the perfusion and by providing a snapshot of the 
organ injury occurred, with the opportunity to assess multiple functional parameters.  
Data from our research NMP perfusions showed that a proportion of poor-quality livers exposed 
to prolonged cold storage do not recover their function and fail our viability criteria. Whilst 
hypothermic and normothermic perfusion were developed as distinct strategies, we 
hypothesised that HOPE might be seen as a beneficial therapeutic intervention by restoring liver 
metabolism prior to a period of normothermic perfusion which permits liver viability testing. 
The present study aimed to assess the feasibility of a protocol combining HOPE with NMP and 
to investigate its potential benefits over NMP alone.  
3.3 Materials and methods 
3.3.1 Study design 
The study was designed to compare two perfusion strategies to restore function of high-risk 
ECD livers, following a period of SCS, within the certified 6-hours timeframe allowed by the 
perfusion device used. 
The study endpoints were evaluation of hepatocellular injury and liver function assessment. 
Ten discarded human donor livers were consecutively assigned to two study groups, each 
consisting of 5 organs and all perfused for 6 hours. Livers in one group were exposed to 
normothermic perfusion alone (NMP group, performed first), whilst the other group underwent 
2 hours of hypothermic oxygenated perfusion, followed by 4 hours of normothermic perfusion 








Figure 3.1: Study design. 
Discarded human livers were subjected to our routine organ procurement procedure and then cold flushed and cold stored. The organs were allocated randomly in two 
experimental groups of end-ischaemic machine perfusion. The NMP group was subjected to 6 hours NMP at 37 C; and, the HOPE+NMP group, was subjected to 2 
hours of hypothermic oxygenated perfusion (HOPE) followed by 4 hours of NMP. Menghini and wedge biopsies were collected at time 0 and 6-hours (**) and 
immediately fixed in formalin or snap-frozen in liquid nitrogen. The HOPE+NMP group had an extra liver biopsy taken at 2 hours. Blood gas analysis was carried out 




3.3.2 Source of discarded human livers 
All included livers were procured with the intention of transplantation according to the National 
Organ Retrieval Service standards. The organs were declined for clinical use by all the UK liver 
transplant centres and subsequently offered for research purposes. The livers were preserved in 
University of Wisconsin fluid under standard clinical practice of SCS prior to commencing 
perfusion. The study ethical approval was obtained by the London-Surrey Borders National 
Research Ethics Service and the National Health Service Blood and Transplant Ethics 
Committee (references 13/LO/1928 and 06/Q702/61, respectively).  
3.3.3 Liver perfusion procedure 
The liver preparation for the perfusion was carried out using a standard clinical back-table 
procedure as described elsewhere (14). The cystic duct was ligated, and coeliac trunk, portal 
vein and bile duct cannulated with a 12 French biliary drain. Before commencing machine 
perfusion, the liver was flushed with two litres of 5% Glucose solution, placed into the device 
reservoir and the cannulas connected to the perfusion circuits. The Liver Assist device (Organ 
Assist, Groningen, The Netherlands) provides dual perfusion of the hepatic artery and portal 
vein, in a semi-closed circuit, by two rotatory pumps to produce pulsatile and non-pulsatile 
flows respectively (15). The perfusate temperature and perfusion pressures were set by the 
operator, and the measured flow rates and calculated resistances, shown on the device’s display 
in real-time, recorded every 30 minutes. Oxygen was supplied via a Sechrist air/oxygen blender 
(S3500CP-G, Inspiration Healthcare Ltd., Leicester, UK) with the fraction of inspired oxygen 
(FiO2) and air flow adjusted as specified below.    
3.3.4 Hypothermic oxygenated perfusion  




University of Wisconsin Machine Perfusion Solution (Bridge to Life Ltd, EU), with the 
temperature set at 10 ˚C. The target flow was 0.1 mL/min/g of liver with a maximum pressure 
of 3 mmHg. The target oxygen perfusate pressure was 80–100 kPa. After 2 hours of HOPE, the 
perfusion was stopped, and the liver temporarily placed on ice. The system was then drained 
and subsequently refilled with the NMP perfusion solution. The hepatic artery and common 
bile duct were cannulated and the NMP perfusion commenced. The perfusion fluid exchange 
until the start of NMP took on average 20 minutes. 
3.3.5 Normothermic machine perfusion 
The perfusion fluid for the NMP consisted of 1000 mL (4 units) of an acellular, polymerised 
bovine haemoglobin-based oxygen carrier Hemopure® (Hemoglobin® Oxygen Therapeutics 
LLC, Cambridge, USA) complemented with human albumin solution and additional 
supplements as described in Supplementary Table S3.1. For superior oxygen delivery, 
rheological characteristics and research logistic, this solution became our preferred perfusate 
(16).  
The target of flow was 0.25 mL/min/g liver tissue on the arterial side and 0.75 mL/min/g liver 
tissue in the venous circuit. To achieve these flows, perfusion pressures on the device were 
adjusted between 30–50 mmHg (mean pressure) on the arterial side and 8–10 mmHg on the 
portal vein. The temperature was initially set at 20 °C and increased incrementally to 37 °C 
within 30 minutes of starting NMP. The target perfusate oxygen pressure was 40 kPa.  
3.3.6 Samples and data collection protocol 
Liver biopsies were taken before commencing the perfusion (t = 0), after finishing the HOPE 
perfusion (t = 2 hours), and on completion of NMP (t = 6 hours; Figure 3.1). Biopsies were 
immediately either placed in formalin or snap-frozen in liquid nitrogen for subsequent analysis. 




analyses were done on biopsies from the beginning and end of the perfusion. The perfusate was 
sampled every 30 minutes throughout the perfusion in both groups and analysed immediately 
for blood gases, or snap-frozen and stored for later analyses. Bile produced during the perfusion 
was collected via a 12 French silicon tube inserted into the common bile duct and weighed at 4 
and 6 hours of machine perfusion in both groups. The density of bile was considered 1 g/mL 
and this was normalised for liver mass.  
3.3.7 Assessment of liver function 
Arterial and venous perfusates were assessed using a Cobas b 221 (Roche Diagnostics, 
Indianapolis, USA) point of care system blood gas analyser. Parameters included pO2 and 
pCO2, pH, base excess, bicarbonate, O2 saturation, haemoglobin, haematocrit, sodium, 
potassium, chloride, calcium, glucose and lactate concentrations.  
Oxygen uptake was calculated during the HOPE perfusion as the difference between the oxygen 
inflow minus the outflow in kPa, corrected by liver weight and litres of perfusate. During NMP 
the oxygen consumption was calculated from the difference between the oxygen content after 
the oxygenator and the return into the oxygenator in the venous circuit. Oxygen content was 
calculated as the sum of the free dissolved oxygen fraction to the haemoglobin-bound oxygen 
fraction (equation in the supplementary methods) as described elsewhere (17). 
The viability of the organ was assessed at the end of the perfusion by our unit’s clinical criteria, 
based on perfusate lactate levels falling to concentrations of less than 2.5 mmol/L within 6 
hours, in combination with evidence of bile production, stable vascular flows and homogeneous 
parenchymal perfusion (12).  
3.3.8 Histopathological assessment of hepatocyte injury 
Menghini needle and wedge biopsies obtained prior to perfusion and at the end were fixed in 




with haematoxylin and eosin and periodic acid-Schiff (PAS). Haematoxylin and eosin sections 
were semi-quantitatively graded for ischaemic-type coagulative necrosis, large and small 
droplet macrovesicular steatosis and pre-existing acute or chronic liver disease. The PAS-
stained sections were scored for percentage of hepatocytes depleted of glycogen, and the 
variation between the beginning and the end of the perfusion compared across groups. 
Histological assessment was conducted by an experienced liver transplant pathologist without 
prior knowledge of the designated perfusion category or outcome. 
3.3.9 Immunohistochemical assessment of oxidative stress and tissue inflammation  
Immunohistochemistry was performed on formalin-fixed parafin-embedded sections to assess 
surrogate markers of oxidative injury and tissue inflammation. 
For oxidative injury we assessed expression of: (1) uncoupling protein 2, a mitochondrial inner 
membrane protein that uncouples the electron transport chain from oxidative phosphorylation. 
Elevated uncoupling protein 2 expression is associated with increased reactive oxygen species 
(ROS) production (17,19); (2) 4-hydroxynonenal (4-HNE) as a marker of cell membrane 
phospholipid peroxidation (18).  
For the assessment of tissue inflammation, the following markers were analysed: (1) cluster of 
differentiation 14 (CD14), a lipopolysaccharide receptor which is part of the toll-like receptor 
4 signalosome. It is essential for activation of the toll-like receptor 4 via the recognition of 
ligands such as damage-associated molecular patterns known to be upregulated during 
ischaemia reperfusion injury (18, 19). (2) CD11b is an integrin on the surface of leukocytes; 
upregulation on its expression indicates activation of the cells by substances including ROS. 
(3) The vascular cell adhesion molecule 1 (VCAM-1) expression is upregulated on vascular 
endothelial cells and Kupffer cells when activated by ROS and proinflammatory cytokines 




ImmPRESS™ Excel Amplified HRP Polymer Staining Kit specific to the respective mouse or 
rabbit immunoglobulin isotype. A list of primary antibodies and the dilution it was used is 
provided in the supplementary material. 
3.3.10 Immunohistochemistry quantitation 
Four pictures of each section excluding the edges were randomly selected for analysis (x400 
magnification). For UCP-2, 4-HNE, CD14 and CD11b, a semiquantitative scoring system, the 
modified immunoreactive score (IRS) (21), was obtained by multiplying the score for intensity 
(0: no colour reaction; 1: mild reaction; 2: moderate reaction; 3: intense reaction) and 
distribution (0: no positive cells; 1: < 10% positive cells; 2: 10–50% positive cells; 3: 51–80% 
positive cells; 4: > 80% positive cells) to obtain a final score between 0 and 12. Change in the 
overall tissue expression of staining (ΔIRS), was determined by subtracting the IRS scores after 
6 hours of perfusion from the score prior to perfusion: negative values indicated a decrease and 
positive an increase in the expression of the staining. 
 VCAM-1 tissue expression was assessed by image analysis using an established system of 
colour differentiation (ImageJ, U. S. National Institutes of Health, Bethesda, USA) and the 
variation in the percentage of the positive area of staining (Δ%VCAM-1) over the time was 
compared between groups.   
3.3.11 Assessment of tissue adenosine triphosphate concentration 
Quantification of ATP levels was done by homogenisation of liver tissue. With concentration 
determined using the ATP Bioluminescent Assay kit (FLAA, Sigma-Aldrich Inc, St Louis, 
USA). More details are provided in the supplementary material. 
3.3.12 Statistical analysis 




variables as absolute number with percentage frequencies. Comparisons between groups were 
performed using Fisher’s exact test for categorical variables, the Mann–Whitney U test for 
independent continuous variables and the Wilcoxon signed-rank test for repeated measurements 
over time on the same sample. The statistical level of significance was set at p < 0.05. GraphPad 
Prism (version 6.04 for Windows, GraphPad Software, La Jolla, USA) software was used for 
all statistical analyses and graph creation. 
3.4 Results 
3.4.1 Donor demographics and discarded liver characteristics 
Seven livers (70%) were from donors after circulatory death (DCD). The median donor age of 
the entire cohort was 52 (IQR: 38–54) years and the body mass index 25 (21–31) kg/m2. Median 
cold ischaemia time was 510 minutes (446–682) for DCD, and 491 minutes (454–586) for 
donors after brainstem death (DBD). The median donor risk index (DRI) was 2.2 (1.9–2.6). 
There were no significant differences in donor demographics between the groups as shown in 
Table 3.1 and they had similar median DRI (NMP 2.4 vs. HOPE+NMP 2.5, p = 0.78). There 
was a trend towards NMP livers having shorter SCS preservation times for DCD (449 vs. 682 












Table 3.1: Donor demographics, liver characteristics and machine perfusion parameters. 
Abbreviations:  NMP: normothermic machine perfusion of the liver; HOPE: hypothermic oxygenated perfusion 
of the liver; DCD: donation after circulatory death; DBD: donation after brain death; US: United States; UK: 
United Kingdom; ET: Eurotransplant; ALT: alanine aminotransferase; HTN: hypertension; ICH: intracranial 
haemorrhage; HBD: hypoxic brain damage; NA: not applicable; WIT: warm ischaemic time; CIT: cold ischaemia 
time; MaS: macrovesicular steatosis (paraffin sections).  
Note: Donor warm ischaemic time was defined as the interval between the systolic blood pressure less than 
50mmHg or/and arterial oxygen saturation to less than 70% to commencing the aortic cold perfusion in the donor. 












Age 70 36 50 25 60 54 50 54 38 55 
Donor type DCD DCD DBD DCD DCD DCD DBD DBD DCD DCD 
Sex Male Male Male Male Male Male Female Female Male Female 
Height (cm) 165 181 187 175 189 179 158 170 183 160 
Bodyweight 
(kg) 
80 70 90 82 75 123 60 87 85 90 
Body mass 
index (kg/m2) 
29 21 25 26 21 38 24 30 25 35 
US - Donor risk 
index 
3.2 2.6 1.6 2.2 2.2 2.5 2.0 1.9 1.8 3.0 
UK - donor 
liver index 
4.0 2.1 0.9 2.1 27.4 16.3 6.9 1.2 3.1 4.9 
ET - donor risk 
index 
3.3 2.2 1.7 1.9 2.4 2.9 2.2 1.9 2.3 2.8 
Peak ALT 
(IU/L) 
168 17 44 476 137 189 14 271 37 741 
Days on 
ventilator 
1 5 1 3 8 5 2 2 4 4 
Co-morbidities 























Cause of death ICH ICH ICH Trauma Trauma HBD ICH ICH ICH HBD 
Liver characteristics 
Liver weight (g) 2208 2218 2380 1998 1555 2600 1838 2060 1753 1935 
Donor WIT (min) 24 20 NA 10 17 31 NA NA 42 8 














































Large MaS 60% 0% 0% 0% 0% 10% 0% 15% 3% 30% 
Machine perfusion parameters 
Lactate (mmol/L)          
Highest 9.6 20.0 10.3 10.4 9.0 9.1 8.9 10.4 4.6 7.8 
Lowest 4.1 8.8 0.3 1.4 0.6 0.6 1.1 1.8 0.2 0.8 
At 6-hour 5.3 11.6 0.3 1.6 1.4 0.6 1.1 1.8 0.2 0.8 
Total Bile 
production (g) 
0.0 0.0 17.6 26.0 38.0 57.0 0.0 0.0 15.9 24 
Mean Arterial 
flow (mL/min) 




1188 926 1500 1015 1020 1412 1523 1602 1406 1582 
Mean liver mass 
perfusion(mL/g/min) 
0.78 0.53 0.95 0.77 1.05 0.66 0.99 0.89 0.89 1.02 





Table 3.2: Donor demographics, liver characteristics and machine perfusion data. 
Abbreviations: NMP: normothermic machine perfusion of the liver; HOPE: hypothermic oxygenated perfusion 
of the liver; DCD: donation after circulatory death; UK: United Kingdom; ET: Eurotransplant; ALT: alanine 
aminotransferase; DBD: donation after brain death. 
Note: Continuous variables presented as median and interquartile range, dichotomous variables as absolute 
number and percentage. Donor warm ischaemic time was defined as the interval between the systolic blood 
pressure less than 50mmHg or/and arterial oxygen saturation to less than 70% to commencing the aortic cold 






 NMP (n = 5) HOPE+NMP (n = 5) p-value 
Donor information 
Age, years 55 (43–65) 54 (46–54) 0.84 
DCD livers 4 (80%) 3 (60%) 0.50 
Sex, male 5 (100%) 2 (40%) 0.17 
Height (cm) 184 (173–188) 179 (169–181) 0.19 
Bodyweight (kg) 78 (73–85) 90 (87–106) 0.39 
Body mass index 
(kg/m2) 
23 (21–27) 35 (30–37) 
0.08 
Donor risk index 2.4 (1.9–2.8) 2.5 (2.2–2.7) 0.78 
UK donor liver index 3.1 (1.5–15.7) 4.9 (4.0–10.6) 0.89 
ET donor risk index 2.3 (1.9–2.9) 2.8 (2.6–2.8) 0.80 
Peak ALT (IU/L) 68 (44–137) 189 (37–271) 0.24 
Days on ventilator 3 (1–5) 4 (2–4) 0.89 
Liver characteristics 
Liver weight (g) 2208 (1998–2218) 1935 (1838–2060) 0.87 
Donor warm ischaemic  
time (minutes) 
20 (16–22) 31 (19–36) 
0.42 
Cold ischaemia time 
(minutes), DCD 
449 (423–532) 682 (586–708) 
0.09 
Cold ischaemia time 
(minutes), DBD 




0 (0–30) 10 (1–22) 
0.98 
Machine perfusion parameters 
Lactate (mmol/L)    
Highest 10.3 (9.6–10.4) 8.9 (7.8–9.1) 0.14 
Lowest 1.4 (0.6–4.1) 0.8 (0.6–1.1) 0.22 
Last 1.6 (1.4–5.3) 0.8 (0.6–1.1) 0.17 
Total Bile production 
(g) 





3.4.2 Vascular flows  
Portal flow patterns and end-perfusion volumes differed between the groups. During the initial 
60 minutes of the NMP group perfusion the livers’ portal flow rate increased rapidly and 
plateaued after 180 minutes. For the HOPE+NMP group steady, low volume flow rates 
approximating 300 mL/min were achieved during the HOPE phase. The flow rate subsequently 
increased for the first 2 hours of rewarming during the NMP phase. The median flow rates in 
the HOPE+NMP group exceeded the NMP group after 210 minutes and continued to increase 
until the end of the perfusion (1300 vs. 1930 mL/min, p = 0.03). In contrast, the arterial flows 
in the NMP livers increased more rapidly during the rewarming phase and remained higher 
throughout the perfusion (365 vs. 732 mL/min, p = 0.09), while the vascular resistance patterns 
and levels were similar. The detailed data are presented in Figure 3.2 and Table 3.1.  
3.4.3 Mitochondrial function and oxygen consumption 
During the HOPE phase, livers demonstrated a decrease in the oxygen uptake rate and CO2 
release in the perfusate. The oxygen uptake during the HOPE phase peaked within the initial 
30 minutes (0.009 [0.005–0.010] kPa/gram liver/litre perfusate), then declined steadily (0.006 
[0.001–0.007] kPa/gram liver/litre perfusate) until the end of the 2-hour perfusion (p = 0.04). 
There was a concomitant decrease in the median partial pressures of carbon dioxide dissolved 
in the perfusate from time 0 to 2 hours of hypothermic perfusion (1.27 [1.17–1.86] to 0.69 
[0.57–0.82], p = 0.04). This change in mitochondrial respiration was associated with a median 
1.77-fold (range 1.33–3.89) increase in tissue ATP levels.  
The oxygen consumption in the NMP group increased sharply within the initial 60 minutes with 
distinct patterns in viable compared to non-viable groups (Figure 3.2). In the HOPE+NMP 
livers, oxygen consumption increased slower during the normothermic phase and was maximal 




similar to livers that had HOPE (p = 0.19).  
Both groups had similar ATP stores at the end of the 6 hours’ perfusion (p = 0.31), however 
there was a significant difference in the incremental rate between viable and non-viable livers 
in the NMP group (NMP viable 2.53-fold [2.40–10.9]; NMP non-viable 1.10-fold [1.08–1.15]; 
































Figure 3.2: Perfusion parameters. Section 1: Liver functional assessment- Panel A: Perfusate lactate 
concentration (mmol/L) - measured throughout the perfusion. Here the NMP group was stratified in the 
viable livers –continuous red lines- (60%, n = 3) or non-viable livers –dotted red lines- (40%, n = 2). 
Blue lines represent the HOPE+NMP group livers. Panel B: Perfusate glucose concentration (mmol/L) 
- Data presented as median and IQR. Panel C:  Cumulative bile production for individual livers after 4 
and 6 hours of perfusion corrected for liver weight in kilograms. Panel D: Bile pH at 6 hours of perfusion 
was comparable between the study groups, as was glucose (Panel E). Section 2: Vascular parameters of 
the perfusion. Panel F: Portal vein flow rate in mL/min showing that flow increased steadily in the NMP 
group plateauing after 2 hours. For HOPE+NMP it remained low and stable during the HOPE phase 
increasing during the rewarming phase and achieving higher rates at the end of the perfusion compared 
with NMP alone. Panel G: Hepatic artery (HA) flow rate expressed in mL/min plotted on the right Y 
axis and hepatic artery vascular resistance in mmHg/mL/min/kg liver plotted on the left Y axis. Despite 
similar resistances at the end of the perfusion, the HA flow reached higher values at the end of the 
perfusion in the NMP group. Section 3: HOPE phase and mitochondrial function. Panel H: Oxygen 
uptake during the HOPE phase of the HOPE+NMP group (ΔinflowO2-outflowO2), expressed as median 
and IQR. Panel I: pCO2 released in the perfusate decreased steadily throughout the hypothermic 
perfusion phase. Panel J: Tissue ATP levels (nmol/gram), time 2-hours normalised for the concentration 
in time 0 and expressed as fold increase. Data presented as median and minimum/maximum. Section 4: 
Energy status during perfusion. Panel K: Oxygen consumption during NMP phase for both groups, NMP 
stratified according to viability criteria the continuous red line representing viable and the dotted red 
line representing non-viable respectively. Data presented as median and IQR. Oxygen consumption 
increased sharply within the initial 60 minutes of NMP whereas the HOPE+NMP livers presented a 
slower increase in oxygen consumption during the normothermic phase. Panel L: pCO2 released in the 
perfusate during the NMP phase showing that figures were similar between the viable livers of the NMP 
group and the HOPE+NMP group. Non-viable livers from the NMP group presented with higher 
perfusate pCO2 levels throughout the entire duration of perfusion. Panel M: Tissue ATP levels 
(nmol/gram) over during 6 hours of perfusion. Figures at time 2-hour and 6-hour were normalised for 
the concentration at t = 0 and expressed as fold increase. Levels of significance: *p < 0.05 (Wilcoxon 
signed-rank test). 
 
3.4.4 Liver function assessment 
The lactate levels and clearance dynamics differed between the groups. In the NMP group, 
lactate levels peaked after 60 minutes, reached the viability criteria within 150 minutes and 
subsequently remained low. In the HOPE+NMP livers, it did not change through the 
hypothermic phase, and slowly increased in the rewarming phase with a subsequent rapid 
clearance just after 2 hours of NMP. The end-perfusion lactate levels were similar in viable 
livers from the NMP group and the HOPE+NMP group (1.6 mmol/L vs. 0.8 mmol/L, p = 0.17). 
In the non-viable livers, lactate levels peaked after 60 minutes with minimum levels achieved 




in the HOPE+NMP were deemed viable (p = 0.22). Details of the achievement of viability 
parameters are presented in Table 3.3. The two non-viable livers from the NMP group had the 
highest DRI, however this difference was not statistically significant (non-viable DRI 2.8 [2.5–
3.2] vs. viable DRI 2.2 [1.9–2.2], p = 0.13).  
The glucose levels slowly increased within the initial 120 minutes of perfusion in the NMP 
group, followed by slow clearance until the end of the perfusion. In the HOPE+NMP group, 
they slowly increased through the hypothermic perfusion, followed by a drop (related to the 
perfusate fluid replacement) with a subsequent slow increase, and then decreased, reaching 
similar figures to the NMP group at the end of the perfusion (26 [20–40] vs. 16 [15–31] mmol/L, 
p = 0.22).  
Bile production at 6 hours of the perfusion was similar between both groups (NMP 7.39 mL/kg 
liver vs. HOPE+NMP 5.16 mL/kg liver, p = 0.82). Bile pH (HOPE+NMP 7.27 [7.19–7.36] vs. 
NMP 7.26 [7.20–7.45], p > 0.99) and bile glucose (HOPE+NMP 13 [9–16] vs. NMP 21 [14–
27], p = 0.40) were comparable between the groups at the end of the perfusion. Data is 














Table 3.3: Viability criteria achievement by the livers in each group 
Criteria 
NMP 
(n = 5) 
HOPE+NMP 
(n = 5) 
Lactate clearance (≤ 2.5 mmol/L) 3 (60%) 5 (100%) 
pH > 7.3 perfusate 2 (40%) 2 (40%) 
Glucose metabolism 3 (60%) 4 (80%) 
HA flow (> 150 mL/min) 5 (100%) 5 (100%) 
PV flow (> 500 mL/min) 5 (100%) 5 (100%) 
Homogeneous perfusion/ soft parenchyma 5 (100%) 5 (100%) 
Bile production 3 (60%) 3 (60%) 
Viable liver 3 (60%) 5 (100%) 
Abbreviations: NMP: normothermic machine perfusion of the liver; HOPE: hypothermic oxygenated perfusion 
of the liver; HA: hepatic artery; PV: portal vein 
 
3.4.5 Histological assessment of the livers 
Routine histological assessment showed no observable differences between the groups on the 
biopsy prior to the perfusion. At the end of the perfusion none of the livers presented with areas 
of parenchymal necrosis, congestion or cytoplasmic vacuolization. The median large droplet 
macrovesicular steatosis percentage was not significantly different between the groups (NMP 
0% [0–30] vs. HOPE+NMP 10% [1–22], p = 0.98) and only one liver from each group 
presented with steatohepatitis. The levels of hepatocyte glycogen depletion from start to end of 
the perfusion were similar in both groups [NMP 0% (–20/+10) vs. HOPE+NMP +10% 
(+2.5/+32.5), p = 0.22] with a positive value reflecting an increase in the percentage of 












Figure 3.3: Liver histology before and after machine perfusion. The upper panel of images shows 
haematoxylin and eosin and the lower periodic acid-Schiff (PAS) staining at the beginning (t = 0) and end of 
the perfusion (t = 6 hours). No observable histological differences were seen between the two groups prior 
to or at the end of perfusion. There was no evidence of perfusion related ischaemic coagulative necrosis 
developed in any liver during perfusion. The percentage of areas of glycogen deposition (parenchymal PAS 
staining) from start to end of the perfusion was also similar in both groups. 
 
3.4.6 Immunohistochemical assessment of oxidative stress and tissue inflammation  
Immunohistochemical analysis showed that livers subjected to NMP alone expressed higher levels 
of tissue markers of oxidative injury and inflammation compared to those subjected to HOPE+NMP 
by the end of the perfusion run. Livers which had HOPE showed a significant reduction in 
expression of markers associated with mitochondrial ROS production (uncoupling protein 2; NMP 
ΔIRS: +1 vs. HOPE+NMP ΔIRS: –2, p = 0.02) and oxidative stress-mediated cellular injury 
(4HNE) expression reflecting lipid peroxidation (NMP ΔIRS: +1 vs. HOPE+NMP ΔIRS: –2, p = 
0.008). Both proteins were present predominantly in hepatocytes. Similarly, they showed decreased 
expression of CD14 at the end of the perfusion compared with commencement. A statistically 
significant opposite trend was seen for the livers perfused using NMP only (NMP ΔIRS: +3 vs. 
HOPE+NMP ΔIRS: –2, p = 0.008). The intensity of the tissue inflammatory response was shown 
by different patterns of non-parenchymal cell staining for CD11b which was present on 
polymorphonuclear leukocytes (neutrophils and monocytes/macrophages). There was a significant 
difference in its level of expression between the two groups throughout the perfusion (NMP ΔIRS: 
+3 vs. HOPE+NMP ΔIRS: –1, p = 0.02),  suggesting a potential beneficial effect of the combined 
protocol. Intrahepatic endothelial cells play a key role in reperfusion injury by promoting leukocyte 
adhesion and retention. To evaluate the (cytokine-mediated) activation of endothelial cells, the 
percentages positive areas of VCAM-1 staining were determined. VCAM-1 expression decreased 
in both groups, however this was more pronounced in livers that had undergone HOPE (NMP 





Figure 3.4: Immunohistochemical analysis for markers of reactive oxygen species 




Figure 3.4: Immunohistochemical analysis for markers of reactive oxygen species mediated 
damage and tissue inflammation. Upper row of each panel shows representative images for the 
HOPE+NMP group and the lower images for the NMP group respectively prior to and at the end of 
perfusion (t = 0 and t = 6 hours). Section A shows there was a consistent reduction in expression of 
markers for oxidative injury in the HOPE+NMP group as reflected by the immunoreactive score (IRS). 
Contrastingly an opposite trend was seen for the NMP livers over the course of the perfusion. (B) 
Markers indicative of activation of the inflammatory cascade also showing reduced expression by the 
end of perfusion in the HOPE+NMP group. Whilst VCAM 1 expression decreased in both groups it 
trended towards being more pronounced in livers that had undergone HOPE+NMP. Bold outside border 
white squares at the bottom of figures represents 50 µm and no border white squares 100 µm scaling 
respectively. Levels of significance: *p < 0.05 (Wilcoxon signed-rank test). 
 
3.5 Discussion 
Machine perfusion was developed to minimise damage during organ preservation and early 
clinical experience proved its superiority over SCS and positive impact on extended criteria 
liver utilisation (8, 12, 13, 22, 23). The two leading perfusion strategies, hypothermic and 
normothermic technique, have previously been viewed as diverse, or even competing, 
approaches each having advantages and disadvantages (24). In the present study, we compared 
a protocol which combined the two methods to evaluate whether the combination would 
provide the potential benefits of both. We found that initial HOPE perfusion promoted recovery 
of mitochondrial function, increased ATP energy stores and lowered tissue injury during 
subsequent NMP. Normothermic perfusion allowing viability assessment is seen by our group 
as an essential aspect of patient safety for transplantation of the highest-risk and / or currently 
unutilised livers. The combination of HOPE with NMP translated into the increased rate of 
functional recovery of livers pre-treated with HOPE compared to livers subjected to NMP 
alone.  
Our team became an early adopter of the NMP technique, and we observed that a proportion of 
livers failed to recover their function (12). Those poor-quality organs, often exposed to 
prolonged cold ischaemia times, were unable to maintain vascular flows, clear lactate or 




designed the combined perfusion to assess if this intervention would yield a superior functional 
recovery for the highest-risk discarded livers (7, 22, 24, 25). Our key objective in designing this 
experiment was to imitate the real-life situation where clinical decisions are required regarding 
transplantability of a clearly suboptimal liver upon its arrival to the transplant centre.  
Whilst the use of HOPE with subsequent NMP was reported by the Groningen group 
previously, their experiment was aimed at assessing benefit of HOPE compared to SCS and 
used the NMP phase to simulate in vivo reperfusion (26). In this scenario, the overall perfusion 
time on the device at the point of the functional assessment was beyond the certified scope of 
6-hour use, limiting its value for translation towards clinical adoption (26, 27).  
Our study represents a novel approach and shows unique data, being the first observations on 
human donor livers with viability assessment benchmarked by clinically used criteria (12, 28, 
29). Previous rodent models of ECD livers showed that a short period of HOPE was able to 
promote recovery of mitochondrial function, optimising oxygen utilisation and recovering 
cellular ATP energy stores (30, 31). HOPE was suggested to promote metabolism of the 
succinate accumulated during the ischaemic period under hypothermic conditions, 
subsequently diminishing the reversal flow of electron from the mitochondria and the 
production of ROS during the rewarming (32).  
Although there has been extensive mechanistic research using animal models, showing a 
downregulation in the tissue inflammatory responses, including activation of endothelial and 
resident immune cells of the liver, the evidence from human livers, especially those from the 
highest-risk donor pool, is very scarce (19, 24). In order to assess the extent of the injury 
developed during rewarming on the machine, we analysed numerous markers of non-




putative benefits of HOPE, in comparison to negligible changes or even an upregulation of 
detrimental processes observed during NMP perfusion alone (24, 32). We have shown changes 
in the mitochondrial respiratory rate during the HOPE phase of the combined perfusion group 
that correlated with lower activation of the inflammatory cascade and oxidative injury at the 
end of 6-hours of machine perfusion in comparison with NMP alone. Replacement of the 
perfusate, which may reduce toxic metabolites and detritus accumulated during the SCS and 
recirculating perfusate may also further enhance reduction of the tissue inflammatory response 
and injury in the HOPE+NMP group. The lack of the liver flush following the HOPE phase 
might alter the perfusion fluid constitution for the normothermic perfusion in the HOPE+NMP 
group; however, analysis of these minimal differences between the groups were beyond the 
scope of the present study (33, 34).  
NMP provides a near-physiological environment for the liver by supplying oxygen and 
nutrients at normothermic condition, enabling the organ functional assessment. Our previous 
work on end-ischaemic NMP of declined human livers allowed us to define the viability criteria 
employed for transplantation of discarded human livers (12, 28). Setting an endpoint of 
achieving the objective criteria already used in our unit for clinical transplantation is an 
important strength of this study, though we appreciate there does not yet exist a widely accepted 
consensus regarding parameters for organ viability assessment (17, 26, 35, 36). Lactate 
clearance to levels lower than 2.5 mmol/L is a principal parameter for viability criteria used at 
our unit. Whilst this marker is seen in our clinical practice as highly sensitive and specific 
parameter to predict early graft failure due to primary non-function, Watson et al. recently 
advocated transaminase levels in the perfusate and bile quality assessment, by the pH and 
glucose content, to be superior in terms of predicting late graft loss due to biliary complications 




advantage of HOPE perfusion being prevention of non-anastomotic biliary strictures in DCD 
livers, and these organs might benefit most from the combined protocol (7, 37). The presented 
data showed improved viability also in DBD livers. Despite the limited number of perfusions 
included in our study, all assays from the HOPE+NMP group consistently showed 
cytoprotective effects and superior parameters, including clinical viability criteria (a 
diagrammatic summary is presented in Figure 3.5). This was demonstrated by all HOPE+NMP 
organs achieving the viability criteria, whilst 40% (2/5) of organs perfused by NMP alone failed 


























Figure 3.5: Diagrammatic summary of the findings and proposal for the use of a 
combined protocol of ex situ machine perfusion encompassing hypothermic 
oxygenated perfusion (HOPE) and normothermic machine perfusion (NMP) for the 






Figure 3.5: Diagrammatic summary of the findings and proposal for the use of a combined 
protocol of ex situ machine perfusion encompassing hypothermic oxygenated perfusion (HOPE) 
and normothermic machine perfusion (NMP) for the recovery of extended criteria donor livers. 
The top panel of the diagram illustrates current clinical practice for standard or low-risk extended criteria 
organs which are preserved using the traditional static cold storage. The middle panel shows the 
potentially beneficial effects of each machine perfusion protocol. HOPE perfusion does not permit 
objective organ viability assessment, which limits its potential use for high-risk extended criteria donor 
livers. NMP does allow viability assessment prior to transplantation making this option extremely 
valuable for viability assessment of high-risk extended criteria albeit resulting in less ECD livers 
achieving transplantable criteria than the combined protocol described here. Finally, the bottom panel 
summarises the outcome and possible mechanistic benefits of the combined protocol studied importantly 
showing the cumulative benefits of combining both cold and warm perfusion. This is reflected by 
demonstrating a higher rescue of high-risk ECD livers in the HOPE+NMP group than NMP alone.    
 
The use of an acellular haemoglobin-based oxygen carrier was shown by our group and others 
to be a suitable alternative to the use of packed red cells in the context of NMP (16, 38). An 
acellular oxygen carrier-based fluid could be potentially used throughout the whole perfusion, 
avoiding any change of perfusate. Nevertheless, in logistic terms, the disconnection of the liver 
from the perfusion circuit for about 20 minutes, necessary to exchange the device perfusate, 
seemingly did not cause any measurable harm to the organs temporarily placed on ice. HOPE 
perfusion via portal vein only was previously shown to provide sufficient oxygenation for the 
entire liver, including the extra-hepatic biliary tree, without any need for manipulation of the 
hepatic artery at this stage (7, 24, 39).  
The feasibility of combining variant perfusion techniques has been suggested before, though 
the advantages, caveats and logistics aspects of different combinations are yet to be seen (40). 
The current study is the first to show a combined protocol of HOPE+NMP that might be easily 
adopted to clinical practice. A short-term HOPE phase would optimise mitochondrial oxidative 
function decreasing oxidative injury, downregulating inflammatory response with subsequent 
mitigation of the ischaemia reperfusion injury during NMP. Those factors together might be  
essential to minimise any damage and improve functional recovery in  the highest-risk ECD 




This approach differs from NMP preservation when the organs are exposed only to a very short 
period of ischaemia (23).The Liver Assist device enables variation of perfusion strategies in 
temperatures ranging from 10 °C to 37 C within the device-certified 6-hour timeframe. The 
presented study used 2 hours of HOPE and 4 hours of NMP, durations previously recommended 
by other groups, allowing use of a single perfusion kit and rendering the combined perfusion 
cost-effective (23, 26).   
The present study has some caveats. It is not a transplant model, as this would not be clinically 
possible in the UK at this early investigative stage. Whilst the reperfusion injury could be 
simulated by a subsequent NMP with whole blood, we opted to study the organ functional 
recovery only, and have applied our current viability criteria to define its potential 
transplantability. Those criteria have been used by our team in clinical trials to safely transplant 
discarded human livers, allowing us to compare the findings and predict transplantability and 
clinical relevance of our pre-clinical proof of concept studies (12, 29).  The use of discarded 
human livers for research confers the advantage of eliminating between-species variability, 
which is a limitation for animal models where the extrapolation of results to humans is 
questionable. The scarcity and intrinsic heterogeneity amongst discarded human livers, 
however, makes it difficult to achieve perfectly matched study groups.  
Using an acellular oxygen carrier fluid also precludes any direct comparison of our data with 
frequently published machine perfusion studies’ endpoints, including perfusate transaminases 
(23, 35, 36). The free haemoglobin concentration in the Hemopure®-based perfusate exceeded 
the maximum haemolytic index tolerance for our hospital clinical laboratory assessment, and 
we were unable to measure those subsequently by alternative methods from re-thawed frozen 
samples. As a similar perfusion fluid has already been used for clinical perfusions, however, 




In conclusion, this proof of concept study demonstrated that the combination of sequential 
HOPE and NMP is not only feasible, but that it may potentially improve the functional recovery 
of high-risk ECD livers compared with NMP alone. Whilst we do not suggest that this is an 
optimised protocol, this novel approach might be particularly beneficial for DCD organs. 
Further studies are needed to explore whether the combined protocol confers other benefits, 

















3.6.1 Complementary Methods 
3.6.1.1 Immunohistochemistry 
Immunohistochemistry was performed on parafin-embedded sections using the primary 
antibodies described below. Specie specific ImmPRESS™ (Peroxidase) Excel Amplified HRP 
Polymer Staining Kit detection was used for the staining. 
• anti-uncoupling protein 2 (UCP2) antibody (ab203244 – Abcam, Cambridge, UK) 
rabbit polyclonal at 1/600 dilution. 
• anti-4-hydroxynonenal (4-HNE) antibody (ab46545 – Abcam, Cambridge, UK) rabbit 
polyclonal at 1/200 dilution. 
• anti-cluster of differentiation 14 (CD14) antibody (ab36595 – Abcam, Cambridge, UK) 
mouse monoclonal at 1/500 dilution. 
• anti-vascular cell adhesion molecule 1 (VCAM-1) antibody (SAB1406579 - Sigma-
Aldrich Inc, St Louis, MO, USA) mouse polyclonal at 1/400 dilution. 
• anti-cluster of differentiation 11b (CD11b) antibody (ab52478 – Abcam, Cambridge, 
UK) rabbit monoclonal at 1/200 dilution. 
All sections were wholly digitalized using the Axio Scan.Z1. Four areas at a magnification of 
400x were randomly selected using the ZEN image analysis software. Areas of tissue edge were 
not included due to artefacts that could confound the analysis. Thereafter, the four random 
images were analysed for overall expression of the staining.   
3.6.1.2 Adenosine trisphosphate quantification 
Measurement of adenosine trisphosphate (ATP) levels was done accordingly with the following 




(0.372g EDTA in 130 mL ddH2O [adjusted to pH 10.9 with NaOH] = 370 mL of 96% Ethanol) 
using the GentleMacs system. Particulates were removed by centrifugation at 13,000xg. The 
protein concentration was determined in the supernatant with the use of a Pierce BCA Protein 
Assay kit (Thermo Fisher Scientific, Rockford, Illinois, USA) and the concentration adjusted 
to 300 µg/mL protein with the SONOP buffer. Samples were then diluted 10-fold in 100 µM 
phosphate buffer and ATP concentration determined using the ATP Bioluminescent Kit (FL-
AA - Sigma-Aldrich Inc, St Louis, MO, USA). Concentrations were determined from a 
calibration curve on the same plate, corrected for amount of protein and expressed as nmol/g 
protein. 
3.6.1.3. Oxygen content in the perfusate equation 
O2 content =  (pO2 × K)+(sO2 × Hb × c), pO2 in kPa, K equals 0.027 for O2 in water at 37 °C, 













3.6.2 Supplementary Table S3.1 
Table S3.1: Normothermic machine perfusion fluid constitution 
1000 mL (4 units) acellular oxygen haemoglobin carrier Hemopure®  
(haemoglobin glutamer-250-bovine; HBOC-201, Hemoglobin Oxygen Therapeutics LLC, 
Cambridge, MA) 
1000 mL 5% w/v human albumin solution (Alburex 5, CSL Behring GmbH, Germany) 
10,000 IU heparin (Wockhardt, UK) 
30 mL sodium bicarbonate 8.4% (B. Braun Medical Limited, UK) 
10 mL calcium gluconate 10% 
500 mg vancomycin (Wockhardt, UK) 
60 mg gentamicin (Cidomycin, Sanofi, UK) 
50 mL 10% v/v Aminoplasmal (B.Braun Medical Limited, UK) 
0.2 mL Cernevit (Baxter Healthcare Ltd., UK) 
0.1 mg phytomenadione (Konakion, Roche Products Ltd, UK) 
Epoprostenol (Flolan, GlaxoSmithKline, UK, 2 µg/mL) continuous infusion commencing at 4 
mL/hour 
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Background: Ex situ machine perfusion improves the metabolic parameters of donor livers, 
with reports of both hypothermic and normothermic approaches being used. However, 
combining both techniques may derive individual benefits. We investigated whether the use of 
an acellular haemoglobin-based oxygen carrier (HBOC)-based perfusate may facilitate this 
combination, the cold-to-warm machine perfusion. Methods: Ten discarded human donor 
livers were perfused for a total of 6 hours. Five in each group had: (1) 2 hours of hypothermic 
oxygenated perfusion (HOPE) using an oxygen carrier-free perfusate; followed by perfusate 
exchange and NMP with an HBOC-based perfusate; or (2) 2 hours of dual-hypothermic 
machine perfusion (D-HOPE) with sequential controlled oxygenated rewarming (COR) for 1 
hour and then NMP using the HBOC-based perfusate uninterruptedly throughout the perfusion 
(cold-to-warm group). Markers of liver function and tissue injury were investigated and 
compared between groups. Results: Donor characteristics were comparable. Methaemoglobin 
levels were constant during D-HOPE and increased during NMP similarly to the HOPE+NMP 
group, whereas it did not affect tissue oxygen delivery. Hypothermic perfusion phase 
downregulated mitochondrial respiration and increased adenosine triphosphate levels in both 
groups. The cold-to-warm group presented higher arterial vascular resistance during 
rewarming/NMP (0.2 [0.2–0.3] vs. 0.1 [0.1–0.2] mmHg/mL/min/kg, p = 0.03) with lower 
arterial flows (204 [155–230] vs. 318 [200–373] mL/min, p = 0.09). At the end of NMP tissue 
expression of markers of reactive oxygen species production (uncoupling protein-2), oxidative 
injury (4-Hydroxynonenal, CD14) and inflammation (CD11b, VCAM-1) were comparable 
between the groups. Conclusion: This study suggests that despite changes in vascular 
dynamics, the use of an HBOC-based perfusate uninterruptedly from cold to warm is feasible 




of hypothermic and normothermic perfusions, offering the possibility of controlled rewarming 
of the organ. 
4.2 Introduction 
Ex situ machine perfusion (MP) demonstrates superior preservation for extended criteria donor 
(ECD) livers compared to static cold storage and thus represents an option to safely expand 
their utilisation (1–3). The MP field has largely focused on oxygenated hypothermic MP 
(HMP) and normothermic MP (NMP) to date. 
Briefly, NMP provides full metabolic support for donor organs which limits ischaemia and 
allows assessment of their metabolic function prior to transplantation (4, 5). Whilst viability 
assessment is fundamental to increase safely ECD livers utilisation, standardised objective 
protocols for their assessment are lacking (4–6). Alternatively, HMP performed either via 
portal vein (PV) only (hypothermic oxygenated machine perfusion [HOPE]) or via hepatic 
artery (HA) and PV (dual hypothermic oxygenated machine perfusion [D-HOPE]) was shown 
to enhance mitochondrial oxidative function, mitigating tissue injury during reperfusion and 
replenishing cellular adenosine triphosphate (ATP) stores (7–9).  
Both MP techniques have reported benefits over standard static cold storage (3, 7, 8). There 
remains controversy as to whether markers of liver injury and function are comparable between 
HMP and NMP (5, 10). Our group has recently asserted that a combined protocol of HMP and 
NMP derives individual benefits of both techniques improving the metabolic parameters of 
ECD organs compared to NMP alone (11). In that study HOPE was performed using an oxygen 
carrier-free based perfusate, as at hypothermic temperatures, the supply of oxygen provided by 
diffusion is adequate to attend the reduced metabolic demand of the cells (9, 12); in addition, 
the use of red blood cells would not be possible owing to their risk of sludging at hypothermia 




metabolic demand of oxygen; and, therefore the perfusate was exchanged for an acellular, 
polymerised bovine haemoglobin-based oxygen carrier (HBOC) Hemopure® (hemoglobin 
glutamer-250 [bovine]; HBOC-201, Hemoglobin® Oxygen Therapeutics LLC, Cambridge, 
USA) based perfusate. Previous studies had reported the feasibility of using this compound in 
the setting of NMP and its advantages over red blood cells (14–16). Results showed that 
switching the perfusate from the HOPE to NMP phase in a combined perfusion protocol did 
not cause any harm to the liver. However, incorporating a single perfusate, compatible with 
perfusions over a range of temperatures, into the protocol would be a more feasible option as 
it would eliminate entirely any concerns of exposing the organ to additional unnecessary 
ischaemia time.   
In the present study we hypothesised that with initial cannulation of the HA and PV, also known 
as the D-HOPE technique for the hypothermic phase, and with the use of a single HBOC-based 
perfusate throughout the entire perfusion, we would completely eliminate any concerns of 
additional unnecessary ischaemia time and optimise the logistics of a combined perfusion, 
thereby, increasing its clinical applicability. In addition, it would allow gradual rewarming of 
the organs (controlled oxygenated rewarming [COR]), which has also been suggested to 
mitigate reperfusion injury and improve graft function post-transplantation (17, 18). The aim 
of this study was to investigate the feasibility of a combined protocol of D-HOPE with 
sequential slow COR and NMP using a single HBOC-based perfusate during the perfusion 
process and assess its impact on the functional recovery of the organs. 
4.3 Methods 
Ten discarded human livers were sequentially allocated to two experimental matched groups: 
(1) the HOPE+NMP group that had two hours of HOPE, using a Belzer MPS® UW Machine 




NMP employing an HBOC-based perfusate [previously published group (11)]; and (2) the 
cold-to-warm group — this group had an HBOC-based perfusate since starting at time 0 that 
permitted simplifying changes to the protocol: HA and PV were cannulated at starting and D-
HOPE was carried out for the hypothermic phase. Following this, the organs were gradually 
rewarmed (COR) and then had NMP for reperfusion and viability assessment. The total 
perfusion time was six hours for both groups. Perfusate, bile and tissue biopsies were sampled 
systematically. The detailed sampling protocol is presented in Figure 4.1.      
4.3.1 Source of discarded human livers 
All livers were retrieved with the intention of clinical transplantation according to the National 
Organ Retrieval Service standards. After the procurement, they were stored on ice in Belzer 
University of Wisconsin (UW®) Cold Storage Solution (Bridge to Life) and then rejected for 
transplantation by all transplant centres in the United Kingdom and offered for research. The 
study ethical approval was obtained by the London-Surrey Borders National Research Ethics 







Figure 4.1: Study design. 
 
Donor human livers had standard procurement, they were cold flushed and stored. Once rejected 
for transplantation, they were offered for research and consecutively allocated to the two 
experimental groups. Image A shows the protocol for the HOPE+NMP group, livers had 
hypothermic oxygenated perfusion (HOPE) using Belzer MPS® UW Machine Perfusion Solution 
for 2 hours. HOPE was performed at 10 °C via portal vein only, as represented on Image C. After 
2 hours the perfusate was changed to an acellular, haemoglobin-based oxygen carrier (HBOC) 
Hemopure® (HBOC-201, Hemoglobin® Oxygen Therapeutics LLC, Cambridge, USA) based 
perfusate for the rewarming and normothermic machine perfusion (NMP). The livers from the 
cold-to-warm group (Image B) were fully cannulated at the start of the perfusion, including portal 
vein, hepatic artery and common bile duct (Image D). They received an HBOC-based perfusate 
from time 0. For this group, the livers had 2 hours of dual hypothermic oxygenated perfusion (D-
HOPE) at 10 °C followed by 1 hour of slow rewarming to 20 °C (controlled oxygenated 
rewarming [COR]) and then NMP. Menghini and wedge biopsies were collected at time 0, 2 and 
6 hours (**) and immediately fixed in formalin or snap-frozen in liquid nitrogen. Blood gas 
analysis was carried out and perfusate was sampled at 30 min time intervals throughout. In 




4.3.2 Organ preparation and machine perfusion procedure 
After arrival at our centre the livers had a standard bench preparation as described elsewhere 
(19) followed by flushing with two litres of 5% glucose solution. The Liver Assist Device 
(Organ Assist, Groningen, Netherlands) was used for MP. The perfusate temperature and 
perfusion pressures were set by the operator as specified below. The measured flow rates and 
calculated resistances, as shown on the device’s display in real time, were recorded every 30 
minutes. 
4.3.2.1 Hypothermic oxygenated perfusion (HOPE) 
The HOPE phase was performed via PV only, using three litres of UW-MPS, with the 
temperature set at 10 °C. The target flow was 0.1 mL/min/g of liver with a maximum pressure 
of 3 mmHg. The target oxygen perfusate pressure (pO2) was 80–100 kPa. After 2 hours of 
HOPE, the perfusion was stopped, and the liver temporarily placed on ice. The system was then 
drained and subsequently refilled with the NMP perfusion solution. The HA and common bile 
duct were cannulated and the NMP perfusion commenced. The perfusion fluid exchange until 
the start of NMP took on average 20 minutes. 
4.3.2.2 Dual hypothermic oxygenated perfusion (D-HOPE) 
Before initiation of the perfusion the cystic duct was ligated, and the common bile duct 
cannulated with a 12 French biliary drain. The PV was cannulated with the designated cannula 
provided by the manufacturer and the coeliac trunk with a 16 French plastic tube. The D-HOPE 
perfusion was performed via PV and HA, using a perfusate consisted of 1000 mL (4 units) 
Hemopure® complemented with human albumin solution. Temperature was set at 10 C and 




The pressure on the HA was 20–25 mmHg and oxygen offered to achieve a pO2 of 60 kPa. 
After two hours of D-HOPE, livers were slowly rewarmed using the COR technique. 
4.3.2.3 Controlled oxygenated rewarming (COR) 
This phase was sequential to the D-HOPE period and lasted for 1 hour. At the beginning PV 
pressure was increased to 5 mmHg and HA pressure to 30 mmHg. The temperature was raised 
3 °C each 20 minutes during the period targeting 20 C until the end of 1 hour. At the beginning 
of this phase the HBOC-based perfusate was supplemented with antibiotics and other 
complements (specified in Supplementary Table S4.1). 
4.3.2.4 Normothermic machine perfusion (NMP) 
The perfusion fluid for the NMP phase was Hemopure®-based as detailed in Supplementary 
Table S4.1. The UW-MPS was changed for the NMP perfusate before commencement of the 
NMP for the HOPE+NMP group. The cold-to-warm group already had this perfusate 
circulating in the system and, therefore, there was no change. Both groups had, at the start of 
the NMP phase, a perfusate temperature of 20 C, pressures of 5 mmHg on the PV and 30 
mmHg on the HA. From there, the temperature was raised incrementally to 37 °C. The target 
of flow was 0.25 mL/min/g liver tissue on the arterial side and 0.75 mL/min/g liver tissue on 
the venous circuit. To achieve these flows, perfusion pressures on the device were adjusted 
between 30–50 mmHg (mean pressure) on the arterial side and 8–10 mmHg on the PV. pO2 
was set at 40 kPa in both groups at this phase.   
4.3.3 Assessment of liver metabolism 
Oxygen uptake was calculated during the HOPE perfusion (oxygen carrier-free based perfusate) 




based perfusate the oxygen consumption was calculated from the difference between the 
oxygen content after the oxygenator and return into the oxygenator in the venous circuit. 
Oxygen content was calculated as the sum of the free dissolved oxygen fraction to the 
haemoglobin-bound oxygen fraction (equation located in the supplementary methods) as 
described elsewhere (20). 
The recovery of appropriate liver metabolism was assessed during NMP by our unit’s published 
criteria. The major criterion was perfusate lactate levels < 2.5 mmol/L within 6 hours of 
perfusion, associated with the evidence of bile production, glucose consumption, stable 
vascular flows and homogeneous parenchymal perfusion (4, 21). 
4.3.4 Histopathological assessment of hepatocyte injury 
Liver biopsies obtained prior to and at the end of perfusion were immediately fixed in formalin, 
processed and embedded in paraffin. Thereafter, 4 μm sections were cut and stained with 
haematoxylin and eosin (H&E) as well as periodic acid-Schiff (PAS). H&E sections were semi-
quantitatively graded for ischaemic-type coagulative necrosis, macrovesicular steatosis (large 
lipid droplets filling up the hepatocytes and displacing the nucleus to the periphery) and pre-
existing liver disease. The PAS-stained sections were scored for the percentage of positive areas 
of glycogen, and the variation between the beginning and end of the perfusion was compared 
across groups. Histological assessment was blinded and conducted by an experienced liver 
transplant pathologist. 
4.3.5 Immunohistochemical assessment of oxidative stress and tissue inflammation  
Immunohistochemistry was performed on formalin-fixed parafin-embedded sections to assess 
surrogate markers of oxidative injury and tissue inflammation. The uncoupling protein 2 




from oxidative phosphorylation. Elevated UCP2 expression is associated with increased 
reactive oxygen species (ROS) production (22–24). Oxidative tissue injury was evaluated by 
the expression of the 4-hydroxynonenal (4-HNE), a product of lipid peroxidation in cells. For 
the assessment of tissue inflammation, we analysed the following markers: (1) cluster of 
differentiation (CD)14, a lipopolysaccharide receptor which is part of the toll-like receptor 4 
signalosome. It is essential for the recognition of ligands such as damage-associated molecular 
patterns known to be upregulated during ischaemia-reperfusion injury (25–27); (2) CD11b is 
an integrin on the surface of leukocytes; upregulation of its expression indicates activation of 
the cells by substances, including ROS (28, 29); and (3) the vascular cell adhesion molecule 1 
(VCAM-1), a cell adhesion molecule expressed in cytokine-activated endothelial cells that 
mediates leukocyte transendothelial migration. All primary antibodies were detected using 
specific ImmPRESS™ Excel Amplified HRP Polymer Staining kits (Vector Laboratories, 
Burlingame, CA, USA) specific to the respective mouse or rabbit immunoglobulin isotype. A 
list of primary antibodies and dilutions used is provided in the supplementary material. 
Four images of each section, excluding the edges, were randomly selected for analysis (400 
magnification). A semiquantitative scoring system, the modified immunoreactive score (IRS) 
(30), was obtained by multiplying the score for intensity (0: no colour reaction; 1: mild reaction; 
2: moderate reaction; 3: intense reaction) and distribution (0: no positive cells; 1: < 10% positive 
cells; 2: 10–50% positive cells; 3: 51–80% positive cells; 4: > 80% positive cells) to obtain a 
final score between 0 and 12. The change in overall tissue expression of staining (ΔIRS) was 
determined by subtracting the IRS scores after 6 hours of perfusion from the score prior to 
perfusion: negative values indicated a decrease and positive values an increase in the expression 
of staining. 




Quantification of ATP levels was carried out by homogenisation of liver tissue. The 
concentration was determined with the ATP Bioluminescent Assay kit (FLAA, Sigma-Aldrich 
Inc, St Louis, USA). More details are provided in the supplementary material. 
4.3.7 Statistical analysis 
Continuous variables were expressed as median with interquartile range (IQR) and categorical 
variables as the absolute number with percentage frequencies. Comparisons between groups 
were performed via Fisher’s exact test for categorical variables, the Mann–Whitney U test for 
independent continuous variables and the Wilcoxon signed-rank test for repeated measurements 
over time on the same sample. The statistical level of significance was set at p < 0.05. GraphPad 
Prism (version 6.04 for Windows, GraphPad Software, La Jolla, USA) software was employed 
for graph creation and all statistical analyses were performed on the Statistical Package for the 
Social Science version 22 software (IBM Corp, Armonk, NY). 
4.4 Results 
4.4.1 Donor demographics and organ characteristics 
The median donor age for all livers  was 54 years (IQR: 51–55), donor body mass index 31 
kg/m2 (24–36) and donor risk index 2.1 (2.0–2.6). Median cold ischaemia time was 663 minutes 
(510–712) and warm ischaemia time for donors after circulatory death (DCD) 8 minutes (7–
31). Detailed donor demographics and donor organ characteristics are presented in Table 4.1. 
Each experimental group had three DCD livers and the groups were comparable regarding 





Table 4.1: Donor demographics, liver characteristics and machine perfusion parameters. 
Liver number Cold-to-warm 1 Cold-to-warm 2 Cold-to-warm 3 Cold-to-warm 4 Cold-to-warm 5 HOPE+NMP 1 HOPE+NMP 2 HOPE+NMP 3 HOPE+NMP 4 HOPE+NMP 5 
Donor information 
Age 73 51 55 57 52 54 50 54 38 55 
Donor type DBD DCD DBD DCD DCD DCD DBD DBD DCD DCD 
Sex Male Male Male Female Female Male Female Female Male Female 
Height (cm) 164 189 172 160 160 179 158 170 183 160 
Bodyweight (kg) 90 76 85 70 90 123 60 87 85 90 
Body mass index (kg/m2) 33 21 29 27 35 38 24 30 25 35 
US - Donor risk index 2.0 2.1 2.0 2.5 2.9 2.5 2.0 1.9 1.8 3.0 
UK - donor liver index 1.4 1.8 1.1 1.9 2.1 1.8 1.1 1.0 1.8 1.9 
ET - donor risk index 2.0 2.7 2.0 2.5 2.8 2.9 2.2 1.9 2.3 2.8 
Peak ALT (IU/L) 33 74 72 135 81 189 14 271 37 741 
Days on ventilator 4 3 2 11 4 5 2 2 4 4 
Co-morbidities and risk history HTN Smoker Diabetes (type 2) Alcohol misuse Smoker, HTN 




Diabetes (type 1), 
Smoker 
Active Smoker HTN 
Cause of death HBD HBD ICH ICH HBD HBD ICH ICH ICH HBD 
Liver characteristics 
Liver weight (g) 1652 1900 1920 2140 1598 2600 1838 2060 1753 1935 
Donor warm ischaemic time (minutes) NA 8 NA 10 14 31 NA NA 42 8 
Cold ischaemia time (minutes) 532 645 793 430 934 497 682 491 660 510 
Retrieval location Regional Extra-zonal Extra-zonal Regional Extra-zonal Extra-zonal Extra-zonal Extra-zonal Extra-zonal Extra-zonal 
Reason for clinical rejection Donor cancer Steatosis Steatosis Steatosis Donor cancer Poor flush Steatosis Steatosis Poor flush Steatosis, poor flush 
Large droplets macrovesicular steatosis 
(paraffin sections) 
0% 0% 20% 40% 0% 10% 0% 15% 3% 30% 
Machine perfusion parameters 
Lactate (mmol/L)           
Highest 6.7 9.1 12.0 12.6 10.2 9.1 8.9 10.4 4.6 7.8 
Lowest 0.3 0.7 5.1 2.4 0.2 0.6 1.1 1.8 0.2 0.8 
At the end of 6-hour perfusion 0.3 0.7 6.3 2.4 0.2 0.6 1.1 1.8 0.2 0.8 
Total Bile production (g) 5.0 3.2 0.0 10.0 0.0 57.0 0.0 0.0 15.9 24 
Mean Arterial flow (mL/min) 92 102 132 77 127 292 299 234 152 398 
Mean Portal vein flow (mL/min) 636 619 390 322 451 1412 1523 1602 1406 1582 
Mean liver mass perfusion (mL/g/min) 0.4 0.4 0.3 0.2 0.4 0.7 1.0 0.9 0.9 1.0 
Viability criteria met  Yes Yes No Yes Yes Yes Yes Yes Yes Yes 
Abbreviations: HOPE: hypothermic oxygenated perfusion of the liver; NMP: Normothermic machine perfusion of the liver; DCD: donation after circulatory death; DBD: donation after brain death; US: 
United States; UK: United Kingdom; ET: Eurotransplant; ALT: alanine aminotransferase; HTN: hypertension; ICH: intracranial haemorrhage; HBD: hypoxic brain damage; NA: not applicable. Note: 
Donor warm ischaemic time was defined as the interval between the systolic blood pressure less than 50mmHg or/and arterial oxygen saturation to less than 70% to commencing the aortic cold perfusion 




Table 4.2: Donor demographics, liver characteristics and machine perfusion data. 
Abbreviations: NMP: normothermic machine perfusion of the liver; HOPE: hypothermic oxygenated 
perfusion of the liver; DCD: donation after circulatory death; UK: United Kingdom; ET: Eurotransplant; 
ALT: alanine aminotransferase; DBD: donation after brain death. 
Note: Continuous variables presented as median and interquartile range, dichotomous variables as 
absolute number and percentage. Donor warm ischaemic time was defined as the interval between the 
systolic blood pressure less than 50mmHg or/and arterial oxygen saturation to less than 70% to 





 Cold-to-Warm (n = 5) HOPE+NMP (n = 5) p-value 
Donor information 
Age, years 55 (52–57) 54 (46–54) 0.87 
DCD livers 3 (60%) 3 (60%) > 0.99 
Sex, male 3 (60%) 2 (40%) 0.53 
Height (cm) 164 (160–172) 179 (169–181) 0.11 
Bodyweight (kg) 85 (76–90) 90 (87–106) 0.98 
Body mass index 
(kg/m2) 
29 (27–33) 35 (30–37) 
0.73 
Donor risk index 2.1 (2.0–2.5) 2.5 (2.2–2.7) 0.20 
UK donor liver index 1.8 (1.2–2.0) 1.8 (1.0–1.8) 0.55 
ET donor risk index 2.5 (2.0–2.8) 2.3 (2.0–2.8) 0.84 
Peak ALT (IU/L) 74 (72–81) 189 (37–271) 0.18 
Days on ventilator 4 (3–4) 4 (2–4) 0.45 
Liver characteristics 
Liver weight (g) 1900 (1749–2020) 1935 (1838–2060) 0.58 
Donor warm ischaemic 
time (minutes) 
8 (6–11) 31 (19–36) 
0.10 
Cold ischaemia time 
(minutes), DCD 
705 (537–789) 682 (586–708) 
0.86 
Cold ischaemia time 
(minutes), DBD 




0 (0–30) 10 (1–22) 
0.97 
Machine perfusion parameters 
Lactate (mmol/L)    
Highest 10.2 (9.1–12.0) 8.9 (7.8–9.1) 0.37 
Lowest 0.7 (0.3–2.4) 0.8 (0.6–1.1) 0.45 
Last 0.7 (0.3–2.4) 0.8 (0.6–1.1) 0.45 
Total Bile production 
(g) 





4.4.2 Stability of an HBOC-based perfusate at variable temperatures 
Haemoglobin levels of the HBOC-perfusate were comparable between the start and end 
of the hypothermic phase (D-HOPE) (53.2 [44.7–65.6] vs. 52.8 [42.5–64.7] g/dL, p = 
0.59). At the beginning of the COR phase, the supplements were added to the HBOC-
based perfusate and a dilutional effect was observed between 2 and 3 hours. The median 
haemoglobin levels were similar at the end of NMP between the groups (HOPE+NMP 
46.7 [42.9–47.7] vs. cold-to-warm 47.5 [38.2–50.4] g/dL). Methaemoglobin (MetHb) 
levels were stable during the D-HOPE and COR phases and then rose with the rewarming/ 
NMP phase. Despite this trend the levels of oxygen saturation were constant. Details are 
found in Figure 4.2. 
4.4.3 The effectiveness of an HBOC-based perfusate on mitochondrial respiration 
and energy replenishing during the hypothermic phase 
During the HOPE phase, the livers exhibited down regulation of mitochondrial respiration 
with a decrease in the oxygen uptake rate and CO2 release in the perfusate. Similarly, 
during D-HOPE, the livers presented a fall in oxygen consumption rate from time 0 to 2 
hours (26810 [23466–30154] vs. 12399 [11062–44705] mLO2/min/kg liver, p = 0.10) 
with a drop in pCO2 levels, reaching similar levels at 2 hours (HOPE+NMP 0.8 [0.6–1.0] 
vs. cold-to-warm 1.2 [1.0–1.7] kPa, p = 0.28). Pre-perfusion ATP levels were comparable 
between groups (p > 0.99). At the end of the 2 hours HMP, it increased 1.8-fold in the 







Figure 4.2: Stability of HBOC-201-based perfusate at different temperatures and its 
impact on mitochondrial function at hypothermic temperatures. 
 
Panel A shows on the left-hand graph that haemoglobin levels were stable during the D-HOPE 
phase, and after rewarming, they were similar to the HOPE+NMP group that received fresh 
HBOC-based perfusate.  Methaemoglobin levels (middle graph) were stable during D-HOPE and 
increased slowly during the rewarming, reaching comparable levels to the HOPE+NMP group 
during the normothermic phase. Despite the increase in the levels of methaemoglobin, arterial 
oxygen saturation was constant throughout the perfusion. Panel B compares markers of 
mitochondrial respiration between the study groups. Both groups presented a downward trend in 
oxygen requirements (oxygen uptake—HOPE+NMP group and oxygen consumption—cold-to-
warm group), with a similar drop in the release of carbon dioxide (CO2) in the perfusate. 
Reflecting an efficient mitochondrial oxidative function, both groups replenished adenosine 
trisphosphate (ATP) stores during the hypothermic phase. In the graphs, dots represent individual 
organs at the time points, and the line is the median of the values for each group. For the bar 




4.4.4 The effect of hypothermic perfusion on the rewarming and the normothermic phase 
During the COR phase, oxygen consumption increased slightly and reached 40641 
mLO2/min/kg liver (36576–44705). After rewarming, during the NMP phase, despite not being 
statistically significant, the peak of oxygen consumption was higher for the cold-to-warm group 
(138603 [52261–149192] vs. 75883 [59226–89717] mLO2/min/kg, p = 0.22). The CO2 levels 
increased steadily for the cold-to-warm during the NMP phase and were stable for the 
HOPE+NMP group. At the end of the perfusion run, the levels of ATP increased 2.7-fold in the 
















Figure 4.3: Mitochondrial and hepatic functional markers during the normothermic phase. 
 
Panel A shows a similar incremental rate of oxygen consumption during the rewarming period, 
which finally culminated in a higher peak at the beginning of the normothermic phase for the 
cold-to-warm group. The rate of carbon dioxide (CO2) release in the perfusate followed a similar 
trend to the oxygen consumption, and the adenosine triphosphate (ATP) levels reached higher 
figures at the end of the 6 hours of perfusion in the cold-to-warm group than with the 
HOPE+NMP. Panel B represents parameters of metabolic function of the organs during the 
perfusion. During the hypothermic phase, lactate levels increased slightly for the livers that had 
D-HOPE and were constant throughout HOPE. After rewarming, the lactate peak was comparable 
between groups, and then the lactate clearance was more effective in the cold-to-warm group 
resulting in similar levels at the end of the perfusion. There was evidence of gluconeogenesis at 
the beginning of the D-HOPE perfusion, and thereafter the organs start to consume glucose during 
the NMP phase. For the HOPE+NMP group, there was a sudden drop related to perfusate change 
at 2-hour perfusion and then the livers start to metabolise glucose during the NMP phase. 
Perfusate pH was similar between groups during the perfusion. Three livers in each group 
produced bile along the perfusion (Panel C). The bile pH was comparable between them, as was 
the glucose content. In the graphs, dots represent individual organs at the time points, and the line 
is the median of the values for each group. For the bar graph, the median and interquartile range 




4.4.5 Vascular flow dynamics 
Median flow rate on the HA for the cold-to-warm at the beginning of the HMP phase was 42 
mL/min (24–89) and it reached 54 mL/min (19–70) at the end of this phase. Those figures were 
similar during the COR phase (59 mL/min [55–118]). During the NMP phase, at 4 and 4.5 hours 
of perfusion, there was a trend of higher arterial flows on the HOPE+NMP group (p = 0.09 and 
p = 0.06, respectively). As appropriate arterial flows (0.25 mL/g liver) were achieved the 
pressure were not further increased to the maximum of 50 mmHg, as it was done for the cold-
to-warm group. Despite this adjustment, the perfusion pressures during NMP phase were 
similar between the experimental groups along the perfusion (p = 0.22). At the end of the NMP 
the median flow rates were comparable between the groups (HOPE+NMP 365 [256–388] vs. 
cold-to-warm 310 [250–332] mL/min). 
Median arterial vascular resistances were high during D-HOPE (0.3 mmHg/mL/min/kg) and 
decreased slightly during the COR phase (0.2 mmHg/mL/min/kg). When arterial perfusion was 
started in the HOPE+NMP group, HA vascular resistance was lower than in the cold-to-warm 
(0.2 [0.1–0.3] vs. 0.4 [0.3–0.7] mmHg/mL/min/kg, p = 0.03). It remained significantly lower in 
the HOPE+NMP group until 5 hours of perfusion and then decreased for the cold-to-warm 
group, reaching a non-significant difference at the end of the normothermic phase (0.1 [0.1–
0.2] vs. 0.2 [0.1–0.2] mmHg/mL/min/kg, p = 0.22).  
A maximum portal venous pressure of 5 mmHg was used for the cold-to-warm group to 
increase the flows, because the vascular resistance was higher (Figure 4.4). This was kept at 3 
mmHg for the HOPE+NMP group. The difference in flow in the PV did not reach statistical 
significance; however, values were higher for the HOPE+NMP group at the beginning of the 




[125–305] mL/min). At the end of the NMP both groups had adequate PV flow (HOPE+NMP 
1740 [1140–1675] vs. cold-to-warm 1600 [1210–1740] mL/min). Figure 4.4 portrays the 
vascular flow and resistance over the time of the perfusion. 
 
 
Figure 4.4: Vascular parameters throughout the perfusion protocols. 
 
Panel A shows hepatic artery vascular parameters. The flow was higher for the HOPE+NMP group, 
despite slightly higher pressures used for the cold-to-warm group in an attempt to overcome the higher 
vascular resistance. A similar trend was seen for the portal vein vascular parameters (Panel B). The cold-
to-warm group had higher vascular resistance mainly during the hypothermic phase, which improved 
during the rewarming. The higher vascular resistance required increases in the perfusion pressures, 
although the vascular flows were still lower during the initial period of the NMP phase. In the graphs, 








4.4.6 Assessment of metabolic parameters during normothermic machine perfusion 
Perfusate lactate levels were similar at the start of the perfusion (HOPE+NMP 4.7 [2.5–7.4] vs. 
cold-to-warm 6.6 [4.9–9.1] mmol/L, p = 0.31). Those levels were constant for the HOPE+NMP 
group and increased for the cold-to-warm group, reaching higher levels at the end of the 
hypothermic phase (5.5 [2.4–6.9] vs. 9.8 [7.5–11.3] mmol/L, p = 0.01). After rewarming, the 
lactate peak was similar between groups (HOPE+NMP 9.1 [5.7–10.0] vs. cold-to-warm 10.2 
[7.9–12.3] mmol/L, p = 0.55). Both groups metabolised lactate effectively at rewarming and 
NMP achieving comparable figures at the end of the perfusion (HOPE+NMP 0.8 [0.3–1.4] vs. 
cold-to-warm 0.7 [0.2–1.4] mmol/L, p = 0.84).  
Venous perfusate glucose was also comparable between groups at the commencement of the 
hypothermic phase (HOPE+NMP 10.3 [9.6–10.1] vs. cold-to-warm 11.6 [11.2–12.6] mmol/L, 
p > 0.99). It increased significantly in the cold-to-warm and reached higher levels at the end of 
this phase (17.9 [12.7–23.7] vs. 40.0 [18.1–40.0] mmol/L, p = 0.07). For the HOPE+NMP 
group, there was a slow concentration increase during the hypothermic phase and then a drop 
(related to the perfusate fluid replacement). After 2 hours of NMP, the livers started to consume 
glucose from the perfusate and both groups reached similar figures at the end of 6 hours 
perfusion (HOPE+NMP 27.1 [14.1–40.0]  vs. cold-to-warm 24.5 [21.9–31.8] mmol/L, p = 
0.15). Perfusate pH levels were comparable between both groups throughout the entire 
perfusion. Bile production at 6 hours of perfusion was similar for both groups (HOPE+NMP 
5.2 mL/kg liver vs. cold-to-warm 3.2 mL/kg liver). Figure 4.3 outlines these results in further 
detail. 
Finally, all five livers submitted to the HOPE+NMP protocol were deemed viable at the end of 




was from a 55-year-old brain stem dead donor with a donor risk index of 2.0 and more than 13 
hours of cold ischemia time. Information surrounding the fulfilment of the viability criteria are 
presented in Table 4.3. 
 
Table 4.3: Viability criteria achievement by the livers in each group. 
Criteria 
Cold-to-Warm 
(n = 5) 
HOPE+NMP 
(n = 5) 
Lactate clearance (≤ 2.5 mmol/L) 4 (80%) 5 (100%) 
pH > 7.3 perfusate 4 (80%) 2 (40%) 
Glucose metabolism 3 (60%) 4 (80%) 
HA flow (> 150 mL/min) 5 (100%) 5 (100%) 
PV flow (> 500 mL/min) 5 (100%) 5 (100%) 
Homogeneous perfusion/ soft parenchyma 5 (100%) 5 (100%) 
Bile production 3 (60%) 3 (60%) 
Viable liver 4 (80%) 5 (100%) 
Abbreviations: HOPE: hypothermic oxygenated perfusion of the liver; NMP: Normothermic machine perfusion 
of the liver; HA: hepatic artery; PV: portal vein 
 
4.4.7 Histological assessment  
Histologically there were no signs of pre-existing acute or chronic liver disease at the beginning 
of the perfusion in both groups. In terms of severity of macrovesicular steatosis two livers in 
the HOPE+NMP were mildly steatotic (5–30%) and two were moderately steatotic (30–60%) 
in the cold-to-warm group. All the other organs were non-steatotic (< 5%). At the end of the 6 
hours of perfusion, none of the livers exhibited areas of parenchymal necrosis, congestion or 




Figure 4.5: Histological assessment of the perfused organs. 
Panel A shows two haematoxylin–eosin (H&E)-stained paraffin sections at the end of the 
perfusion run. The left-hand picture is a large portal tract showing well preserved bile duct 
(arrow), artery (circle) and portal vein (arrowhead). A similar picture was seen for smaller 
intrahepatic portal tracts in the right-hand picture, where the same well-preserved structures can 
be identified; and, interestingly, the presence of the HBOC-based perfusate can be visualized 
(asterisk) in the vein, artery and even in the sinusoids. Panel B shows the change in glycogen 
content over time. The first figure on the left shows one liver from the cold-to-warm group at time 
0 with severely depleted glycogen stores; at the end of 6 hours of perfusion, this was slightly 




4.4.8 Immunohistochemical assessment of oxidative stress and tissue inflammation 
The expression of tissue markers of oxidative injury and activation of inflammatory cells were 
comparable for the two groups at the start of the perfusion. During the 6 hours of perfusion, 
there was an overall decrease in the tissue expression of UCP2, a marker associated with 
mitochondrial ROS production, (HOPE+NMP ΔIRS: –2.0 [IQR: –2.5/ –0.5] vs. cold-to-warm 
ΔIRS: –1.0 [–2.7/ 2.2], p = 0.48) and 4-HNE, a product of the lipid peroxidation of cells 
(HOPE+NMP ΔIRS: –2.0 [–2.0/ –1.5] vs. cold-to-warm ΔIRS: –1.5 [–2.0/ –1.0], p = 0.43). 
These markers were present mainly in hepatocytes. Considering downstream activation of the 
inflammatory cascade, the expression of CD14, part of the signalosome of the toll-like receptor 
4, decreased in the HOPE+NMP group and was stable for the cold-to-warm, however, the 
difference was not statistically significant (ΔIRS: –2.0 [–3.5/ –1.0] vs. ΔIRS: 0 [–1.5/ 0], p = 
0.08). Tissue inflammatory response was assessed by the expression of CD11b on activated 
polymorphonuclear leukocytes (neutrophils and monocytes/macrophages) and VCAM-1. Its 
levels of expression decreased similarly between the two groups for both CD11b (HOPE+NMP 
ΔIRS: –1.0 [–2.5/ –0.5] vs. cold-to-warm ΔIRS: –1.0 [–1.7/ –1.0], p = 0.80) and VCAM-1 
(HOPE+NMP ΔIRS: –1.0 [–2.0/ –1.0] vs. cold-to-warm ΔIRS: –1.5 [–2.0/ –1.0], p = 0.85). 









Figure 4.6: Immunohistochemical assessment of oxidative tissue injury and activation of the 
inflammatory cascade. 
 
Panel A shows the tissue expression of the uncoupling protein 2, a marker for reactive oxygen 
species (ROS) generation; the left-hand picture shows a moderate diffuse reaction of the staining 
at time 0, mainly localised at peri-portal areas, which changed to a mild reaction at the end of the 
6 hours perfusion. The graph on the right shows the variation in the two groups at these time 
points. This downregulation in ROS production is associated with a reduction in tissue expression 
of 4-hydroxynonenal (4-HNE) (Panel B), an established marker for lipid peroxidation during 
oxidative stress. The lowered oxidative injury decreases the tissue expression of the cluster of 




CD14 is part of the signalosome of the toll-like receptor 4, which in turn leads to the activation of 
inflammatory and endothelial cells, perpetuating and aggravating tissue injury. In accordance, a 
downward trend can be seen during the perfusion in the presence of activated leukocytes, identified by 
the expression of the CD11b (Panel D) and activated endothelial cells, as represented by the expression 
of the vascular cell adhesion molecule 1 (VCAM-1) (Panel E). Therefore, both combined protocols 
exhibited a similar decreasing trend in the expression of markers of ischaemia-reperfusion injury during 
the perfusion. In the graphs, dots represent individual organs at the time points, and the line is the median 
of the values for each group. 
 
4.5 Discussion 
In the present study we have shown the feasibility of using an HBOC-based perfusate for a 
combined protocol of cold to warm ex situ MP. Whilst the use of a single perfusate throughout 
the entire perfusion simplified the logistics of combining HMP and NMP with a slow and 
controlled rewarming period, it was associated with high vascular resistance and low flow 
dynamics. However, this difference did not affect either tissue oxygenation or the enhancement 
of the bioenergetic status of the organs during the hypothermic phase and allowed effective 
recovery of the metabolic function of the organs during the normothermic phase.    
Our group has recently shown that the combination of a short-term period of HOPE can improve 
the metabolic parameters of discarded high-risk ECD livers, as evaluated by a subsequent 
period of NMP (11). Whilst HMP replenishes cellular energy stores and mitigates ischaemia-
reperfusion injury, NMP offers full metabolic support to donor organs allowing metabolic 
function assessment. Importantly, tests to assess liver function during HMP are still not readily 
available. The use of nuclear magnetic resonance spectroscopy to determine the bioenergetic 
status of organs during perfusion or to analyse perfusate composition are possibilities to be 
further investigated (9, 31, 32). The inability to utilise a red blood cells-based perfusate during 
HMP as well as the need for an oxygen carrier during NMP impose the need for a perfusate 




the advantage that it can potentially be used under a wide range of temperatures with reports on 
subnormothermic MP at 20 C and NMP (14, 16).  
A previous study that performed D-HOPE on human livers using UW-MP as perfusate reported, 
at 2 hours of perfusion, median flows of 365 mL/min for PV and 84 mL/min for HA (8). Our 
experiments utilised the same perfusion device and applied the same protocol in terms of 
perfusion pressures and temperature for the D-HOPE phase. However, using an HBOC-based 
perfusate we accomplished lower median vascular flows at 2 hours of D-HOPE (150 mL/min 
and 42 mL/min, respectively). Median vascular arterial resistance at the same time point was 
proportionally higher for the livers of our experiment (0.4 mmHg/mL/min/kg) than with this 
previous study (approximately 0.2 mmHg/mL/min/kg). These findings suggest a possible 
association between the use of an HBOC-based perfusate at 10 °C, higher vascular resistance 
and reduced flow. 
The association between HBOC and impaired microcirculation has been reported previously 
and diverse theories were proposed in an attempt to explain this (33). It has been suggested that, 
based on their small size, HBOCs molecules may be able to permeate into the subendothelial 
space and acellular haemoglobin consumes the nitric oxide (NO) produced by endothelial cells, 
thereby preventing its biological vasodilatory effect (34, 35). Alternatively, the low viscosity 
of HBOCs may affect the regulation of flow within the microcirculation (36, 37). 
Mechanistically, the lower shear stress may potentially decrease the production of NO and, 
therefore, have an impact of vasoconstriction (33, 38). Finally, the autoregulatory theory 
proposes that terminal arterioles adjust flow according to needs based on PO2 levels (39, 40). 
HBOC would potentially be delivering high concentrations of oxygen at this site paradoxically 
triggering vasoconstriction. Whether these theories explain the effect observed in our study 




HOPE study (60 kPa) (8) was the same as that for our HBOC-based perfusate. However, we do 
not have comparative data regarding the amount of oxygen delivered at the level of terminal 
arterioles in each of these models. In addition, in this study we are unable to comment on the 
difference in viscosity between Hemopure® and UW-MP at 10 °C. Thus far, the theory that 
acellular haemoglobin scavenges the NO produced in the subendothelial space remains 
plausible; however, MetHb levels were stable during HMP, contrary to what would be expected 
— NO binds to the oxygen sites in haemoglobin, thus generating MetHb.  
More importantly, despite these differences in vascular parameters, the enhanced oxygen 
delivery of the HBOC is likely to have balanced it because adequate oxygen supply was offered 
to the cells. Both groups showed a reduction in mitochondrial respiration, as represented by a 
fall in the oxygen requirements associated with lowered CO2 production during the hypothermic 
phase. These findings were associated with enhanced mitochondrial oxidative function and 
ATP synthesis. This improved mitochondrial oxidative function resulted in lower oxidative 
tissue injury and activation of inflammatory cells mitigating reperfusion injury during 
rewarming. Similar findings were reported previously using HOPE and D-HOPE techniques 
without the use of an oxygen carrier in the perfusate (8, 9). The initial lactate levels differed 
slightly between groups at the beginning of the perfusion as a result of different perfusate 
composition. Whilst those levels were flat during HOPE, they increased slightly during the first 
hour of D-HOPE. A similar initial trend was described in previous publications (7, 8). 
Importantly, this initial elevation is most likely related to the initial flush out of the organs 
because in isolation, without other markers of reduced perfusion, lactate does not reflect 
anaerobic metabolism. 
Previous clinical studies have reported minor increases in MetHb levels after transfusion of 




oxygen and has a reduced ability to release oxygen to tissues (43). Physiologically, 
erythrocytes’ enzymes reduce the MetHb formed, keeping levels lower than 2% (44). 
Clinically, levels under 15% are only associated with a greyish skin without further 
complications (43, 44). In the context of MP, a previous report on a porcine model showed 
stable MetHb levels around 2% during subnormothermic MP (16). We established similarly 
stable levels during HMP and rewarming, nevertheless, during NMP, MetHb levels increased 
steadily at a similar rate for both groups, reaching median levels of around 7% at the end of the 
perfusion. Despite this increase, there was no suggestion of any ischaemic injury to the livers 
until 6 hours of perfusion. 
To explore fully the advantages of having a perfusate that could be used in a wide range of 
temperatures, we incorporate a COR period in the HBOC-based perfusate group. This technique 
permits avoiding subtle changes in the temperature of the organs and was shown to be beneficial 
for mitochondrial function yielding optimized results in a clinical study (17). We have 
employed the same protocol as that clinical study in our experiments, with the difference of the 
HBOC-based perfusate instead of the Custodiol-N (Dr. Köhler Chemie, Bensheim, Germany) 
used by the original authors. During this phase, no significant differences were seen in terms of 
perfusion parameters or liver metabolism features.  
The current work has also shown that while an oxygen carrier-free-based perfusate was equally 
effective during the hypothermic phase, it is feasible to use a single HBOC-based perfusate 
within a range of temperatures in the setting of MP of donor livers. This can be logistically 
advantageous considering the combination of HMP and NMP techniques, because it eliminates 
the need for perfusate exchange and can increase the clinical applicability of the combined 
protocol. Despite an effect on flow dynamics with higher vascular resistances and lower flows, 




effects to the organs. Such findings facilitate and support the safety of the use of a combined 
protocol of MP that can improve the metabolic functions of high-risk discarded ECD livers. 
The Groningen group recently reported the transplantation of one donor liver after performing 
a similar protocol of D-HOPE+COR+NMP using a single HBOC-based perfusate (45). The 
authors perfused 3 donor livers discarded for transplantation performing D-HOPE followed by 
COR and then assessed organ function within 150 minutes of NMP. Only one organ was 
deemed viable and transplanted with the recipient doing well after 3 months of transplantation. 
The authors conclude that combination of these perfusions using a single HBOC-based 
perfusate is feasible (45). 
The present study does have limitations. First, the organs were not transplanted, therefore 
viability remains theoretical, and the singularity of human donor livers makes the experimental 
groups imperfectly matched. The uninterrupted cold-to-warm MP protocol using an HBOC-
based perfusate was compared with a previously published combination of HMP+NMP, and 
the differences in the perfusate composition and technique employed limited isolated 
comparison of HMP techniques exclusively. We were unable to evaluate transaminases in the 
perfusate, traditionally used as markers of hepatocellular injury, because our clinical 
laboratories could not perform the analysis and we could not retrieve reliable concentrations 
from rethawed frozen samples. Moreover, the absolute values and proportional ATP increase 
were lower than those reported by other studies performing D-HOPE on human livers (8). This 
is most likely related to a longer cold ischaemia time in our study, because this can 





This study shows that despite changes in flow dynamics and vascular resistance, the use of an 
HBOC-based perfusate in a wide range of temperatures during ex situ MP of the liver is feasible 
and not deleterious to the organs. The use of a single perfusate facilitated the combination of 
HMP and NMP in an uninterrupted fashion, from cold to warm. It eliminates entirely any 
concerns of exposing the organs to additional unnecessary ischaemia time required for perfusate 
exchange and thus increases the clinical applicability of the combined protocol of hypothermic 
and normothermic perfusions. This approach, in turn, can finally enhance the rescue of 


















4.7.1 Supplementary Methods 
4.7.1.1 Immunohistochemistry 
Immunohistochemistry was performed on parafin-embedded sections using Specie specific 
ImmPRESS™ (Peroxidase) Excel Amplified HRP Polymer Staining Kit. The primary 
antibodies used were: 
• anti-uncoupling protein 2 (UCP2) antibody (ab203244 – Abcam, Cambridge, UK) 
rabbit polyclonal at 1/600 dilution. 
• anti-cluster of differentiation 14 (CD14) antibody (ab36595 – Abcam, Cambridge, 
UK) mouse monoclonal at 1/500 dilution. 
• anti-cluster of differentiation 11b (CD11b) antibody (ab52478 – Abcam, Cambridge, 
UK) rabbit monoclonal at 1/200 dilution. 
• anti-4-hydroxynonenal (4-HNE) antibody (ab46545; Abcam, Cambridge, MA, USA) 
rabbit polyclonal IgG at 1:200 dilution. 
• anti-vascular cell adhesion molecule 1 (VCAM-1) antibody (SAB1406579 - Sigma-
Aldrich Inc, St Louis, MO, USA) mouse polyclonal at 1/400 dilution. 
All sections were wholly digitalized using the Axio Scan.Z1. Four areas at a magnification of 
400x were randomly selected using the ZEN image analysis software. Areas of tissue edge 
were not included due to artefacts that could confound the analysis. Thereafter, the four 
random images were analysed for overall expression of the staining.   
 
4.7.1.2 Adenosine trisphosphate quantification 
Adenosine trisphosphate (ATP) concentration was determined using the ATP Bioluminescent 




liver tissue was immediately homogenised in 1 mL SONOP Buffer (0.372g EDTA in 130 mL 
ddH2O [adjusted to pH 10.9 with NaOH] = 370 mL of 96% Ethanol) using the GentleMacs 
system. Particulates were removed by centrifugation at 13,000xg. The protein concentration 
was determined in the supernatant with the use of a Pierce BCA Protein Assay kit (Thermo 
Fisher Scientific, Rockford, Illinois, USA) and the concentration adjusted to 300 µg/mL 
protein with the SONOP buffer. Samples were then diluted 10-fold in 100 µM phosphate 
buffer and then the ATP concentration determined. Concentrations were determined from a 
calibration curve on the same plate, corrected for amount of protein and expressed as nmol/g 
protein. 
 
4.7.1.3 Oxygen content in the perfusate equation 
O2 content =  (pO2 × K)+(sO2 × Hb × c), pO2 in kPa, K equals 0.027 for O2 in water at 37 °C, 















4.7.1.4 Supplementary Table S4.1 
Table S4.1: Machine perfusion fluid constitution 
1000 mL (4 units) acellular oxygen haemoglobin carrier Hemopure®  
(haemoglobin glutamer-250-bovine; HBOC-201, Hemoglobin Oxygen Therapeutics LLC, 
Cambridge, MA) 
1000 mL 5% w/v human albumin solution (Alburex 5, CSL Behring GmbH, Germany) 
10000 IU heparin (Wockhardt, UK) 
30 mL sodium bicarbonate 8.4% (B. Braun Medical Limited, UK) 
10 mL calcium gluconate 10% 
500 mg vancomycin (Wockhardt, UK) 
60 mg gentamicin (Cidomycin, Sanofi, UK) 
50 mL 10% v/v Aminoplasmal (B.Braun Medical Limited, UK) 
0.2 mL Cernevit (Baxter Healthcare Ltd., UK) 
0.1 mg phytomenadione (Konakion, Roche Products Ltd, UK) 
Epoprostenol (Flolan, GlaxoSmithKline, UK, 2 µg/mL) continuous infusion commencing at 
4 mL/hour 
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Longstanding research has shown that increased lipid content in donor livers is associated with 
inferior graft outcomes post-transplantation. The global epidemic that is obesity has increased 
the prevalence of steatosis in organ donors, to the extent that it has become one of the main 
reasons for declining livers for transplantation. Consequently, it is one of the major culprits 
behind the discrepancy between the number of donor livers offered for transplantation and 
those that go on to be transplanted. Steatotic livers are characterised by poor microcirculation, 
depleted energy stores due to an impaired capacity for mitochondrial recovery and a propensity 
for an exaggerated inflammatory response following reperfusion injury culminating in poorer 
graft function postoperatively. Ex situ machine perfusion, currently a novel method in graft 
preservation is showing great promise in providing a tool for the recovery and reconditioning 
of marginal livers. Hence, reconditioning these steatotic livers using machine perfusion has the 
potential to increase the number of liver transplants performed. In this review, we consider the 
problematic issues associated with fatty livers in the realm of transplantation and discuss 
pharmacological and non-pharmacological options that are being developed to enhance 






Liver transplantation (LT) is currently the only curative option for end-stage liver disease, or 
cirrhosis, and early-stage hepatocellular carcinoma (1, 2). However, there is a continuing 
discrepancy between organ availability and quality and the ever-increasing number of patients 
eligible for LT (3–6). One potential method to bridge this discrepancy is the increased 
utilisation of extended-criteria donors (ECD) or marginal donors (3). These donor livers include 
fatty livers/steatotic livers (referred to as steatotic livers hereafter), donors with advanced age, 
donor livers with prolonged cold ischaemia times (CIT) and donation after circulatory death 
(DCD). Transplantation of ECD livers is associated with a higher incidence of graft 
dysfunction, including primary graft non-function (PNF), and inferior patient survival after LT 
(5, 7, 8). Recently ex situ machine perfusion (MP) of ECD livers has generated considerable 
interest with early preclinical and clinical series suggesting it may improve organ preservation, 
as well as allowing real-time organ function assessment (9, 10).  Indeed, many in the transplant 
community are suggesting that MP may be a potential method to increase the donor pool (11). 
Importantly, steatosis is the primary reason for declining donor livers in the United Kingdom 
as it is in other countries (12, 13).  Hence the potential use of MP to reduce steatosis in donor 
livers and/or improve its metabolic function may be a useful avenue to improve organ utilisation 
for transplantation.  
Despite clinical need the use of MP for steatotic livers still relatively under-researched. The 
objective of this review was to investigate how MP could be a tool to expand the use of steatotic 





The following databases were searched for the development of this review: PubMed, Web of 
Science, EMBASE, MEDLINE, Cochrane Library and Scopus. The literature search was 
performed until March 1, 2018 and the medical subject heading (MeSH) terms and Emtree 
keywords ‘machine perfusion, liver transplantation’ combined with the free text terms 
‘steatosis’, ‘fatty livers’, ‘defatting’ and ‘steatosis reversal’. The search strategy used is shown 
in supplementary Table S5.1. There was no initial limit of date for inclusion in an attempt to 
identify most of the papers published.  
Two authors (Y.L.B. and A.P.C.S.B) selected the articles independently to include in the review 
according to the Preferred Reporting Systematic Reviews and Meta-Analyses (PRISMA) 
protocol (14). Initially article titles that completely did not match the aims of this review were 
excluded and the remaining abstracts analysed. In this second step abstracts identified as not 
relevant were excluded. Finally, full papers that could be retrieved were analysed and included 
in the review. Figure 5.1 provides a flow diagram of the selection process. 
Inclusion criteria were: (1) articles studying MP and steatotic livers; (2) animal models or 
human liver experimentation; (3) In vitro models of intracellular fat loading and/or defatting; 
and (4) articles written in English and published. Exclusion criteria were: (1) studies with MP 
not involving steatotic livers; (2) studies on MP of other organs; and (3) articles not written in 
English. 
The reported impacts of MP on steatotic livers were critically analysed. Studies were assessed  
by the authors in terms of study design, methods and outcomes. A focus was given on defatting 
strategies due to their promising potential significance. No assumptions or simplifications were 
made, and risks of biases identified for individual studies are discussed in this review. 




investigated in a non-systematic way as it was not the primary objective of the review, however 
the authors felt it was essential for readers to fully understand the field.  No review protocol 
was registered before starting this manuscript. 
 
Figure 5.1: Study flow diagram for systematic review of the literature on ex situ machine 
perfusion of the liver and steatosis/ defatting.  
 
After initial literature search duplicates articles were removed and titles screened, if related to other 
machine perfusion (MP) of other organs they were excluded. Remaining abstracts were then assessed 
and excluded if not related to the topic. Full papers found were then included in the study. 
 
5.4 Results 
Fifteen articles met our inclusion/ exclusion criteria and are described hereafter. The complete 
screening process is presented in Figure 5.1.  




Obesity is a global issue and according to the World Health Organization it is responsible for 
2.8 million deaths per year. In 2008, the global prevalence of obesity (i.e. BMI ≥ 30 kg/m2) was 
estimated to be 10% for men and 14% for women (15).  
Obesity is linked to the metabolic syndrome and its hepatic manifestation is steatosis known as 
Non-Alcoholic Fatty Liver Disease (16). At the cellular level, steatosis is characterised by the 
accumulation of triacylglycerol in the cytoplasm of hepatocytes. Insulin resistance plays a 
central role leading to increased lipolysis in adipocytes and therefore an increased availability 
of free-fatty acids (FAs) to the liver. Furthermore, obesity is associated with increased release 
of inflammatory cytokines (e.g. IL-6 and TNF-α) and low levels of adiponectin (17).  
5.4.1.1 Steatosis Classification and Grading  
Histologically, steatosis is classified as follows: (1) ‘macrovesicular steatosis’ (MaS), which 
describes the presence of a large lipid droplet (LD) within the hepatocyte cytoplasm which 
displaces the nucleus; and (2) ‘microvesicular steatosis’ (MiS), when numerous small LDs can 
be found in the cytoplasm without any alteration in the position of the cell’s nucleus. In ‘pure’ 
MiS small LDs uniformly occupy the whole cell. The former is a rare condition associated with 
specific conditions (e.g. Reye’s syndrome, acute fatty liver of pregnancy and mitochondrial 
hepatopathies) and such livers would not be considered for donation (18). However, the 
presence of areas of MiS have been described in non-alcoholic and alcoholic liver disease (19). 
Mixed forms of large and small LDs are common in steatotic donor livers and classified as MaS 
(18, 20). Later the terms large-droplet and small-droplet MaS were created to differentiate 
mixed forms (21). Large-droplet MaS was used for single LD larger than half of the cell 
displacing the nucleus; and, small-droplet MaS if smaller than half of the cell and not displacing 




relation to pathology remains unclear with most studies reporting just the presence of MaS and 
MiS. 
Traditionally MaS has been graded according to the percentage of cells infiltrated by fat as mild 
≤ 30%, moderate 30–60% and severe ≥ 60%. However, there is still no consensus in the 
literature on the standardisation of methods for sample collection or analysis to quantify hepatic 
steatosis what may cause discrepancy in results between different studies (22).  
5.4.1.2 The cellular effects of steatosis 
Steatosis has several effects upon cellular metabolism. Adenosine triphosphate (ATP) synthesis 
is impaired and it has been linked to impaired mitochondrial ATP synthase activity (23). When 
exposed to stressful stimuli such as ischaemia-reperfusion injury (IRI) these livers demonstrate 
increased injury relative to non-steatotic livers (24–26). Diminished ATP stores have also been 
correlated with higher rates of necrosis in steatotic livers during IRI (27). 
The mitochondrion plays an integral part in regulating the fate of steatotic hepatocytes. In a 
normal lean liver, the inner-membrane mitochondrial protein Uncoupling Protein 2 (UCP2) acts 
as a mitochondrial antioxidant, dissociating oxidative phosphorylation from ATP production 
(28). UCP2 is overexpressed in the mitochondria of fatty livers, promoting increased proton 
leakage (29) and it has a direct relationship with Reactive Oxygen Species (ROS) production 
(27). Furthermore, UCP2 was also related to necrotic cell death, stalling the cell cycle at the G1 
phase and interrupting apoptotic pathways as well as hepatic regeneration (28). Figure 5.2 












Figure 5.2: The β-oxidation of fatty acids in the mitochondria. Cytosolic fatty acid reacts with ATP 
producing fatty acyl adenylate which in turn react with free coenzyme A originating fatty acyl-CoA. 
Carnitine palmitoyltransferase I catalyse the reaction of acyl-CoA with the hydroxyl group of carnitine 
by carnitine palmitoyltransferase. Acyl-carnitine is transported inside by a Carnitine-acyl-CoA 
transferase and a carnitine is transferred outside. Acyl-CoA is processed by β-oxidation releasing acyl-
CoA molecule 2 carbons shorter than it was at the beginning of the process, acetyl-CoA, NADH and 
FADH2. Acetyl-CoA will undergo to the cycle of Krebs releasing more NADH and FADH2. Electrons 
from NADH and FADH2 will be utilised in the electron transport chain transferring electrons from 
donors to recipients, and this movement of electrons is linked with transfer of protons (H+). This 
electrochemical proton gradient generated is essential in the production of adenosine triphosphate 
(ATP). Complex I (NADH dehydrogenase) and complex III (coenzyme Q) generates superoxide (O2.−), 
which interacts with superoxide dismutase producing hydrogen peroxide (H2O2). H2O2 in the presence 
of transition metals generates hydroxyl radical (HO−). Hydroxyl radical causes lipid peroxidation in 
membrane phospholipids, DNA injury that could culminate with cell death. Lipid peroxidation leads to 
the production of malondialdehyde (MDA) and 4-hydroxynonenal (HNE) which are eliminate from 
damaged hepatocytes into the space of Disse. UCP2 is overexpressed in the mitochondria of fatty livers 
promoting increased leakage of protons (H+) which dissipates the mitochondrial membrane potential 
and dissociates the electron transport chain from the oxidative phosphorylation. Lowering the proton 
gradient UCP2 decreases the generation of superoxide anion at the complex 1 of the electron transport 
chain. 
 
5.4.1.3 The microcirculation of steatotic livers 
Early studies using steatotic rodent livers retrieved and stored cold for 6 hours demonstrated damage 
to the hepatic microcirculation characterised by narrowing of the hepatic sinusoids relative to lean 
controls (30). These changes are due to a reduced sinusoidal diameter secondary to compression by 
fat-laden hepatocytes (26, 31–34) and/or obstruction of the microcirculation by cells or debris as 
verified by Doppler studies (33–37). Indeed, the degree of steatosis correlates with reduced total 
blood flow as well as the hepatic parenchymal microcirculation in livers histologically classified as 
moderately or severely steatotic (37).  
Microcirculatory dysfunction leads to a ‘secondary’ ischaemic hit during reperfusion, allowing the 
production of more ROS and activation of Kupffer cells (38). Activated Kupffer cells produce 
endothelin-1, a vasoconstrictor, in excess of the counterbalance provided by nitric oxide (NO), a 
vasodilator. Lastly, cytokines released cause endothelial dysfunction with expression of adhesion 
molecules (E-selectin, VCAM-1 and ICAM-1) and activation, migration and accumulation of 




Figure 5.3: Mechanisms of interaction between fatty loaded hepatocytes and the 
other cell types of the liver. 
 
 
Microcirculatory dysfunction in fatty livers during reperfusion is a multi-factorial process 
involving complex metabolic pathways. Firstly, ballooned lipid-laden hepatocytes cause 
reduction in sinusoidal diameter that causes a mechanical effect worsening the flow in steatotic 
livers. During the restoration of blood flow, after periods of ischaemia, oxygen offer overcomes 
the capacity of the mitochondrial electron transport chain to recover. Consequently, there is a 
leakage of electrons that reacts with oxygen and generate reactive oxygen species (ROS) 
(superoxide anion, hydrogen peroxide). Kupffer cells get activated by this production and start a 
sustained production of endothelin-1 (ET-1) a potent vasoconstrictor associated with 
inflammatory mediators including ROS, tumour necrosis factor-α (TNF- α), interleukin-1β (IL-
1β), and chemokines. All these mediators damage the sinusoidal endothelial cells (SEC) and 
activate the expression of adhesions molecules which in turn cause accumulation of platelets and 





5.4.1.4 The pro-inflammatory microenvironment within steatotic livers 
In experiments using a mouse model of endotoxin liver injury, Kupffer cells from steatotic 
livers were shown to exhibit lower phagocytic activity and overproduction of ROS, interleukin-
6 and interleukin-1β, when compared to lean controls (41). These observations were associated 
with increased endothelial dysfunction and activation of neutrophils. Persistent activation of 
these cells enhances the production of ROS and proteases which aggravate the hepatocellular 
injury (23, 42).  
5.4.1.5 From bench to bedside: Rapid deterioration of steatotic livers during ischaemia 
and the impact on liver transplantation 
The cellular changes of steatotic livers described above are probably the main reason for their 
increased vulnerability to static cold storage (SCS). Briefly, when exposed to ischaemia during 
SCS the cells consume the diminished ATP stores and then struggle to replenish it due to 
impaired mitochondrial functioning associated with uncoupling of the electron transport chain, 
as described above. The resulting generation of ROS causes oxidative injury and mediates the 
activation of the inflammatory response leading to tissue damage. Those problems are 
exacerbated by impaired microcirculation perpetuating ischaemia even after reperfusion and 
worsening the cellular injury induced by the reperfusion resulting in cell death. Altogether those 
factors contribute to an exacerbated IRI and an impaired early functional recovery.    
5.4.1.6. Impact of Steatosis on Liver Transplantation  
MiS has been shown to be less deleterious in the setting of liver transplantation. Livers with 
even more than 60% of MiS were shown to be safe for transplantation in terms of patient and 




part be explained by less mechanical compression of the sinusoids by hepatocytes laden with 
smaller LDs (45). 
Early experience with steatotic livers in transplantation was poor with clinical series 
demonstrating high incidence of PNF (13, 30, 46–50). Mildly steatotic livers are widely 
considered to be safe for transplantation as there is no evidence to support increased risk of 
postoperative complications with the use of these grafts (51). Studies on the use of moderately 
steatotic livers describe varying outcomes, particularly with respect to graft survival and early 
graft dysfunction (52–59). Westerkamp et al. 2015 reported results of transplantation of 19 
moderately steatotic livers compared with non-steatotic in the context of short CIT (< 8 hours) 
(60). Similar patient and graft survival were reported with an increase in the rate of 
postoperative complications and markers of hepatic injury (60). A summary of these studies is 
presented in Table 5.1, the lack of standardisation for the timing of liver biopsy, type of biopsy 
(core needle or wedge), staining performed, and definition of MaS is evident. It is important to 
note that these studies employed strict selection criteria for moderately steatotic donor livers 
keeping other associated risk factors to a minimum, such as the exclusion or avoidance of 
moderately steatotic DCD livers, elderly donors, selection of recipients that may cope better 
with possible delayed graft functioning and consideration of only steatotic organs with short 
CIT (6–8 hours) (61). Salizzoni et al. 2003 followed a cohort of 64 donors after brain death 
(DBD) with more than 15% of MaS and concluded that CIT greater than 10 hours, donor age > 
65 years old and a hepatitis C positive status in the recipient were predictive factors for poor 
prognosis after transplantation (62). Applying these criteria to the UK donor pool would 
significantly limit the expansion of the donor pool, thereby justifying investigation of new 




Severely steatotic livers are usually declined for transplantation because of the risk of PNF and 
poor prognosis. However, McCormack et al. 2007 followed the outcomes of 20 severely 
steatotic DBD transplanted livers (> 90% total steatosis) and showed excellent results, although 
only 2 grafts had more than 60% MaS (63). Wong et al. 2016 analysed 19 biopsies of severely 
steatotic livers (defined as > 60% large fat droplets occupying more than half of the hepatocyte, 
usually causing displacement of the nucleus of the cell) from DBD donors and showed no early 
allograft dysfunction post-transplant and a 3-year survival rate of 94.7% (64). They go on to 
emphasise, however, that these results were based on low risk donors and short CIT (64). 
Although these authors have suggested that transplantation of those livers can yield acceptable 
results, these series should be treated with caution because of variability in steatosis 
quantification and the constraints stated by the authors. 
In summary, the current literature suggests that MaS does have a negative impact on outcomes 
following transplantation although the studies have variation in the methodology used (42, 44, 
61, 65). To date, the use of these organs relies heavily on the absence of other criteria of donor 
marginality. However, for clinicians an aging population associated with increasing rates of 
obesity requires the development of strategies to maximise the utilisation of these grafts from 









Table 5.1: Characteristics of clinical studies reporting transplantation of moderately 
macrovesicular steatotic livers. 














2016 19 60% 
Post-reperfusion core 
needle biopsy. H&E 
staining. MaS: large lipid 
droplets (more than half 
of the cell) displacing the 
nucleus. 
DBD 384 
3-year survival 94.7%; 
0% of early allograft 
dysfunction 
Westerkamp 
et al. (60) 
2015 19 30–60% 
Core needle biopsy 
performed during the 
bench. H&E staining. 
MaS: fatty vesicles larger 
than and often displacing 





1-year patient survival 
of 95%; 1-year graft 
survival 84%; 1 case of 
primary non-function; 





2010 22 > 35% 
Post-reperfusion and 
organ procurement core 
needle biopsy. H&E and 
frozen sections included. 
MaS: Definition not 
provided. 
DBD 330 
5-year survival 74.4%; 
Prolonged 
hospitalisation, more 
frequent transfusion of 
hemocomponents and 
higher peak of 
transaminases 
Li et al.(54) 2009 23 
21–40% 
(excluded 
if > 60%) 
Post-reperfusion and 
during hospitalisation 
core needle biopsies. 
H&E on frozen sections. 
MaS: Definition not 
provided. 
DBD 355 
1-year survival 87%; 






2009 24 16–30% 
Bench wedge and core 
needle biopsies. H&E 
and oil red O staining. 
MaS: single vacuole 
larger than and displacing 
the nucleus of the cell. 
Pathologist plus digital 
analysis of steatosis 
DBD 487 
6-month graft survival 
80%; Primary 
dysfunction was 




2008 50 > 30% 
Post-reperfusion core 
needle and wedge 
biopsies. H&E staining. 
MaS: single vacuole 
larger than and displacing 




5-year survival 58%; 4 
cases primary non-







if > 60%) 
Not specified timing or 
biopsy type. H&E 
staining. MaS: Definition 
not provided, and 
assessment performed 





1-year survival 73%; 
No mention to delayed 
graft function or 






2007 6 30–60% 
Core needle biopsy 
during organ 
procurement. H&E 
staining. MaS: Definition 
not provided. 
DBD 562 





2005 67 30–60% 
Post-reperfusion and 
organ procurement core 
needle biopsy. H&E 
staining. MaS: lipid 
droplets displacing the 
hepatocyte nucleus and 
occupying the majority of 
the cytosol. 
DBD 166 
90-day graft survival 
72%; 1.5% primary 




2003 48 30–60% 
Post-reperfusion biopsy 
(not specified type). 
Staining used not 
mentioned. MaS: 




3-month survival 78%; 
35% poor initial graft 




2001 8 > 25% 
Not specified timing or 
type of biopsy. H&E 





Overall shorter patient 
survival; 62.5% 
delayed non-function 




1999 14 30–60% 
Biopsy taken during 
transplantation and type 
not specified. Staining 
used not mentioned. 





65% initial dysfunction 
and 14% initial 
nonfunction 
Abbreviations: MaS- Macrovesicular steatosis; DBD: Donation after brain death; DCD: Donation after 
circulatory death; CIT: cold ischaemia time. 
 
5.4.1.7 Steatosis and organ donation 
In the literature, the prevalence of steatosis in donor organs range from 13% to 28% (66). 
Steatosis was the reason for 42% of donor livers being declined for transplantation in Spain in 
2000 (67). The National Health Service annual report on liver transplantation revealed that in 
2016, in the United Kingdom, 16.6% of the total 1001 livers retrieved in the period of 2015–
2016 were not transplanted (12). More importantly, steatosis was the main reason for declining 
the liver in 39% of cases (12). Hence reducing liver steatosis and recovering its function with 




5.4.2 Ex situ machine perfusion of donor livers 
Ex situ MP of donor livers has been demonstrated to be a safe intervention and may improve 
the liver quality (10, 68). This beneficial effect may be more apparent in high-risk ECD organs 
which are more susceptible to ischaemic injury during cold preservation (9). The two most 
explored techniques of MP are briefly discussed below. 
Hypothermic machine perfusion is performed at temperatures close to 10 C using a dual vessel 
perfusion (hepatic artery and portal vein) model or a single vessel perfusion model through the 
portal vein alone. The perfusate oxygenation may be derived from a non-oxygenated perfusion 
scheme (69) to a highly oxygenated hypothermic perfusion set-up through the portal vein 
(HOPE) alone (70). HOPE was shown in experimental models to improve mitochondrial 
function decreasing the production of ROS and reducing the activation of the inflammatory 
cascade (71, 72).  
Normothermic machine perfusion of the liver (NMP) is performed at 37 C. Its main benefit is 
its ability to maintain the organ in a near-physiological environment at full metabolism. This 
allows the assessment of metabolic parameters for liver viability prior to transplantation (68). 
Moreover, it also provides a window of opportunity for ex situ pharmacological interventions 
during preservation with the aim of organ reconditioning.  
5.4.2.1 Ex situ machine perfusion of steatotic donor livers 
There is limited data on the use of MP in steatotic donor livers. Defatting of steatotic livers is 
an intuitive idea to allow the utilisation of these organs for transplantation. Defatting strategies 
should not only aim to reduce the triglyceride load in steatotic hepatocytes but attempt to 




enhancing the lipid metabolism, increasing the cellular exportation of intracellular triglyceride 
as Very Low-Density Lipoprotein (VLDL) and the fatty acid mitochondrial β-oxidation (73).  
5.4.2.2 Potential targets for intervention in the lipid metabolism during NMP 
Therapeutic targets to manipulate the lipid metabolism during NMP involve mainly the 
modulation of the production of enzymes involved with oxidation of FA for energy production 
and/ or FA cellular exportation. As a consequence, cytoplasmic lipases play a key role as 
initiators in the mobilisation of intracellular triacylglycerol stores and conversion into FAs and 
glycerol (74). Between those lipases the adipose triglyceride lipase (ATGL) is considered to be 
the limiting rate factor for intracellular lipolysis in hepatocytes (75–77). The FAs released into 
the cytosol apart from being a substrate for metabolism also act as a ligand for nuclear receptors 
(NR) promoting the transcription of enzymes related to the catabolism and exportation of FAs 
(78, 79). In addition, pharmacological interventions can also activate the expression of those 
NRs and hence modulate the intracellular catabolism of FAs (75, 79). Peroxisome proliferator-
activated receptors (PPAR) are a class of NRs that, when activated, promote transcription of 
hepatic mRNAs related to mitochondrial β-oxidation of FA, such as acyl-CoA oxidase, 
carnitine palmitoyltransferase-1, liver-fatty acid binding protein and peroxisomal ketothiolase 
(80, 81). The delta-isoform of PPAR is also associated with a concomitant drop in inflammatory 
marker levels, namely transforming growth factor-beta 1, IL-6, monocyte chemoattractant 
protein 1, tumour necrosis factor, alpha and nuclear factor kappa B 1 (82). The α-isoform of 
PPAR has been shown to decrease serum triglycerides levels, as fenofibrate (83). Moreover, it 
was shown in obese animal models that PPAR-α transcription levels are increased during 




Another NR associated with lipid metabolism is the pregnane X receptor (PXR). PXR is a NR 
involved in the cellular elimination of toxic drugs and xenobiotics (84). Transgenic PXR-
knock-out mice were shown to have a reduction in the acyl-CoA oxidase 1 (Acox-1) mRNA 
levels. This enzyme is responsible for the peroxisomal β-oxidation of very long chain FA and 
concomitantly higher protein levels of the gene CYP4A14. In turn, CYP4A14 converts long 
chain FA to toxic dicarboxylic acids that will be used for peroxisomal β-oxidation. Dicarboxylic 
acid, which accumulates as a consequence of reduced ACOX-1 peroxisomal β-oxidation, is 
implicated in mitochondrial damage and steatosis (85). 
Hormones are also involved in the modulation of the lipid metabolism. The stimulation of β-
adrenergic receptors on hepatocytes activates via the cyclic adenosine monophosphate (cAMP) 
the protein kinase A (PKA) recruiting cytoplasmic lipases as ATGL to the surface of the lipid 
droplets initiating the process of lipolysis. Glucagon binding to its receptor also acts via the 
cAMP-PKA pathway to promote lipolysis on hepatocytes. Glucagon was shown to reverse 
hepatic steatosis in rats that receive the hormone in parenteral nutrition (86). Visfatin or pre-B-
cell colony-enhancing factor 1 is an adipokine increased in obesity. It has insulin mimetic 
effects in many tissues and enhances the nicotinamide phosphoribosyltransferase (Nampt) 
activity in the nicotinamide adenine dinucleotide (NAD+) pathway and leads to a decrease the 
glucose serum levels (87, 88). The exact mechanism linking it to lipid metabolism in steatotic 
livers is not clear yet (89). These signalling pathways maybe targeted by pharmacological and 
non-pharmacological methods and these strategies are discussed below. Figure 5.4 illustrates 










Figure 5.4: Potential cellular targets for defatting therapies. Stimulation of β-adrenergic and/or 
glucagon membrane receptors activates the cyclic adenosine monophosphate (cAMP) - protein kinase 
A (PKA) pathway that in turn recruits cytoplasmic lipases as the adipose triglyceride lipase (ATGL) to 
the surface of the lipid droplets. Fatty acids and glycerol will be released into the cell, as a result of the 
intracellular lipolysis, serving not only as substrates for the cell metabolism but also as ligands to nuclear 
receptor (peroxisome proliferator receptor [PPAR] and liver X receptors [LXR]) increasing the 
transcription of enzymes involved in the catabolism of fatty acids in the mitochondria and peroxisome. 
The squares contain the specific enzymes that have an upregulation in the transcription as a consequence 
of this stimulus. Cytosolic fatty acid reacts with adenosine triphosphate (ATP) molecules producing 
fatty acyl adenylate, which in turn react with free coenzyme A originating fatty acyl-CoA. Carnitine 
palmitoyltransferase I catalyse the reaction of acyl-CoA with the hydroxyl group of carnitine by 
carnitine palmitoyltransferase. Acyl-carnitine is transported inside the mitochondria by a Carnitine-acyl-
CoA transferase and a carnitine is transferred outside. Acyl-CoA is processed by β-oxidation. 
Alternately, long and very-long-chain fatty acids are also oxidized in the peroxisomes. 
       
5.4.3 Defatting Strategies 
5.4.3.1 Non-pharmacological interventions  
NMP alone without the administration of additional therapy has been associated with 
hepatocyte defatting in animal models (90, 91). Jamieson et al. 2011, using a porcine model, 
showed that NMP decreases hepatic steatosis over periods of 24 and 48 hours. Moreover, NMP 
increased urea production and sustained factor V and bile production with expression of 
markers for reperfusion injury comparable to normal livers (91). Nagrath et al. 2009 reported a 
30% reduction in triglycerides content in rats’ liver over a 3 hours’ period of NMP (90).  
One recent published study with discarded human livers presenting different degrees of 
steatosis showed that NMP alone for up to 24 hours can increase the lipid content in the 
perfusate, however it has not found any histological change in the fatty content of the organs 
(92). The authors discuss the divergent findings from animal models associating it with 
differences across species and the process of chronic fat accumulation in human livers (92).  




In 1989 Pégorier et al., demonstrated that glucagon, dibutyryl cyclic AMP and forskolin 
induced ketogenesis in newborn rabbit hepatocytes using sodium oleate as a substrate in a L-
carnitine supplemented medium (93). Forskolin and glucagon modulate adenylate cyclase and 
stimulate production of the second messenger cyclic AMP. cAMP is a secondary messenger, 
acting as a signal transducer as it is instrumental in providing a link across the cell membrane 
between extracellular hormone molecules and intracellular processes (94).  
The androstane receptor ligand Scorparone (6,7-dimethoxycoumarin) was shown to improve 
the viability of hepatocytes preserved in Euro-Collins solution, with lower levels of 
malondialdehyde and alanine aminotransferase (ALT) found in the supernatant (95). It also has 
vasodilatory properties, enhancing the production of prostacyclin which blocks platelet 
aggregation and possesses oxygen radical’s scavenger-like properties (96). Scorparone, used 
with other drugs into a cocktail, is associated with reversal of hepatocyte steatosis through the 
higher production of adiponectin and upregulation of PPAR-γ (97).  
5.4.3.2.1 The defatting cocktail 
In 2009, Nagrath et al. reported that a combination of PPARα ligand GW7647 and GW501516, 
PXR ligand Hypericin, the constitutive androstane receptor ligand Scorparone, the glucagon 
mimetic cAMP activator forskolin, and the insulin-mimetic adipokine visfatin caused a 
reduction in intracellular lipid content of 35% within 48 hours in rat hepatocytes which were 
made steatotic by FA supplementation in static culture (90). Furthermore, this cocktail of drugs 
at the same concentration was added to the perfusion fluid in a model of NMP of whole fatty 
rat livers. This model accelerated the process of defatting and a simultaneous reduction of 50% 
in intracellular triglycerides levels within 3 hours. Interestingly, a reduction in 30% intracellular 




combination of drugs in the perfusion fluid. Histological analysis of the tissue revealed a lower 
amount of intracellular lipid droplets in the peri-portal areas. The authors correlated this reversal 
in steatosis with increased mRNA levels of triacylglycerol hydrolase (an enzyme that promotes 
triglyceride hydrolysis in hepatocytes), apolipoprotein B-100, carnitine palmitoyltransferase I 
and acyl coenzyme A oxidase. The acceleration in the defatting process was considered to be 
related to greater oxygen availability and therefore increased beta-oxidation rate (90).  
Following this study, Nativ et al. employed a rat hepatocyte cell culture model to investigate 
the impact of this cocktail of drugs during IRI. They noted enhanced exportation of intracellular 
triglycerides and increased ketone body secretion. The last observation was considered to be 
consequence of augmented mitochondrial oxidation of FAs by improved acetyl coenzyme A 
delivery to the mitochondria. In addition, they reported a 32% reduction in ROS production, 
27% increase in ATP levels and high cell viability with lower lactate dehydrogenase (LDH) 
release. This suggested improved resistance of the treated cells to IRI (98).  
The same protocol was later applied to human hepatoma cells (HepG2 cells) by Yarmush et al. 
(99). They found that the cells’ lipid content decreased if left in an environment free of FAs. 
Analysis of metabolites present in the culture media showed that this defatting process was 
attributed to increased mitochondrial β-oxidation through upregulation of the tricarboxylic acid 
and urea cycles. Furthermore, the defatting process was accelerated when exposed to the 
defatting combination of drugs and hyperoxic conditions in comparison with the cells that 
received only the cocktail (99). Thereafter, the same author used HepG2 cells to study the 
impact of flow on the defatting process in an in vitro model using a bioreactor where the cells 
were kept under constant flow with controlled shear stress force (100). Similar defatting rates 
were observed using the cocktail over 6 hours under flow conditions and 48 hours under static 




the mitochondria, is a key factor in the modulation of defatting under flow conditions and flow 
rates should be adequate enough to ensure that this is delivered to the cells (100).  
Liu et al. 2013 attempted to defat rat steatotic livers using the cocktail at midthermic 
temperatures (101). Steatotic livers were perfused using a model of MP at 20 C for 6 hours. 
VLDL and triglyceride concentrations increased in the perfusate of vehicle and drug group. 
However, no significant changes were observed in histology and intracellular triglyceride 
content at 20 C. It was concluded that defatting is a process dependent on physiological 
temperatures (with the organ’s metabolism in full swing) to be effective (101). 
5.4.3.2.2 Glial cell line–derived neurotrophic factor 
Another pharmacological defatting intervention reported in the literature is the use of glial cell 
line–derived neurotrophic factor (GDNF). This growth factor is involved in the development 
of enteric nervous cells and it has been shown to optimise glucose control in rats by promoting 
pancreatic β-cell proliferation (102). GDNF transgenic mice, which overexpress GDNF, were 
fed a fatty rich diet and exhibited resistance to weight gain, diminished insulin resistance, 
dyslipidaemia, hyperleptinemia, and less hepatic steatosis (103). Vakili et al. 2016 used this 
agent in an in vitro model of HepG2 cells which were made fatty by supplementation with 
palmitic acid. They exposed the fatty cells to 48 hours of incubation with 100 ng/mL GDNF 
and observed a reduction in intracellular triglyceride content, reaching levels similar to lean 
cells. However, it should be highlighted that these cells are not primary human hepatocytes and 
this response could be different. Furthermore, using a model of NMP, the authors perfused 4 
fatty mice livers for 4 hours with GDNF in the perfusate and reported an effective reduction of 
40% in intracellular lipid content. Another interesting point of this study was that fatty livers 




and showed that GDNF was effective in clearing lipid droplets, decreasing intracellular 
triglyceride levels and leaving less LDH in the perfusate (104). Hence GDNF may be a 
promising option for defatting steatotic livers although the latter study did not include 
histological analysis of livers subjected to defatting strategies.    
Large animal models of steatosis (e.g. pigs) would potentially be more reliable for further 
investigations as they present metabolic functions closer to human livers (105). However, 
despite one study reporting successful induction of steatosis in pigs using a protein deficient 
diet, to our knowledge, no other studies have explored or reported on similar models (105).  
5.4.3.2.3 Considerations for human livers 
Banan et al. 2016 supplemented the perfusate of two human livers during NMP with 10 mM of 
L-carnitine to enhance mitochondrial oxidation of FAs. Over 8 hours of perfusion a decrease 
of 10% in MaS was reported (106). From the two organs, one with 30% MaS had minimal 
changes over time and the other one with 80% MaS pre-perfusion exhibit a 10% reduction in 
large droplet MaS (106). This variability between the two organs reported and the lack of a 
control group dampen enthusiasm for these preliminary results. 
The results reported by studies in pharmacologically-induced ex situ defatting of steatotic livers 
using MP have limitations. First and foremost, all studies properly designed to study this subject 
up to this point in the literature involved rat models as or in vitro work with tumour cells. 
Consequently, it is still not explored how whole human livers would respond to these specific 
interventions. Secondly, steatotic livers in these models were perfused at normothermic 
temperatures immediately after retrieval. Due to the logistics involved with current methods of 
organ preservation and transportation, donor livers still currently subjected to a cold ischaemic 




whole human liver is not known. Furthermore, it remains to be seen whether any benefit is 
sustained after the liver is removed from the machine. The extrapolation of results of the ideal 
concentration of drugs from animal models to human livers is also a challenging issue. In 
addition, individual effect of some of drugs included into the defatting cocktail on lipid 
metabolism (e.g. scorparone and visfatin) still not fully characterized. Theoretical benefits of 
using filters to either remove solubilised lipids from the perfusate or prevent lipotoxicity still 
needs to be proven. 
In terms of time required for defatting we would ideally envisage periods of few hours when 
concomitant assessment of metabolic parameters could offer an indication of organ viability 
before transplantation. However apart from animal studies data suggesting that it is achievable 
within 3 hours, there is no data in the literature to support assertions in human livers and at this 
time conclusions remain speculative (90). Models of discarded steatotic donor human livers are 
likely to provide valuable insights into these outstanding questions however only 
transplantation would offer a definitive answer as criteria for organ viability during NMP still 
under investigation (107). Table 5.2 summarizes the drugs used in experimental models for 
defatting and the pathway involved.  
Spontaneous reversal of steatosis after LT has been described (53, 60, 63). Westerkamp et al. 
2015 reported a decrease from 30–60% to ≤ 10% within a median of 12 days (60). Considering 
the mechanisms of defatting explored in this review, we hypothesize that the stress response to 
surgery with the release of glucagon and catecholamines may enhance lipolysis and promote 







Table 5.2: Drugs employed in experimental models for ex vivo defatting of steatotic livers 
and its metabolic pathway involved. 
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Not established (89). Enhances nicotinamide 
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(Nampt) activity in the 
nicotinamide adenine 
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pathway and leads to a 
decrease the glucose serum 
levels (87, 88).  
Glial cell line–derived 
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(GDNF) 
Peroxisome proliferator activated receptor-α 
and β1- and β3-adrenergic receptor genes, 
which are associated with increased lipolysis 
and enhanced lipid β-oxidation (103, 104). 
 
*Effect reported for Scorparone as one of the active compounds of a cocktail of Chinese herbs. 
 
5.4.4 Other potential strategies to rescue steatotic organs  
The main target for the use of MP in steatotic livers nevertheless should not be only defatting, 
instead MP should rescue their metabolic parameters into limits considered safe for 
transplantation. Preconditioning of steatotic livers using HMP or midthermic machine 
perfusions, may improve their metabolic activity and enable them to negate IRI (108).  
5.4.4.1 Hypothermic perfusion and steatotic livers 
Bessems et al. 2007, using a murine model reported that hypothermically perfused steatotic 
livers had a higher rate of bile production, ammonia clearance, urea production, oxygen 
consumption and recovery of ATP levels in comparison with SCS (109). Kron et al. 2017, in a 
transplant rat model of severely steatotic livers submitted to 12 hours of SCS showed that short 
term HOPE prior to implantation was able to diminish IRI assessed by oxidative injury, nuclear 




organs (110). The same study reported results of six moderately steatotic human livers that had 
HOPE prior to transplantation suggesting achievement of similar benefits. However, some 
observations deserve attention as HMP period was variable (1.8–4.8 hours), livers had short 
CIT (median 4.1 hours) and MaS rates differ slightly from controls (HOPE 20–40% vs. controls 
25–60%).  
Conversely, one study performing non-oxygenated HMP for 24 hours on human livers 
discarded mainly for steatosis reported impaired ATP recovery rate, increasing perfusate lactate 
levels over time with significant differences in release of markers of hepatocellular injury in 
the perfusate (AST and LDH) between steatotic livers and ‘transplantable’ discarded livers 
(111). In contrast to the former non-transplantable steatotic organs presented with irreversible 
mitochondrial damage on electron microscopy at the end of 24 hours perfusion (111).  
5.4.4.2 Midthermic MP and steatotic livers 
Midthermic MP at 20 C was shown in experimental rat models to offer beneficial preservation 
for steatotic organs in comparison with SCS by potentially optimising energy status (112).  It 
was also suggested to play a protective role in IRI by decreasing TNF-α, caspase-3 activity thus 
being associated with lower levels of oxidative injury and damage to the intrahepatic biliary 
tree (113–115). Conversely, another study examining the metabolic profiles of discarded human 
livers perfused for 3 hours at 20 C, steatotic livers were found to show higher expression of 
markers of injury, impaired ATP recovery rate and higher hepatic artery flow resistance (116). 
Importantly these studies were performed in non-transplant models and further highlight the 
differences between human livers and current animal models. 




Pharmacological strategies to lessen the impact of organ injury during reperfusion can also be 
a means of overcoming the risks associated with steatotic livers. A prominent example is the 
proposed use of the antibiotics minocycline and the cyclophilin inhibitor NIM811. These have 
been shown, in a rodent model to promote preservation of mitochondrial polarization and lower 
activation of  apoptosis/ necrosis pathways with higher graft survival rates (117). NIM811 has 
also associated with better liver regeneration after extended hepatectomy, blocking ATP 
depletion and activation of cell apoptosis (118).  Marshall et al. 2014 studied the inhibition of 
the terminal membrane attack complex using a site-targeted murine complement inhibitor 
(CR2-CD59) to inhibit the complement pathway in the context of IRI. CR2-CD59 enhanced 
cellular proliferation/regeneration after extended liver resection and improved survival rates 
from 0 to 70% (119).  
Recently He et al. 2018 described the first case of ischemia-free organ transplantation (IFOT) 
for a severely steatotic donor liver (120). The authors reported that the recipient did not have 
post-reperfusion syndrome, and the organ demonstrated minimal signs of hepatobiliary injury 
and reduced pro-inflammatory response (120). IFOT might be a promising approach to decrease 
IRI increasing not only the utilisation, but also reducing complications associated with ECD 
organ transplantation. Logistically mobile preservation devices would allow ‘rollout’ of this 
strategy from in-house to inter-hospital. In terms of steatotic organs, it highlights that strategies 
to ameliorate IRI can improve the outcomes of such organs post-transplant.    
The use of NMP in steatotic livers immediately after retrieval as a preservation technique would 
eliminate additional cold injury, avoiding intense depletion of ATP and offering additional time 
for defatting procedures and viability assessment. Other interventions associated with a 
reduction in post-transplant complications of steatotic livers have been described. In the context 




procurement suffered less postoperative complications. Although the results are promising, the 
therapy cannot be applied to deceased donors (51, 121).  
5.5 Discussion 
In this review we described how the cellular changes induced by steatosis could translate into 
higher incidence of post-transplant complications. The evidence for the clinical use of these 
organs and the current ‘other risk factor minimisation strategy’ was briefly explored. However, 
despite this approach being already known by transplant surgeons, steatosis remains a major 
discarding reason for livers worldwide (12). MP has a potential role to increase organ utilisation 
by offering opportunities for organ reconditioning and functional assessment (9, 11). Therefore, 
the use of this device for preconditioning steatotic donor livers deserves urgent attention. The 
current evidence suggests that the key point for its safe utilisation is avoidance of detrimental 
effects of IRI. Defatting involves pharmacological modulation of intracellular metabolic 
pathways. Enhancing lipolysis intracellular triglycerides stores serve as the substrate for energy 
production and ligands for nuclear receptors optimizing mitochondrial function. It also leads to 
lower production of ROS, release of markers of cellular injury and improved cell viability (90, 
104). Moreover, there is the potential to improve the hepatic microcirculation, lower activation 
of Kupffer cells and decrease release of inflammatory mediators during reperfusion, resulting 
in less subsequent tissue injury. Finally, improvements in organ functioning may potentially be 
observed during NMP (107). 
At present the studies investigating defatting strategies have focused heavily upon animal 
models and the extrapolation of these to the clinical setting is in need of urgent investigation. 
The same applies to steatotic livers and MP where only few studies are available. Data from 




we have used a comprehensive search strategy only few studies addressed this subject, therefore 
the risk of bias within the literature needs to be borne in mind.  
Other strategies described have also the potential to limit the detrimental impact of IRI on 
highly vulnerable steatotic donor livers. The ideal method of MP to improve their utilisation 
still requires definition as comparative clinical data is lacking. This highlights the major 
limitation of the present review. In addition, it is difficult to make firms conclusions regarding 
steatotic organ utilisation once definition of MaS, technique for liver biopsy and steatosis 
assessment is not standardised between studies. 
5.6 Conclusion 
Steatotic livers pose a conundrum in liver transplantation. These organs sustain greater injury 
but form an ever increasing proportion of the donor pool. Although some series report 
successful long-term outcome of patients transplanted with steatotic livers these are limited. 
MP provides a window of opportunity to improve the quality of steatotic donor livers by acting 
as a vehicle for the application of pharmacological and non-pharmacological interventions. 
Defatting of donor livers in MP is a promising approach to organ reconditioning. However, 
further research is required into this field before it can be considered a plausible and feasible 










5.7.1 Table S5.1: Literature search strategy (example for one database). 
Database Strategy 
PubMed ‘machine perfusion’ (MeSH) AND ‘liver transplantation’ (MeSH) AND 
‘steatosis’ (text) OR ‘fatty livers’ (text) OR ‘defatting’ (text) OR ‘steatosis 
reversal’ (text) 
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Introduction: Pharmacological defatting of rat hepatocytes and hepatoma cell lines suggests 
that the same method could be used to ameliorate macrovesicular steatosis in moderate to 
severely fatty livers. However, there is no data assessing the effects of those drugs on primary 
human liver cells. We aimed to determine the effectiveness of a pharmacological cocktail in 
reducing the in vitro lipid content of primary human hepatocytes (PHH). In addition, we sought 
to determine the cytotoxicity of the cocktail towards non-parenchymal liver cells.   
Methods: Steatosis was induced in PHH by supplementation with a combination of saturated 
and unsaturated free fatty acids. This was followed by addition of a defatting drug cocktail for 
up to 48 hours. The same experimental method was used with human intrahepatic endothelial 
cells (HIEC) and human cholangiocytes. MTT assay was used to assess cell viability, 
triglyceride quantification and oil red O staining were used to determine intracellular lipids 
content whilst ketone bodies were measured in the supernatants following experimentation.  
Results: Incubation of fat loaded PHH with the drugs over 48 hours reduced the intracellular 
lipid area by 54%, from 12.85% to 5.99% (p = 0.002) (percentage of total oil red O area), and 
intracellular triglyceride by 35%, from 28.24 to 18.30 nmol/million of cells (p < 0.001). Total 
supernatant ketone bodies increased 1.4-fold over 48 hours in the defatted PHH compared with 
vehicle controls (p = 0.002). Moreover, incubation with the drugs for 48 hours increased the 
viability of PHH by 11%, cholangiocytes by 25% whilst having no cytotoxic effects on HIEC.     
Conclusion: These data demonstrate that pharmacological intervention can significantly 
decrease intracellular lipid content of PHH, increase fatty acids β-oxidation whilst being non-






Hepatic steatosis results from the accumulation of triacylglycerol in the cytoplasm of 
hepatocytes which coalesce to form lipid droplets (LD). Large LDs that cause displacement of 
the cell nucleus are termed macrovesicular steatosis. Donor livers with macrovesicular steatosis 
are associated with significantly increased risk of early graft dysfunction after liver 
transplantation (1–4). Intuitively defatting of steatotic donor livers could potentially improve 
both the organ utilisation and patient outcomes after transplantation. Using a static in vitro rat 
hepatocyte model where cells were loaded with fat, Nagrath et al. reported a reduction of 35% 
in the intracellular lipid content over 48 hours by supplementing media with a defatting cocktail 
consisting of peroxisome proliferator-activated receptor (PPAR)α ligands GW7647 and 
GW501516, pregnane X receptor (PXR) ligand Hypericin, the constitutive androstane receptor 
(CAR) ligand Scorparone, the glucagon mimetic cyclic adenosine monophosphate (cAMP) 
activator forskolin and the insulin-mimetic adipokine visfatin (5). Thereafter the defatting 
cocktail was used in a model of ex situ normothermic machine perfusion (NMP) of a whole 
steatotic rat liver and a reduction of 50% in the intracellular triglycerides levels was observed 
within 3 hours (5). Subsequently the same protocol was applied to human hepatoma cells 
(HepG2 cells) by Yarmush et al. and similar findings were reported (6). Consistently these 
studies demonstrate that the defatting cocktail increased mitochondrial beta-oxidation of fatty 
acids (FA) as represented by higher production of ketone bodies and upregulated the 
transcription of key enzymes involved with the exportation of intracellular lipids and oxidation 
of FA in the peroxisome (5, 6). 
However, HepG2 cells do not accurately represent the response of primary human hepatocytes 
(PHH) to drugs or cellular stresses such as hypoxia and hypoxia/reoxygenation (7–9). In 
particular HepG2 cells demonstrate a 90% reduction in cytochrome P450 expression (10). 




of human donor livers, it is imperative that their efficacy and cytotoxicity be determined in 
models using human liver cells (11, 12). In particular the cytotoxicity of the defatting drugs on 
other cell types within the liver, such as intrahepatic endothelial cells (HIEC) and 
cholangiocytes, has not been assessed. The aim of the present study was to investigate the 
efficacy of this defatting drug cocktail on steatotic PHH and its cytotoxicity towards PHH, 
HIEC and cholangiocytes.  
6.3 Methods  
6.3.1 Study design 
Steatosis was induced in PHH by incubation of cells with FAs. Fatty loaded PHH were then 
incubated with a cocktail of defatting agents to test its cytotoxicity and effectiveness in 
reducing the intracellular lipid content. HIEC and cholangiocytes were also incubated with the 
defatting cocktail for 48 hours to assess the cytotoxicity of the cocktail. Three separate 
















Figure 6.1: Study design. Series 1: Isolated primary human hepatocytes (PHH) were left in standard 
media for 2 days and then received media supplemented with fatty acids. After 2 days of fat loading, the 
fatty PHH were allocated to the defatting treatment group where the media was supplemented with the 
defatting cocktail of drugs, and the control groups, the standard control group and the vehicle control 
group that received vehicle only. Lean hepatocytes were kept in standard culture conditions throughout 
the experimental period. The experimentation period lasted for two days thereafter. Series 2: Human 
intrahepatic endothelial cells (HIEC) and cholangiocytes were immuno-magnetically separated with 
Dynabeads conjugated with cell-specific monoclonal antibody. The cells were left in culture for 2 days 
in standard media to reach confluence and then were allocated to the intervention group that received 
the defatting cocktail and the control groups, the standard control group and the vehicle control group 
that had the media supplemented with the vehicle only. The experimentation period lasts for two days 
thereafter. 
 
6.3.2 Source of Liver Tissues  
The human cells were isolated from discarded donor livers. The organs were initially offered, 
accepted, and procured with the intention of clinical transplantation. They were then declined 
by all UK transplant centres and offered for research by the National Health Service Blood and 
Transplant (NHSBT) coordinating office. Specialist nurses in organ donation obtained consent 
to use donor tissue for research as part of the consent process for standard clinical organ 
donation. None of the donor organs were from a vulnerable population and all next of kin 
provided written informed consent that was freely given. Ethical approval for the study was 
granted by the London-Surrey Borders National Research Ethics Service committee as well as 
Loco-Regional and NHSBT Ethics Committees (reference 13/LO/1928 and 06/Q702/61). Cells 
were isolated from three donors after brain stem death declined for transplantation because of 
logistics and were preserved by static cold storage in University of Wisconsin preservation 
fluid. 
6.3.3 PHH cell isolation   
A published collagenase perfusion technique was employed for PHH isolation from liver 




resuspended and then plated on 24-well plates previously coated with rat tail collagen type 1 at 
a density of 3x105 cells/well in Dulbecco’s Modified Eagle’s Medium (DMEM) (Catalogue 
number [CN]:41965-039; Gibco laboratories, Gaithersburg, MD, USA) supplemented with 
10% fetal calf serum (FCS) (CN:10270106; Gibco) and 5% glutamine/penicillin/ streptomycin 
(GPS) (CN:10378016; Gibco). After 2 hours the cells were washed with Phosphate-buffered 
saline (PBS) (CN:10010023; Gibco) and the media changed to our standard medium for PHH 
culture, constituted of Arginine-/Glutamine-free Williams E (CN:12551032; Gibco) with 1% 
GPS, hydrocortisone (2 µg/ml) (H4001; Sigma-Aldrich, St. Louis, MO., USA), insulin (0.124 
U/ml) (I2643; Sigma-Aldrich) and L-ornithine (400 µM) (O6503; Sigma-Aldrich), 
subsequently the cells were kept at 37 C in 95% air/ 5% CO2. 
6.3.4 In vitro steatosis induction for PHH 
The standard media for PHH culture was supplemented with a combination of FAs in order to 
promote increases in the intracellular triglyceride levels stocked as LDs, as previously described 
(14). This fatting media consisted of the saturated palmitic acid (P0500; Sigma-Aldrich), 
polyunsaturated omega-6 linoleic acid (L5900; Sigma-Aldrich) and the monounsaturated 
omega-9 oleic acid (O1257; Sigma-Aldrich) all at a final concentration of 0.25 mM. This 
concentration was determined by performing cytotoxicity titration experiments prior to 
institution of the full experimental protocol. A supplement of 5% fatty-acid-free bovine serum 
albumin weight/volume (BSA) (A3803; Sigma-Aldrich) was added as a protein carrier. The 
media was changed daily, and the steatosis induction period was 48 hours. The lean control 
group was incubated with standard media only throughout the experimental period. 




Following steatosis induction, the fatting media was removed, and cells washed with PBS. 
Experiments were then performed on 4 distinct groups: (1) the fatty vehicle control group, 
which received the cell type specific standard media described above plus the vehicle 
dimethylsulfoxide (DMSO) < 0.1% v/v (D2438; Sigma-Aldrich) used for drugs dilution, 
without any drug or fatty acid supplement; (2) the fatty standard control group, which received 
only the standard culture media; (3) the defatting treatment group, which had the media 
supplemented with the combination of defatting drugs (0.01 mM glucagon mimetic and cAMP 
activator forskolin [F6886; Sigma-Aldrich], 0.001 mM PPAR α ligand GW7647 [G6793; 
Sigma-Aldrich], 0.01 mM PXR ligand hypericin [56690; Sigma-Aldrich], 0.01 mM CAR 
ligand scoparone [254886; Sigma-Aldrich], 0.001 mM PPAR δ ligand GW501516 [SML1491; 
Sigma-Aldrich], 0.4 ng/mL adipokine visfatin [SRP4908; Sigma-Aldrich] and 0.8 mM L-
carnitine [C0283; Sigma-Aldrich]); and, (4) lean cells that were kept on standard media 
throughout. The defatting mixture of drugs was tested previously in rat hepatocytes and HepG2 
cells (5, 6, 15). All groups had the media changed and sampled after 24 hours and 48 hours of 
treatment and the cells harvested for intracellular lipids quantification. 
6.3.6 Isolation and culture of primary cholangiocytes and HIEC 
HIEC and cholangiocytes were isolated from human liver tissue using Collagenase Type 1A 
(C9891; Sigma-Aldrich) digestion for 1 hour at 37 C. The resulting cell suspension was then 
sieved through a fine mesh, separated on a 33%/77% Percoll density gradient and cells retrieved 
from the interphase. This interphase mixed population of cells were then diluted in PBS, 
centrifuged and further immuno-magnetically separated with Dynabeads conjugated with cell-
specific monoclonal antibody (anti-cluster of differentiation 31 [CD31] to purify HIEC 
[M0823, monoclonal mouse antibody anti-CD31, clone JC70A; Dako, Denmark] or anti-




FITC; Miltenyi Biotec, Bergisch, Germany] to purify cholangiocytes). The extracted 
cholangiocytes and HIEC were then plated on 96-well plates previously coated with rat tail 
collagen type 1; Cholangiocytes in DMEM 10% FCS supplemented with 5% GPS and the HIEC 
in Human Endothelial-Serum Free Media (CN:11111044; Gibco) supplemented with 10% heat-
inactivated human serum (CR100; TCS Biologicals, Buckingham, UK) with 5% GPS. After an 
interval of 12 hours the media was changed to our standard specific culture medium. For 
cholangiocytes it was constituted of DMEM/ HAMS F-12 nutrient mixture (CN:21331-020; 
Gibco) 1:1 v/v, 5% GPS, hydrocortisone (0.4 µg/mL), cholera toxin (10 ng/mL) (C8052; 
Sigma-Aldrich), triiodothyronine (T3) (2x10-9 mol/L) (T6397; Sigma-Aldrich), insulin (5 
µg/mL), hepatocyte growth factor (10 ng/mL) (CN:100-39; Peprotech, Rocky Hill, NJ, USA) 
and epidermal growth factor (10 ng/mL) (CN:100-61; Peprotech). For HIEC, Human 
Endothelial-Serum Free Media supplemented with 10% heat-inactivated human serum, 
vascular endothelial growth factor (10 ng/mL) (CN:100-20C; Peprotech) and hepatocyte 
growth factor (10 ng/mL) was used. After isolation the cells were kept in an incubator at 37 C 
in an atmosphere of 95% air/ 5% CO2. 
Cholangiocytes and HIEC were cultured for 48 hours to reach confluence. After this period the 
culture media was changed, and the experimental groups assigned to the various cells. The 
intervention group received the standard culture medium supplemented with the defatting drugs 
(0.01 mM forskolin, 0.001 mM GW7647, 0.01 mM hypericin, 0.01 mM scoparone, 0.001 mM 
GW501516, 0.4 ng/mL visfatin and 0.8 mM L-carnitine). The control group was split into two, 
one that received vehicle (DMSO < 0.1% v/v) and a second one that received only the standard 
culture medium.   




Cell viability was assessed using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay (M5655; Sigma-Aldrich). MTT is initially a yellow-coloured solution which 
turns purple formazan after reduction by reductase enzymes found within mitochondria of 
viable cells. DMSO is added to dissolve the purple formazan into a coloured solution. The 
readout was the difference between the values of the absorbance readings at 570 and 690 nm 
on a plate reader. The amount of purple formazan produced by control cells allows comparisons 
between the effects of different treatments. MTT assay was used to assess the cytotoxicity of 
the mixture of drugs and of the media supplemented with FAs. 
6.3.8 Oil red O staining 
Oil Red O staining was employed for quantifying LDs in the cytoplasm of the cells (O0625; 
Sigma-Aldrich). Following experimentation cells were fixed with buffered formaldehyde and 
the staining was carried out as previously described (16). Mayer’s haematoxylin was used for 
the nuclear counter stain. 
For quantification of staining in PHH four high power field (HPF) images from each experiment 
were selected. Positive areas of staining were calculated by a system of colour differentiation 
and the result expressed in percentage of the total area of the image using ImageJ, U. S. National 
Institutes of Health, Bethesda, Maryland, USA.  
6.3.9 Intracellular triglyceride quantification 
At the end of the incubation period, cells were washed with PBS and harvested with gentle 
scraping. Intracellular lipids were retrieved using the detergent TERGITOL™ Type NP-40 
(NP40S; Sigma-Aldrich) followed by lipase incubation to break down triglycerides into FAs 
and glycerol. Intracellular triglyceride was measured using a colorimetric assay (ab65336; 




The concentration of triglycerides was normalised to control and expressed as nmol per million 
of cells.  
6.3.10 Ketone bodies measurement 
Ketone bodies were quantified in cell supernatants using a commercially available kit 
(MAK134; Sigma-Aldrich) as per the manufacturer’s instructions and detect 3-hydroxybutyric 
acid (BOH) and acetoacetic acid (AcAc).  
6.3.11 Statistical analysis 
Continuous variables were expressed as median/ interquartile range or range and categorical 
variables as absolute number/ frequency (%). Comparison between groups was performed using 
Mann–Whitney U test or two tailed t-test for continuous variables. The statistical level of 
significance was p < 0.05. GraphPad Prism version 6.04 for Windows, GraphPad Software, La 
Jolla California USA was used for statistical analysis and graph creation.  
6.4 Results 
6.4.1 Induction of steatosis in PHH 
Incubation of PHH for 48 hours with media supplemented with the combination of FAs 
increased the median intracellular triglyceride concentration approximately 8-fold, from 14.01 
(range 13.69–14.02) to 112.64 (111.65–113.30) nmol/million of cells (p < 0.001). The PHH oil 
red O staining area increased significantly from 1.4% (0.9–1.7) to 21.8% (14.7–32.0) 
(approximately 14-fold) (p < 0.05). The cellular viability of PHH after 48 hours of incubation 
with the media supplemented with FAs using the MTT-assay was 81% (range 76–87%) in 
comparison with lean cells kept in the standard media throughout. The results from the steatosis 




Figure 6.2: Results of fat loading of primary human hepatocytes. 
 
Panel A: The supplementation of the media with the combination of fatty acids resulted in a cell 
viability rate of 81% after 48 hours of incubation. Panel B: Oil red O staining image of primary 
human hepatocytes (PHH) at the end of the fat loading period. There is predominance of large 
lipid droplets displacing the nucleus of the cells to the periphery (black arrow). Panel C: At the 
end of 48 hours of fatting load there was a significant increase of 14-fold of the positive area of 
oil red O. Panel D: Intracellular triglycerides increased 8-fold within 48 hours of incubation with 
fatty acids. Data report the median of three separate experiments performed in quadruplicate and 




6.4.2 Defatting of PHH 
6.4.2.1 Oil red O analysis 
Digital analysis of oil red O staining of cytoplasmic LDs demonstrated that the combination of 
drugs lead to a decrease from 28% [20.27% (14.67–32.03%) to 14.77% (11.70–22.05%), p = 
0.315] in median positive area of oil red O staining within 24 hours of treatment and 54% within 
48 hours [12.85% (11.07–15.80%) to 5.99% (4.24–8.61%), p = 0.002] compared to the fatty 
vehicle control hepatocytes alone (Figure 6.3). The positive area of oil red O was comparable 
between the fatty vehicle control cells and the fatty standard control cells after 24 hours [20.27% 
(14.67–32.03%) vs. 19.98% (15.03–31.70%), p > 0.999] and 48 hours of treatment (12.85% 
(11.07–15.80%) vs. 13.04% (12.01–16.02%), p > 0.999]. The same pattern was seen for the 
other parameters analysed, therefore, comparisons with the defatting group were made using 
the fatty vehicle control group. In addition to the decrease in the total area of cytoplasmic LDs 
(expressed as percentage oil red O positive area) in the defatting group, it morphologically 








Figure 6.3: Defatting of fat loaded primary human hepatocytes (PHH). 
 
Panel A: The positive are of oil red O of the defatting treatment group was reduced by 28% in 
comparison with the vehicle control group over 24 hours and 54% over 48 hours. Panel B: 
Intracellular triglyceride levels of the defatting treatment group were reduced by 32% within 24 
hours of treatment and 35% within 48 hours, in comparison with the fatty vehicle control group. 
Panel C: Oil red O staining picture of primary human hepatocytes (PHH) of the defatting group 
at the end of the 48 hours of treatment. There is a predominance of small lipid droplets in the 
cytoplasm of the cells and the nucleus is in its usual position. Series 2: shows a series of oil red 
O staining pictures from PHH in culture at different time points of the experiments. Panel D shows 
lean cells in culture, after the incubation with fatty acids they become loaded with fat (Panel E). 
Those fat loaded PHH were then incubated with only the vehicle of the drugs for 48 hours and 
the lipid content decreased over time (Panel F) or had the defatting treatment that showed the 
significant higher decrease in the area of oil red O (Panel G). Data report the median of three 
separate experiments performed in quadruplicate and errors bars the interquartile range. 




6.4.2.2 Intracellular triglyceride quantification 
Treatment with the defatting cocktail decreased the median concentration of intracellular 
triglycerides by 32%, from 30.51 nmol/million of cells (range 30.18–31.50) in the fatty vehicle 
control group to 20.61 nmol/million of cells (range 20.28–21.60) in the defatting group within 
24 hours, p = 0.012. After 48 hours, it reduced 35%, from 28.24 nmol/million of cells (range 
26.88–29.24) to 18.30 nmol/million of cells (range 18.30–18.96) (p < 0.001). Intracellular 
triglyceride concentration reduced over time once the cells were removed from the fatting 
media by approximately 5-fold within 24 hours (Figure 6.3). There was no difference between 
intracellular triglycerides levels of the fatty control vehicle alone and the fatty standard control 
group (p > 0.999). 
6.4.2.3 Fatty acids β-oxidation induction 
The defatting cocktail induced a median increase in the release of total ketone bodies in the 
supernatant of PHH of 1.22-fold (range 1.02–1.26) (p = 0.070) after 24 hours of treatment and 
1.40-fold within 48 hours (range 1.31–1.52) (p = 0.002) (Figure 6.4) when compared to the 
fatty vehicle control group alone at each respective time point. The release of total ketone bodies 









Figure 6.4: Release of total ketones in the supernatants.  
 
Fat loaded primary human hepatocytes that had the defatting treatment showed an increase in cell 
culture supernatant levels of total ketone bodies of 1.22-fold over 24 hours and 1.40-fold over 48 
hours. Data reports the median of three separate experiments performed in quadruplicate and 





6.4.3 Impact of the defatting cocktail on cell viability 
6.4.3.1 Effects on PHH 
After 48 hours of treatment with the defatting cocktail MTT assay showed an increase in the 
viability of PHH of 11% (6–15%) in comparison with the fatty vehicle control cells (p = 0.048). 
Cellular viability was similar between the control groups. Phase contrast light microscopy 
suggested that the defatted hepatocytes were more adherent and spread on the wells in 





Figure 6.5: Assessment of the cytotoxicity of the defatting cocktail to human cells of the liver via MTT assay. 
 
Panel A: The toxicity of the defatting cocktail was tested in primary human hepatocytes (PHH) and results showed a significant improvement of 11% in 
viability of the defatting treatment group compared with the fatty vehicle control group. Panel B: Treatment of human intrahepatic endothelial cells 
(HIEC) with the drugs had no effect on cell viability compared with the control groups. Panel C: treatment of cholangiocytes with the defatting cocktail 
did not demonstrate any cytotoxic effect to the cells and indicated a slight improvement in viability compared to the control groups. Panels D and E: Phase 
contrast microscopy showing representative images of HIEC (Panel D) and cholangiocytes (Panel E) at different time points. No gross modifications in 
cell integrity were observed in either cell type which was consistent and supportive of the MTT data. Data report the median of three separate experiments 




6.4.3.2. Effects of the defatting cocktail on other liver cell types 
Incubation of cholangiocytes and HIEC with the defatting cocktail was not cytotoxic. There 
was no difference in viability between HIEC in the treated group and the vehicle control group 
after 48 hours of incubation (100% [97–101] vs. 100% [90–113], p > 0.999). For cholangiocytes 
the supplementation of the media with those drugs improved cellular viability in 25% although 
the difference did not reach statistical significance (125% [75–166] vs. 100% [57–116], p = 
0.413). Detailed data is presented in Figure 6.5. 
6.5 Discussion 
Defatting of steatotic rat livers using a cocktail of drugs in a model of ex situ normothermic 
machine perfusion was shown to be feasible and a potentially promising translational approach 
to improve the utilisation of steatotic donor livers for transplantation (2). However before 
considering the translational application of such interventions to whole human donor livers, the 
efficacy and cytotoxicity of these agents to human liver cells needed to be evaluated since there 
is inherent variability in responses to drugs between species and different cell lines (7–9). Our 
study demonstrates for the first time using PHH that the defatting cocktail was able to reduce 
its lipid content in vitro enhancing beta-oxidation of FAs. Moreover, we have shown that the 
drugs were not toxic to PHH, HIEC or cholangiocytes. The latter being crucial in the clinical 
setting where these cells are targets in ischaemia-reperfusion injury and ischaemic 
cholangiopathy (17, 18).   
Steatosis is a frequent reason for livers being deemed non-transplantable (19). This is because 
these organs are more susceptible to ischaemic injury during cold preservation and thereafter 
are at a high risk of graft dysfunction after transplantation (1–4, 20, 21). Current strategies for 




risk factors, such as limiting cold ischaemia times, using low risk donors and selecting low risk 
recipients (22). An intervention which may decrease post-transplant complications for such 
livers has been described in the context of living donation. Living donors that had their diet 
supplemented with Ω-3 FAs one month before organ procurement appears to be associated with 
fewer postoperative complications. Although this approach shows promise, it is not applicable 
in the context of deceased donor organs (22, 23).   
Nagrath et al. 2009 tested a cocktail of drugs in an in vitro model of steatotic rat hepatocytes 
and showed a decrease in the intracellular triglyceride levels of 31% within 48 hours (5). This 
cocktail was tested then by Yarmush et al. 2016 in an in vitro model of hepatoblastoma cells 
(HepG2) loaded with lipids via FAs supplementation. The combination of drugs promoted a 
reduction of 83% in intracellular triglycerides within 48 hours of treatment under hyperoxic 
conditions (6). We have employed the same cocktail of drugs in our experiments and in PHH 
we found a reduction of 35% over the same time period. This reduction was more significant 
considering the positive area occupied by LDs (54%). Our data suggests that this finding is 
likely to be related to the reported decrease in size of the LDs gaining appearance of 
microvesicular steatosis. This decrease in macrovesicular steatosis was associated with a 
continuous increase in the production of ketone bodies with the defatting cocktail in comparison 
with fatty control cells further than 24 hours, a product of incomplete oxidation of FAs in the 
mitochondria. 
The defatting cocktail consists of: nuclear ligands for peroxisome proliferator-activated 
receptors (PPAR α- ligand GW7647; and, PPAR δ- ligand GW501516) to stimulate the 
transcription of lipid oxidation/exportation factors (24); an insulin-mimetic adipokine visfatin 
associated with lowering triglyceride levels in the liver (25); forskolin, a glucagon mimetic 




pregnane X Receptor (PXR) ligand hypericin that is reported to improve the transcription of 
the cytochrome P450 (CYP) 3A4 monooxygenase which can increase metabolism of a range 
of drugs in hepatocytes (27); constitutive androstane receptor (CAR) ligand scoparone (6,7-
dimethoxycoumarin) that acts to promote transcription of beta-oxidation enzymes, such as 
carnitine palmitoyltransferase 1 (28), and finally a supplement of L-carnitine, fundamental in 
the transport of FAs across the inner mitochondrial membrane (29).  
In brief, forskolin activating glucagon membrane receptors can stimulate the adenosine 
monophosphate (cAMP) – protein kinase A pathway that regulates the trafficking of 
cytoplasmic lipases to the surface of LDs (30, 31). The glycerol and FAs released from the 
breakdown of LDs could potentially not only serve as substrates for the cell metabolism but 
also as ligands to nuclear receptor (peroxisome proliferator receptor [PPAR] and liver X 
receptors [LXR]) increasing the transcription of enzymes involved in the catabolism of FAs in 
the mitochondria and peroxisome (32, 33). The other drugs (GW7647, GW501516, hypericin, 
scorparone) also act as ligands to other nuclear receptors (pregnane X receptors and androstane 
receptors) boosting the transcription of key enzymes in lipid metabolism (34, 35). Cytosolic 
fatty acid reacts with ATP generating fatty acyl-CoA. Acyl-CoA in turn reacts with 
apolipoprotein B to generate lipoproteins to be exported from the cell and/or reacts with the 
hydroxyl group of carnitine via carnitine palmitoyltransferase 1. Acyl-carnitine is transported 
inside the mitochondria by a Carnitine-acyl-CoA transferase and a carnitine is transferred 
outside. Acyl-CoA is processed by β-oxidation then allowing ketogenesis or complete oxidation 
via the Krebs cycle and the electron transport chain with the production of adenosine 
triphosphate (ATP) (36). Therefore, acting through different pathways, this combination of 
drugs accelerates the process of intracellular triglycerides exportation and improves 




intracellular LD content, but it also serves to enhance lipid metabolism and potentially increase 
intracellular ATP. This increased ATP content can potentially improve the poor outcome of 
steatotic livers during either machine perfusion or after clinical transplantation as loss of energy 
reserves is an important reason for graft dysfunction (38).   
As already stated, experiments testing the defatting cocktail with rat hepatocytes and HepG2 
cells do not wholly reflect the responses of PHH. For example, the expression of enzymes 
involved in drug metabolism as cytochrome P450 is variable between these cells and PHH (7, 
10). Consequently, such experiments although informative, may underestimate the real 
cytotoxicity or metabolic effect of therapeutic interventions in human livers (7, 8, 10, 39). 
Therefore, PHH remain the choice of cells for the study of cytotoxicity and the resultant 
metabolic effect of drugs in human livers (11, 12, 39).        
The present study to the best of our knowledge is the first to examine the cytotoxicity and 
metabolic effect of a combination of drugs intending to promote defatting of fat loaded PHH in 
an in vitro model. It was shown that the defatting cocktail effectively decreased the lipid content 
of PHH in vitro, improving cellular viability and mitochondrial oxidation of FAs. No less 
importantly, we have tested the cytotoxicity of the drugs to HIEC and cholangiocytes. The 
information that the drugs are not toxic to these cells is an important and reassuring step before 
moving towards translational experiments for the delivery of the defatting cocktail to whole 
human donor livers during extra-corporeal normothermic machine perfusion. 
Despite the experimental evidence discussed, defatting of human livers remains challenging 
and under researched. One limitation of our study is that we have not explored what could be 
the impact of flow and the effect of ischaemia-reperfusion on the defatting process of PHH. It 




have the time for defatting shortened from 48 hours to 4–6 hours when submitted to conditions 
of flow using this cocktail of drugs (37). In addition, machine perfusion and/or clinical 
transplantation of livers will involve a period of ischaemia and this may have an effect upon 
defatting (38). 
6.6 Conclusion 
Using an in vitro model of PHH, our study demonstrates for the first time that pharmacological 
interventions can be used to lower intracellular triglycerides stores and promote higher rate of 
FAs mitochondrial β-oxidation. In addition, the drugs were shown to be not toxic to PHH, HIEC 
and cholangiocytes. Hence, the present study supports future translational experiments 
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Background: Strategies to increase steatotic donor livers’ utilisation are required to tackle the 
mortality on the transplant waiting list. We aimed to test the efficacy of pharmacological 
enhancement of the lipid metabolism of human livers during ex situ normothermic machine 
perfusion to promote defatting and improve the functional recovery of the organs. 
Methods: Ten livers discarded because of steatosis were allocated to: a defatting group that 
had blood-based perfusate supplemented with a combination of drugs to enhance lipid 
metabolism or a control group that received perfusion fluid with vehicle only. Steatosis was 
assessed using tissue homogenate and histological analysis. Markers for lipid oxidation and 
solubilisation, oxidative injury, inflammation and biliary function were evaluated by ELISA, 
immunohistochemistry and in-gel protein detection. 
Results: Treatment reduced tissue triglycerides by 38% and macrovesicular steatosis by 40% 
over 6 hours. This effect was driven by increased solubilisation of triglycerides (p = 0.04); and, 
mitochondrial oxidation as assessed by increased ketogenesis (p = 0.008) and adenosine 
triphosphate synthesis (p = 0.01) associated with raised levels of the enzymes ACOX-1, CPT1A 
and acetyl-CoA synthetase. Concomitantly defatted livers demonstrated enhanced metabolic 
functional parameters such as urea production (p = 0.03), higher vascular flows (p = 0.03), 
lower release of alanine aminotransferase (p = 0.049) and higher bile production (p = 0.008) 
with a higher bile pH (p = 0.03). The treatment downregulated the expression of markers for 
oxidative injury, activation of immune cells (CD-14; CD-11b) and reduced the release of 
inflammatory cytokines in the perfusate (TNF-α; IL-1β). 
Conclusion: Pharmacological enhancement of intracellular lipid metabolism during 




also improved the intracellular metabolic support to the organs leading to successful functional 
recovery and attenuated expression of markers of reperfusion injury. 
 
7.2 Introduction 
Steatosis is caused by the abnormal metabolism of fatty acids in hepatocytes, resulting in 
intracytoplasmic accumulation of triacylglycerol as lipid droplets (LD) (1). In the context of 
organ donation, livers presenting with large intracytoplasmic LD displacing the cell nucleus 
(macrovesicular steatosis) are more vulnerable to ischaemic-reperfusion injury (IRI) during 
standard static cold storage (SCS). This is mainly due to impaired mitochondrial function, poor 
microcirculation and exaggerated inflammatory response leading to tissue damage (2). The 
exacerbated IRI is then associated with impaired early functional recovery and a high risk of 
early allograft dysfunction (2–4). Therefore, steatosis or fatty livers is one of the main reasons 
for declining donor livers worldwide (2, 5). 
Animal models have shown that normothermic machine perfusion (NMP) alone is able to 
improve intracellular lipid metabolism and promote steatosis reversal or defatting  (6, 7). 
However, a recent study involving NMP of steatotic human livers for 24 hours did not show a 
decrease in tissue steatosis (5). In a murine model, a combination of drugs (peroxisome 
proliferator activated receptor [PPAR]α ligand GW7647,  PPARδ ligand GW501516, pregnane 
X receptor [PXR] ligand hypericin, the constitutive androstane receptor [CAR] ligand 
scorparone, the cyclic adenosine monophosphate [cAMP] activator forskolin, and the insulin-
mimetic adipokine visfatin), administered during NMP, was able to enhance lipid metabolism 
and reduce tissue triglycerides (TG) by 50% over 3 hours of perfusion (6). Similar results were 




observations could be reproduced in human livers is still to be determined. In addition, those 
organs had not been exposed to ischaemic injury, as is the case in liver transplantation; 
therefore, whether it would affect the defatting process remains under-researched.  
We aimed to study the feasibility of the delivery of this combination of drugs to steatotic human 
donor livers undergoing end-ischaemic NMP within the regular process of organ donation and 
cold preservation. The impact of this intervention on the mobilization and metabolization of 
intracellular lipids leading to defatting was assessed, together with its effects on recovery of the 
metabolic activity of the organs.   
7.3 Materials and Methods 
7.3.1 Study design and source of discarded donor livers             
Ten human livers discarded for transplantation due to surgical macroscopic assessment of 
steatosis were submitted to NMP for 12 hours after variable periods of SCS. They were 
randomly allocated to the experimental groups using the covariate adaptive randomization 
method that accounted for donor type and cold ischaemia time (CIT). The defatting group had 
the perfusion fluid supplemented with a combination of drugs to improve lipid metabolism 
(Defatting cocktail) (5 livers) and a control group (5 livers) which received vehicle only in the 
perfusion fluid (dimethyl-sulfoxide [DMSO] < 0.01%). The comprehensive protocols for 
sampling (including core needle liver biopsies, perfusate and bile analysis) and data collection 
are presented in the supplementary material.  
All study livers were originally retrieved with the intention of transplantation as per policy of 
the National Health Service Blood and Transplant (NHSBT). The authorisation for research use 
of the organ was obtained by the specialist nurse in organ donation in accordance with NHSBT 




National Research Ethics Service and the NHSBT Ethics Committee (references 13/LO/1928 
and 06/Q702/61, respectively).    
7.3.2 Liver perfusion procedure 
After arrival at our centre, the organs were prepared following the standard bench preparation 
as described elsewhere (9). The cystic duct was ligated, and a 12 French bile cannula inserted 
in the common bile duct. The liver was flushed via portal vein (PV) and hepatic artery (HA) 
with two litres of 5% glucose, transferred to the reservoir of the disposable circuit and then 
perfusion was started.  
Liver Assist (Organ Assist, Groningen, Netherlands) was the device used for the perfusions. 
Temperature was set initially at 20 C increasing gradually to 37 C within the first 30 minutes. 
Initial pressure on the HA was 30 mmHg and 5 mmHg on the PV. Both were raised steadily 
with incremental increases in temperature reaching 60 mmHg and 10 mmHg respectively at 30 
minutes. Oxygen supply was adjusted to achieve partial pressure of 20-30 kPa in the perfusate 
on the arterial circuit. The perfusate consisted of 3 units of packed red blood cells, 5% w/v 
human albumin solution and additional drugs as specified in the supplementary Table S7.1.  
7.3.3 The defatting cocktail of drugs 
A previously published cocktail of drugs (6) (10 μM of forskolin; 1 μM of GW7647; 10 μM of 
hypericin; 10 μM of scoparone; 0.4 ng/mL of visfatin; 1 μM of GW501516) was supplemented 
with L-carnitine 0.8 mM diluted in DMSO and added in the perfusate for the defatting group 
when the perfusate reached 37 C. The control group received an equal amount of DMSO 
(<0.01% v/v) in the perfusate within the same timeframe. Drugs were obtained from Sigma-




7.3.4 Histological evaluation 
Tissue biopsies were embedded in paraffin and cut in sections of 4 μm. Staining with 
haematoxylin and eosin (H&E) was performed to assess necrosis, grade of steatosis, pre-
existing acute or chronic liver injury and periodic-acid Schiff (PAS) for glycogen stores. 
Macrovesicular steatosis (MaS) was defined as the presence of a large LD filling up the 
hepatocytes and displacing the nucleus to the periphery. Microvesicular steatosis (MiS) refers 
to the presence of numerous small LDs in the hepatocyte (‘foamy’ aspect) without affecting 
cell nuclei position. MaS was graded based on the percentage of hepatocytes involved (None: 
< 5%; Mild: 5–30%; Moderate: 30–60%; Severe: > 60%). MiS was reported as present or 
absent. Histological assessment was done under lower magnification (4–10) and confirmed 
under higher magnification (20–40), if required. It was conducted by two independent 
pathologists (GR and SR) blinded to the study group.  
7.3.5 Assessment of lipid metabolism 
Perfusate total cholesterol (t-cholesterol), high density lipoprotein (HDL) and TG (P-TG) were 
measured at the hospital clinical laboratories. Tissue TG (T-TG) was assessed from tissue 
homogenates using a commercially available kit (10010303; Cayman chemical, Miami, Florida, 
USA) following manufacture’s guidelines. Total ketone bodies (3-hydroxybutyric acid and 
acetoacetic acid) were measured in the perfusate using a commercial kit (MAK134; Sigma-
Aldrich, St. Louis, MO, USA) following the manufacturer’s instructions.    
In-gel fluorescent protein staining was performed to investigate changes across groups in 
transcription of three key enzymes in the intracellular lipid metabolism: (1) Acetyl-CoA 
synthetase promotes the reaction of coenzyme A (CoA) with FAs generating the substrate 




palmitoyltransferase (CPT1A) responsible for the shuttle of acetyl-CoA into the mitochondrial 
matrix for oxidation; and (3) Peroxisomal acyl-coenzyme A oxidase 1 (ACOX1), an essential 
enzyme for the peroxisomal oxidation of medium to long chain FAs. Detailed techniques and 
the list of antibodies are provided in the supplementary material. 
7.3.6 Assessment of the liver metabolism 
Parameters used in our unit as indicators of ongoing liver metabolism were applied to define 
whether organs would be potentially transplantable (10). Other parameters, such as the 
dynamics of lactate clearance, bile quality (assessed by bile pH), urea production, release of 
transaminases in the perfusate and oxygen uptake were also investigated. For analysis of 
dynamic changes in lactate metabolism over time the area under the curve (AUC) of lactate 
concentrations in the perfusate between 0 and 12 hours was analysed. Oxygen uptake was 
calculated as the difference between the oxygen inflow and the outflow in kPa. 
7.3.7 Biochemistry analysis 
Markers of hepatocellular injury (alanine aminotransferase [ALT], aspartate aminotransferase 
[AST]), biliary injury/function (gamma-glutamyl transpeptidase [GGT]) and protein release 
(albumin and total protein) were measured in the perfusate (time points in the sampling 
protocol).     
7.3.8 Cellular energy status assessment 
Levels of adenosine triphosphate (ATP) were assessed using a fluorometric commercial kit 
from liver tissue homogenates (MAK190; Sigma-Aldrich). Levels were normalised to mg of 
protein.  




Immunohistochemistry was performed on formalin-fixed paraffin-embedded sections for the 
expression of the marker of cell membrane phospholipid peroxidation 4-hydroxynonenal (4-
HNE). To assess tissue inflammation, the cluster of differentiation (CD)-11b, an integrin on the 
surface of activated leukocytes; and, the CD-14, a lipopolysaccharide receptor which is part of 
the toll-like receptor 4 signalosome and participates in the development of the IRI, were 
investigated. For the detailed technique and antibodies list refer to supplementary material. 
Staining expression was scored using a semiquantitative scoring system, the modified 
immunoreactive score (IRS) (11). This takes into consideration intensity of staining (0: no 
colour reaction; 1: mild reaction; 2: moderate reaction; 3: intense reaction) and its distribution 
(0: no positive cells; 1: < 10% positive cells; 2: 10–50% positive cells; 3: 51–80% positive cells; 
4: > 80% positive cells). A final score between 0 and 12 is obtained by multiplying the two 
parameters.       
Perfusate TNF-α, interleukin (IL)-10 and IL-1β levels were determined using sandwich 
enzyme-linked immunosorbent assay (ELISA) (RAB0476, RAB0244, RAB0273; Sigma-
Aldrich). 8-hydroxy-2-deoxyguanosine (8-OHdG) was assessed in the perfusate using a 
commercially available kit (ab201734; Abcam, Cambridge, MA, USA) following the 
manufacturer’s instruction. All samples were tested in duplicate. 
7.3.10 Statistical analysis 
Continuous variables were expressed as median with interquartile range (IQR) and categorical 
variables as an absolute number with percentage frequencies. Comparisons between groups 
were performed using two-tailed Fisher’s exact test for categorical variables, Mann–Whitney 
U test or Student’s t test for independent continuous variables and Wilcoxon signed-rank test 




analysed using Pearson’s correlation coefficient. Area under the curve was calculated using the 
trapezoidal rule. The statistical level of significance was set at p < 0.05. GraphPad Prism 
(version 6.04 for Windows, GraphPad Software, La Jolla, USA) software was used for all 
statistical analyses and graph creation. 
7.4 Results 
7.4.1 Donor demographics and perfusion parameters 
Overall median donor age was 51 years (IQR: 47–58), median donor risk index was 2.02 (1.99–
2.09) and median CIT 737 minutes (717–805). Each study group included three donors after 
brain death (DBD) and two donors after circulatory death (DCD) livers. The groups were 
comparable in terms of donor characteristics and preservation times. Details provided in Table 




Table 7.1: Donor demographics, liver characteristics and machine perfusion data. 
Abbreviation: DCD- Donation after circulatory death; UK- United Kingdom; ET- Eurotransplant; ALT- Alanine 





Parameter Defatting (n = 5) Control (n = 5) p-value 
Donor information 
Age, years 52 (47–61) 49 (44–66) 0.98 
DCD livers 2 (40%) 2 (40%) > 0.99 
Sex, male 3 (60%) 3 (60%) > 0.99 
Height (cm) 174 (162–184) 172 (167–184) 0.72 
Bodyweight (kg) 86 (75–100) 95 (75–105) 0.67 
Body mass index (kg/m2) 30 (28–34) 28 (25–34) 0.52 
Donor risk index 2.04 (1.91–2.80) 2.00 (1.83–2.09) 0.22 
UK donor liver index 1.14 (0.98–1.77) 1.28 (0.94–1.76) 0.94 
ET donor risk index 1.85 (1.75–3.11) 2.00 (1.98–2.50) 0.75 
Peak ALT (IU/L) 66 (39–99) 104 (39–109.5) 0.38 
Peak GGT (IU/L) 110 (46–239) 355 (31–369) 0.29 
Days on ventilator 2 (2–4) 3 (1–4) 0.64 
Liver characteristics 
Liver weight (grams) 1874 (1731–2362) 2130 (1775–2228) 0.93 
Donor warm ischaemic time  
(minutes) 
12 (10–14) 13 (13–13) 0.70 




12:50 (12:20–13:20) 0.65 




12:03 (10:21–12:09) 0.29 
Machine perfusion parameters 
Lactate (mmol/L)    
Start (0-hour) 11.1 (9.2–14.4) 10.6 (9.4–11.8) > 0.99 
Highest 11.6 (10.4–16.3) 14.7 (12.1–18.8) 0.38 
Lowest 0.9 (0.3–1.8) 1.6 (0.7–11.7) 0.14 
Last (12–hours) 1.9 (0.6–2.7) 2.2 (1.0–16.0) 0.003 
Sodium bicarbonate 8.4% 
supplementation (mL) 
20 (15–27) 40 (30–90) 0.04 
Total bile production (mL/hour) 1.7 (1.6–2.6) 0.6 (0.2–1.6) 0.02 
Bile pH (12 hours) 7.84 (7.71–7.95) 7.34 (7.10–7.60) 0.02 
Median arterial flow (mL/min) 360 (283–405) 286 (167–343) 0.09 
Median portal vein flow 
(mL/min) 
1316 (1232–1515) 1020 (900–1302) 0.056 




Treated livers developed higher median PV flows (p = 0.056) with lower vascular resistance (p 
= 0.005) from the start until 12 hours of perfusion. There was a trend of higher median HA 
flows in the defatting group (p = 0.09) with a significantly lower HA resistance (p = 0.003) 
during this period. There was a strong correlation between T-TG and flows at times 6 and 12 
hours on the HA (r = –0.66, p = 0.04 and r = –0.68, p = 0.03, respectively) and PV (r = –0.79, 









Figure 7.1: Perfusion parameters. Section 1 shows the vascular parameters of the livers during 
perfusion. The portal vein flow rate was higher in the defatted livers throughout the perfusion in 
comparison with the control group and this was associated with a faster decrease in vascular resistance 
(Panel B). Panel C shows the hepatic artery (HA) flow rate with a trend of higher values for the defatting 
group. This is potentially associated with the faster decrease in HA vascular resistance at the beginning 
of perfusion (Panel D). Metabolic parameters of the livers during machine perfusion were described in 
Section 2. Perfusate urea concentration increased significantly more in the defatting group in comparison 
with the controls that also had a rising trend (Panel E). Defatted livers metabolised perfusate lactate 
more effectively than controls reaching lower median concentrations (Panel F). Glucose levels peaked 
during the initial two hours of perfusion and then decreased steadily. In the control group figures were 
stable initially and then tend to increase towards the end of the perfusion (Panel G). Section 3 reports 
data from biliary function and injury. Gamma-glutamyl transferase (GGT) levels in the perfusate 
increased significantly more in the control group (Panel H). Concomitantly, treated livers produced 
significantly more bile throughout the perfusion (Panel I) with a higher bile-pH (Panel J). In all panels 
the dots represent individual organs at the time points and the line the median of the values for each 
group. Comparison between groups used the Mann-Whitney U test. Statistical significance at *p < 0.05. 
 
7.4.2 Liver parenchyma histology 
Each experimental group initially had 1 liver histologically classified as severely steatotic, 2 as 
moderately, 1 mildly and 1 non-steatotic. Changes between categories throughout the perfusion 
and the presence of MiS are presented in Table 7.2. Positive PAS staining of parenchymal area 
was constant along the perfusion for the control group whereas the defatting group presented 




Figure 7.2: Tissue triglycerides content and histological steatosis assessment 
analysis.  
 
Tissue homogenate triglycerides were comparable at time 0 and then it decreased over 6 and 12 
hours of perfusion in the defatting group reaching lower levels than the control group (Panel A). 
At the histological assessment of macrovesicular steatosis on haematoxylin and eosin staining 
(Panel B) a similar trend was observed. Panel C shows that defatted livers were more depleted of 
glycogen at time 0, however, their levels increased surpassing the control group already at 6 hours 
of perfusion. The positive areas for periodic-acid Schiff (PAS) were constant for the control group 
throughout the perfusion. Panel D, image from a histologically moderately steatotic liver that 
received the defatting cocktail and presented with a significant reduction in macrovesicular 
steatosis already at 6 hours of perfusion (Panel E). Panel G shows the presence of microvesicular 
steatosis in the same liver at time 0 and the change at 6 hours (Panel H). Panel F illustrates a 
mildly steatotic liver from the defatting group with an important depletion of glycogen stores 
replenishing its stores over 6 hours of perfusion (Panel I). In panels A and B, the bar represents 
the median and error bars the interquartile range. Panel C, the dots represent individual organs at 
the time points and the line the median of the values for each group. Comparison between groups 




7.4.3 Lipid metabolism modulation and defatting 
T-TG levels dropped by 38% (23–51%) in the defatting group and 7% (3–10%) in the control 
group over 6 hours (p = 0.003); and, 30% (21–35%) in the defatting versus 10% (6–13%) in the 
control over 12 hours (p = 0.002) in comparison with time 0. MaS rate of defatted livers 
decreased by 40% (17–50%) over 6 hours and 50% (15–60%) over 12 hours, there were no 



























Macrovesicular steatosis Microvesicular steatosis 
Time 0 Time 6 Time 12 Time 
0 
Time 6 Time 12 
Defat. 1 DBD 823 Moderate Moderate Mild Present Present Present 
Defat. 2 DCD 729 Moderate Moderate Mild Present Present Present 
Defat. 3 DBD 700 Mild None None Present Present Present 
Defat. 4 DBD 754 Severe Moderate Moderate Present Present Present 
Defat. 5 DCD 820 None None None Present Present Present 
Control 
1 
DBD 520 Mild Mild Mild Present Present Present 
Control 
2 
DCD 740 Moderate Moderate Moderate Present Present Present 
Control 
3 
DCD 800 None None None Present Present Present 
Control 
4 
DBD 723 Severe Severe Severe Absent Absent Absent 
Control 
5 
DBD 735 Moderate Moderate Moderate Present Present Present 
Steatosis rates variation analysis 
Parameter Defatting (n = 5) Control (n = 5) p-value 
Tissue triglycerides analysis (mg/gr liver) 
T-TG (Time 0) 2.7 (1.9–3.5) 3.3 (1.9–3.7) 0.84 
T-TG (Time 6) 1.6 (0.9–2.6) 3.2 (1.7–3.6) 0.03 
T-TG (Time 12) 2.0 (1.2–2.6) 3.1 (1.6–3.4) 0.02 
ΔT-TG (Time 0 to 6) 38% (23–51) 7% (3–10) 0.003 
ΔT-TG (Time 0 to 12) 30% (21–35) 10% (6–13) 0.002 
Histological assessment analysis (Macrovesicular steatosis – MaS) 
MaS (Time 0) 31% (10–58) 40% (7–65) 0.82 
MaS (Time 6) 15% (5–35) 30% (7–65) 0.31 
MaS (Time 12) 15% (5–22) 40% (7–65) 0.13 
ΔMas (Time 0 to 6) 40% (17–50) 0% (0–12) 0.02 
ΔMaS (Time 0 to 12) 50% (15–60) 0% (0–12) 0.005 
Abbreviations: Defat.- Defatting group; DBD- Donation after brain death; DCD- Donation after circulatory death; 
CIT- Cold ischaemia time; T-TG- Tissue triglycerides. ΔT-TG and ΔMaS are related to the variation in the figures 
between beginning and end of the period divided by the beginning. Severity of macrovesicular steatosis assessed 
according to the parenchymal are occupied by hepatocytes with the fatty changes: none < 5%, mild 5–30%, 








Ketogenesis was enhanced in the defatting group until 6-hour (p = 0.008). ATP levels were 
similar at time 0 and then it increased significantly until 6 hours of perfusion for the defatting 
group and decreased for the control group (p = 0.01 and p = 0.008, respectively) (Figure 7.3).  
Median P-TG fell over the first 2 hours. Following this, it increased significantly until 6 hours 
in the defatting group (p = 0.04) but not in the control (p = 0.59). The increase in P-TG levels 
showed a correlation with the drop in T-TG between time points 0 to 6 hours (r = –0.58, p = 
0.08) and 0 to 12 hours (r = –0.59, p = 0.07). There was no correlation between median P-TG 
levels and ALT concentrations in the perfusate (r = 0.18, p = 0.65).   
T-cholesterol levels followed the same pattern and they were higher in the defatting group at 6 
(p = 0.02) and 12 hours of perfusion (p = 0.003). HDL-cholesterol was below the limit of 
detection of the laboratory until 6 hours of perfusion (1.9 mg/dL) starting to increase thereafter; 
however, did not achieve statistically significant difference at 12 hours of perfusion (p = 0.28). 
Protein in-gel staining revealed that defatted livers had at 6-hour perfusion a 3-fold increase in 
the protein levels of acetyl-CoA synthetase, 1.4-fold in the Acyl-CoA oxidase 1 and 6-fold in 
















Figure 7.3: Metabolic pathways for elimination of intracellular triglycerides. Enhanced 
mitochondrial oxidation of fatty acids (Series 1) results in increased ketogenesis (Panel A) throughout 
the perfusion, however, it was more pronounced on the treatment group. Mitochondrial respiration 
assessed by pCO2 production increased steadily on both experimental groups (Panel B) and the oxygen 
uptake was higher for the initial 3 hours in the defatting group and then decreased slightly (Panel C). 
This was associated with increased ATP replenishing within the initial 6 hours in the defatting group 
and then decreased steadily maintaining higher concentrations than the control group. In addition, there 
was an increase in exportation of fatty acids (Section 2). The levels of total cholesterol in the perfusate 
increased faster in defatted livers (Panel E) as the triglycerides’ levels (Panel F). HDL cholesterol levels 
were below the detection range and start to increase slowly after 6 hours of perfusion (Panel G). In-gel 
fluorescent protein stain normalised to the total protein was performed for acetyl CoA synthetase, 
carnitine palmitoyltransferase form 1A (CPT1A) and peroxisomal acyl-coenzyme A oxidase 1 
(ACOX1). Experiments were performed n = 5 and representative figures are presented in Panel H. The 
peak of intensity in densitometric analysis at the specific protein band was compared between the groups 
(Panel I). In all panels the dots represent individual organs at the time points and the line the median of 
the values for each group. Comparison between groups used the Mann-Whitney U test. Statistical 
significance at *p < 0.05. 
 
7.4.4 Liver viability, hepatocellular metabolic functional parameters and biomarkers 
Lactate levels were comparable at time 0 and then they decreased significantly until 12-hours 
of perfusion in the treatment group, but not for the control group (p = 0.04 and 0.22, 
respectively). Dynamic changes in the lactate metabolism, as assessed by the AUC, showed 
that, considering both groups, smaller lactate-AUC was associated with higher total perfusion 
flows (r = –0.84, p = 0.002), increased urea production (r = –0.73, p = 0.02), higher bile pH at 
time 6-hour (r = –0.88, p = 0.02), increased release of P-TG (r = –0.90, p < 0.001), lower 
expression of 4-HNE (r = 0.62, p =  0.05) and a trend for higher bile production (r = –0.58, p = 
0.08). The defatting group demonstrated a trend of shorter time to peak lactate and time to 
achieve lactate < 2.5 mmol/L, which were correlated with positive metabolic factors. Further 
details are provided in Figure S7.1. 
All treated livers reached our viability criteria and therefore would be considered transplantable 




functional parameters to be considered transplantable (p = 0.04). Achievements of the 
parameters of the criteria are presented in Table S7.3.  
Defatted livers produced more urea over the initial 6 hours (p = 0.03). There was a strong 
negative correlation between lactate and urea levels at 6-hour (r = –0.82, p = 0.004) and 12 
hours (r = –0.77, p = 0.009). Increased P-TG correlated with an increased production of urea at 
6-hour (r = 0.87, p = 0.001) and 12-hour (r = 0.63, p = 0.05). Median perfusate glucose 
increased from time 0 to 2-hours in the defatting group (p = 0.10) and then decreased towards 
12-hour (p = 0.08). Those levels were constant for the control group. Metabolic parameters of 
the livers are presented in Figure 7.1. Electrolytes and other biochemistry parameters are 
presented in Figure S7.2.  
The viable livers from the control group released less t-cholesterol (17.4 [15.5–19.3] vs. 30.9 
[23.2–38.7] mg/dL, p = 0.02) and P-TG (110.7 [88.6–132.9] vs. 177.1 [177.1–186.0] mg/dL, p 
= 0.048) at 12-hour, produced less ATP (400 [390–410] vs. 1417 [1138–1453] pmol/mg, p = 
0.03) and developed higher expression of 4-HNE (IRS 2 [2–2] vs. IRS 1 [1–1], p = 0.02) at 
time 6-hour in comparison with defatted livers.        
7.4.5 Biliary injury and function 
Cumulative bile production was higher for the defatting group at the 6-hour (p = 0.03) and 12-
hour perfusion time points (p = 0.008). There was no statistically significant correlation 
between t-cholesterol in the perfusate and cumulative bile production at 6 hours (r = 0.59, p = 
0.07) or 12 hours of NMP (r = 0.59, p = 0.07).  
Bile quality, as assessed by bile’s pH measured at 12 hours, was also higher in the defatting 




significantly from time 0 to 12 hours of perfusion in the control group (p = 0.04). Details are 
presented in Figure 7.1. 
7.4.6 Hepatocellular injury, oxidative damage and activation of immune cells 
Perfusate ALT levels were lower in the defatted livers at 12-hour perfusion (p = 0.049) (Figure 
7.4). Perfusate 8-OHdG levels were similar at the 6-hour time point followed by a general 
increase until 12 hours in the control group and a stabilisation of levels in the defatting group 
(p = 0.10). Immunohistochemical analysis for 4-HNE demonstrated similar initial levels at the 
beginning of the perfusion followed by an increase in the control group and a decrease in the 
defatting at 6 hours (p = 0.02). There was a strong negative correlation between P-TG and 4-
HNE expression (r = –0.87, p = 0.001) at 6-hour of perfusion.  
The activation of the Kupffer cells and neutrophils in liver tissue, as assessed by 
immunohistochemical analysis (CD14 and CD11b, respectively), was similar between groups 
at time 0 and then it increased for the control group reaching higher scores at 12 hours (p = 
0.046 and p = 0.045, respectively). The cytokine profile showed a decrease in the perfusate 
levels of the inflammatory TNF-α from time 0 to 6, and 12 hours in the defatting group. IL-1β 
also decreased over the time-course of the perfusions in the treatment group. For both markers, 
the levels in the control were either flat or increased. The anti-inflammatory IL-10 increased in 
both groups from the beginning until time 6 hours and then it decreased faster in the defatting 












Figure 7.4: Assessment of hepatocellular, oxidative injury and activation of the immune cells. 
Alanine aminotransferase (ALT) levels released in the perfusate were investigated as a marker of 
hepatocellular injury (Section 1). Levels flattened along the perfusion in the defatting group and reached 
higher figures in the control group (Panel A). Aspartate transaminase (AST) levels followed a similar 
trend (Panel B). Markers of oxidative injury were also explored (Section 2). Nuclear cells damage 
assessed by 8-HOdG released in the perfusate showed stable levels in the defatting group and a trend to 
increase in the control group (Panel C). The cytokines’ profile (Series 3) was investigated and perfusate 
concentration of the pro-inflammatory cytokines TNFα (Panel D) and IL-1β (Panel E) decreased along 
the perfusion in the defatting group and increased in the group. The anti-inflammatory IL-10 increased 
in both groups at 6 hours and then it decreased faster in the defatted livers (Panel F). 
Immunohistochemical analysis was performed for markers of oxidative injury and activation of an 
inflammatory response. Panel G shows a moderate reaction of the staining committing 10–50% of the 
hepatocytes as assessed by the immunoreactive score (IRS). After 6 hours of defatting the figure shows 
a predominantly mild staining reaction in 10–50% of the hepatocytes (Panel H). The trend for each 
experimental group along the perfusion is presented in Panel I. In accordance, tissue expression of CD-
14 (Panels J and K) and CD-11b (Panels M and N) for the defatting group decreased from the beginning 
to time 6 hours of perfusion. Panel L represents the changes over time for CD-14 and Panel O the 
changes in tissue expression of CD-11b. Scales are provided on the bottom of each figure. In all panels, 
the dots represent individual organs at the time points and the line the median of the values for each 
group. Comparison between groups used the Mann-Whitney U test. Statistical significance at *p < 0.05. 
 
7.5 Discussion 
Steatosis has become the leading reason for declining donor livers for transplantation which, in 
turn, is worsening the growing discrepancy between organ availability and the increasing 
transplant waiting lists (12, 13). We have shown that the delivery of a pharmacological 
intervention during NMP was able to decrease the fat content of whole steatotic human livers 
within 6 hours. This effect was driven by enhanced lipid metabolism as increased oxidation of 
lipids and export to the perfusate. Importantly, this enhanced lipid metabolism increased the 
metabolic support to all organs improving its functional recovery. It was associated with 
enhanced mitochondrial functioning, increased vascular flows, reduced markers of 
hepatocellular injury and inflammation with improved biliary function. These parameters are 
suggested as indicatives of transplantability of extended criteria donor (ECD) organs during 




hepatic lipid metabolism during NMP may defat steatotic organs and increase their functional 
recovery potentially halting the harmful effects of reperfusion injury.  
Previous in vitro studies with fat-laden rat hepatocytes and hepatoblastoma cells demonstrated 
the feasibility of defatting cells with a combination of drugs over 48 hours (6, 16, 17). 
Thereafter, this defatting cocktail was delivered to whole steatotic rat livers during NMP and 
the authors showed a decrease in tissue-TG of 50% within 3 hours (6). Interestingly a decrease 
of 30% could be obtained with NMP alone over the same period (6). However, a recent study 
reporting results of 24-hours perfusion of steatotic human livers could not replicate the same 
results with NMP alone (5). This raised concerns about variability in response between species 
and that the effectiveness of the drugs could be compromised after the inherent ischaemic injury 
during organ retrieval.  
A description of the detailed pharmacological effects of the drugs used is out of the scope of 
this manuscript, however it can be found within a comprehensive review about the subject (18). 
Briefly the drugs increase intracellular lipolysis releasing FAs and glycerol within the cells and 
induce the transcription of enzymes involved in its catabolism in the mitochondria and 
peroxisomes. Hence metabolization of lipid stores not only decreases its intracellular content, 
but also supports cell metabolism enhancing the recovery of the function of the organs. 
Importantly, these cellular metabolic pathways are not dependent on insulin receptors and 
therefore occurrence of insulin resistance, common in non-alcoholic fatty liver disease, should 
not affect the process. Our group recently reported, for the first time, the effectiveness in vitro 
of these pharmacological agents in defatting primary human hepatocytes made fatty by 
supplementation with fatty acids (19). Apart from being non-toxic to these cells, there was a 




were also shown for the first time not be toxic to non-parenchymal liver cells (intrahepatic 
endothelial cells and cholangiocytes) (19).     
In this study we delivered a defatting cocktail to human livers, discarded for transplantation due 
to the surgical macroscopic assessment of steatosis. All livers across both groups had uniformly 
extended periods of CIT. We have found that NMP supplemented with the defatting cocktail 
was able to improve lipid metabolism, decreasing significantly tissue-TG by 38% over a period 
of 6 hours whereas NMP alone reduced it by 7% over the same time. Histologically, it 
corresponded to a decrease of 40% in MaS and 0%, respectively. This defatting effect was 
associated with an enhanced mitochondrial function (β-oxidation of FAs, mitochondrial 
respiration [higher oxygen uptake], ketogenesis, augmented urea cycle and Krebs cycle activity 
with higher ATP synthesis) and increased exportation of intracellular-TG as lipoproteins in the 
perfusate. Mechanistically, it was represented by upregulation in the levels of key enzymes 
involved in the intracellular lipid metabolism in comparison with control livers. Beneficial 
effects were also seen in glucose metabolism, where defatted livers released more glucose in 
the perfusate during the initial hours of perfusion. This enhanced gluconeogenesis is likely to 
be related to an increased availability of glycerol because of the augmented breakdown of lipids 
with higher production of glucose-6-phosphate. Glucose-6-phosphate, in turn, will generate the 
glucose released in the perfusate and activate the enzyme glycogen synthase promoting 
glycogenesis, in accordance with our findings (20).  
In addition, modulation of the lipid metabolism halted hepatocellular injury as assessed by 
diminished release of ALT in the perfusate. Tissue damage during reperfusion is primarily 
related to mitochondrial dysfunction with reactive oxygen species (ROS) production, oxidative 
stress and concomitant pro-inflammatory response. Accordingly, treated livers developed lower 




(4-HNE), production of inflammatory cytokines and activation of immune cells (CD-14, CD-
11b). The former could also have resulted from direct effects of the defatting constituents, such 
as PPARs (21, 22). Our findings corroborate with the previous in vitro studies, where delivering 
the cocktail to fat-laden rat hepatocytes diminished ROS concentration and cellular injury, as 
assessed by the cytosolic lactate dehydrogenase release into media (16).  
Ischaemic cholangiopathy following DCD liver transplantation is of great clinical concern and 
identification of high-risk donor organs during NMP, prior to transplantation, would be a useful 
clinical tool (23). Watson et al. 2018 described that bile-pH < 7.5 during NMP is suggestive of 
biliary tree necrosis and can increase the risk of ischaemic cholangiopathy post-transplantation 
(15). Contrary to this, treated livers demonstrated bile-pH levels higher than 7.5 while the 
converse was seen in control livers. Importantly, there was no correlation between greater bile 
production and the increase in t-cholesterol in the perfusate. This suggests a beneficial effect of 
the cocktail itself on the biliary system. The mechanism involved needs further investigation. 
However, the protective role of defatting lowering oxidative injury and tissue damage can be 
potentially correlated.  
In in vitro studies the defatting cocktail was also associated with a higher resistance to IRI, as 
demonstrated by improved hepatocyte viability (16, 24, 25). In our study pharmacological 
modulation of the lipid metabolism of donor livers during NMP reduced lipid content and 
improved their functional recovery. Urea is produced by the liver and results from an enzymatic 
reaction involving carbon dioxide and the ammonia derived from the deamination of proteins 
in the liver. The increased level of urea suggests increased urea synthesis in defatted livers (17, 
26). Our previously published viability criteria assert that lactate levels < 2.5 mmol/L within 4 
hours is a major criterion for safe transplantation of ECD donor livers. However, it also 




of the dynamic changes in lactate concentration over time; it showed a strong correlation 
between lactate metabolism kinetics (lower AUC, shorter time to peak lactate and the clearance 
from peak to 2.5 mmol/L) and other parameters of appropriate liver metabolism. These findings 
reinforce the significance of this marker in the context of defatting. The Cambridge group has 
advocated the use of transaminases, bile production and bile quality as appropriate markers of 
organ viability (15). The discussion about optimal viability criteria during NMP is out of the 
scope of this paper, and whether the same criteria or machine perfusion technique are applicable 
for all organs (e.g. DBD, DCD or defatted livers) is also another topic for discussion. However, 
defatted livers fulfilled all those criteria currently considered as indicative of adequate liver 
metabolism and, hence, would potentially be deemed transplantable. 
The results obtained from employing our study protocol have shown that pharmacological 
targeting of lipid metabolism can defat steatotic human livers and improve their metabolic 
function within the relatively short timeframe of 6 hours. Beyond this time point, all the benefits 
observed with the defatting protocol appeared to be sustained. This observation suggests that 
the drugs had already been metabolised at the 6-hour perfusion mark. At this point, either a 
second bolus of the cocktail could be considered to amplify its effects, or the aim would be 
considered achieved and the organ potentially used for transplantation. Another point of 
discussion is the use of filters to remove solubilised lipids from the perfusate. It intends 
potentially to prevent lipotoxicity. However, in the context of NMP and defatting we have not 
seen toxic effects of the FAs in organ functioning, tissue damage or inflammatory response. 
Further studies will be needed to investigate its potential advantages.           
Banan et al. showed a reduction of 10% in MaS over 8 hours of NMP for a discarded steatotic 
donor human liver with 80% MaS and negligible reduction for a liver with 30% MaS, 




two organs reported and the lack of a control group limits the interpretation of the results of this 
study. This is the first study designed specifically to deliver a defatting cocktail of drugs to 
steatotic human livers during NMP and assess its impact on lipid metabolism. The increased 
breakdown of intracellular triglycerides was associated with signs of improved mitochondrial 
oxidative function (urea cycle, Krebs cycle, ketogenesis, ATP synthesis) that supported other 
metabolic process, as glycogenesis, gluconeogenesis, and alleviate ROS induced oxidative 
stress and pro-inflammatory response halting hepatocellular injury (a diagrammatic summary 
is provided in Figure 7.5). Defatted livers developed higher vascular flows, lower vascular 
resistances that correlated with the higher solubilisation of triglycerides in the perfusate and 
enhanced biliary function. Importantly, all these observations were made within a scenario of 
clinical organ donation encompassing livers originating from different donors (DCD and DBD) 









Figure 7.5: A suggested relationship between the defatting cocktail and intracellular lipolytic 
metabolic pathways. Forskolin activating glucagon membrane receptors stimulates the cyclic 
adenosine monophosphate (cAMP) – protein kinase A pathway and cytoplasmic lipases are attracted to 
the surface of lipid droplets. Glycerol and fatty acids (FA) will then be released serving not only as 
substrates for the cell metabolism but also as ligands to nuclear receptors (peroxisome proliferator 
receptor [PPAR] and liver X receptors [LXR]) increasing the transcription of enzymes involved in the 
catabolism of FFAs in the mitochondria and peroxisome. Diverse cocktail drugs (GW7647, GW501516, 
hypericin, scorparone) also acts as ligands to other nuclear receptors (pregnane X receptors and 
androstane receptors) boosting the transcription of key enzymes. Cytosolic fatty acid reacts with 
adenosine triphosphate (ATP) molecules producing fatty acyl-CoA. Acyl-CoA in turn reacts with 
apolipoprotein B to generate lipoproteins to be exported from the cell and/or reacts with the hydroxyl 
group of carnitine via carnitine palmitoyltransferase I. Acyl-carnitine is transported inside the 
mitochondria by a carnitine-acyl-CoA transferase and a carnitine is transferred outside. Acyl-CoA is 
processed by β-oxidation. The acetyl-CoA produced then will follow to ketogenesis or for complete 
oxidation via the Krebs cycle and the electron transport chain with the production of ATP. Increased 
production of aspartate and carbon dioxide (CO2) stimulate the urea cycle increasing the production of 
urea. Alternatively, long and very-long-chain FFAs are also oxidized in the peroxisomes. Glycerol is a 
gluconeogenic precursor, it is converted to pyruvate producing glucose-6-phosphate through the 
gluconeogenesis pathway. Glucose-6-phosphate will be released as glucose in the perfusate and 
stimulate the enzyme glycogen synthase increasing the production of glycogen. The squares contain the 
specific enzymes that have an upregulation in the transcription as a consequence of this stimulus. Drugs 
and supplement used in the cocktail are presented in yellow squares. 
 
Although our study has shown that ex situ pharmacological modulation of lipid metabolism of 
donor human livers enhances its function, we have not proven that they are transplantable. This 
clearly demands a pilot study to assess the defatting protocol in clinical transplantation. In the 
United Kingdom histological assessment of donor liver steatosis is not performed routinely, 
and livers are discarded solely based on a surgical macroscopic assessment of steatosis. As a 
consequence, we had various grades of steatosis, assessed at the histological level, in the groups, 
and even two livers with less than 5% MaS. However, they were equally distributed between 
groups. Moreover, despite controlling for donor type, CIT and the groups having livers with 
similar degrees of steatosis, some other unfavourable factors were more predominant in the 
control group (higher GGT peak, higher liver weight, the oldest donor in the cohort). Small 
differences between groups is an intrinsic limitation of research with discarded human livers, 
however, the use of human livers in research has the advantage of eliminating variability 




CIT, this together with steatosis, and other donor factors, explain the poor rescue of control 
livers based on metabolic parameters.  
7.6 Conclusion 
In conclusion, we have shown that pharmacological modulation of lipid metabolism during 
NMP can promote defatting of whole human steatotic livers within 6 hours. More importantly, 
the enhanced lipid metabolism improved the metabolic status of the organs, their functional 
recovery, decreased vascular resistance and reduced the expression of markers of reperfusion 
injury. Those findings support further clinical investigations and open a window of opportunity 



















7.7.1 Supplementary Material and Methods 
7.7.1.1 Sampling protocol 
7.7.1.1.1 Liver biopsies 
Core needle liver biopsies using disposable modified Menghini needle (15G) were taken before 
commencing the perfusion, at time points 6-hour and 12-hour of perfusion for all livers. Two 
biopsies, not more than 1 cm from each other, were taken at each time point. One was stored in 
formalin and the other immediately snap-frozen in liquid nitrogen for further analysis.  
7.7.1.1.2 Perfusate samples 
The perfusate was sampled every 30 minutes throughout the first 4 hours of perfusion and then 
at 6-hour, 9-hour and 12-hour of perfusion for all livers.  
At each time point approximately 1 millilitre (mL) of perfusate was analysed immediately using 
the Cobas b 221 point of care system (Roche Diagnostics, USA) blood gas analyser. The partial 
pressures of oxygen (O2), and carbon dioxide (CO2), pH, concentrations of base excess, 
bicarbonate, O2 saturation, haemoglobin, haematocrit, sodium, potassium, chloride, calcium, 
glucose and lactate were measured. Four mL of perfusate were then freshly collected in serum 
separators tubes for biochemistry analysis at the hospital clinical laboratories. Six millilitres 
were centrifuged at 10,000 rotations per minute for two minutes and the supernatant collected 






7.7.1.1.3 Bile samples  
Bile production was collected into a Jackson-Pratt drain accoupled to the pipe connected with 
the bile duct. The drain was emptied at 2-hour, 4-hour, 6-hour, 8-hour and 12 hours of perfusion 
for all livers. 
At each time point the total volume of bile produced was recorded and the bile analysed using 
the Cobas b 221 point of care system (Roche Diagnostics, USA) blood gas analyser. Four 4 mL 
were collected into cryovials and snapped-frozen for further analysis. 
7.7.1.2 Data collection protocol 
Parameters for the arterial and venous perfusion units (flows, pressure, resistance and 
temperature) showed on the device’s display were registered every 30 minutes throughout the 
first 4 hours of perfusion and then at 6-hour, 9-hour and 12-hour of perfusion for all livers.  
7.7.1.3 Fluorescent protein gel stain 
Equal amounts of frozen liver tissue were homogenised in lysing buffer solution (Tris, 2% SDS 
[sodium dodecyl sulfate], 2 mM EDTA [Ethylenediaminetetraacetic acid], pH = 9.0) at 100 
mg/mL using the Precellys 24 tissue homogeneiser (Bertin instruments, Montigny-le-
Bretonneux France). Protein concentration was determined using the bicinchoninic acid (BCA) 
protein assay (23225; Thermo Scientific Pierce, Waltham, MA, USA) and final concentration 
equalised to 10 mg/mL. Samples were diluted in a 1:1 rate with 2x Laemmli sample loading 
buffer (1610737; Bio-Rad, Hercules, CA, USA) 5% 2-mercaptoethanol. Thereafter 20 µL of 
sample total protein were loaded in each well of a polyacrylamide gel (Sodium dodecyl sulfate-
polyacrylamide gel - SDS-PAGE) (4561045; Bio-Rad, Hercules, CA, USA) on the Criterion 
Dodeca gel apparatus (Bio-Rad) and protein bands were separated by electrophoresis at 200V 




Blotting Standards (Bio-Rad) was used as a protein ladder. An alcohol solution (50% 
isopropanol, 5% acetic acid prepared in ultrapure water), was used to fix protein bands on the 
matrix and the gel was incubated for 1 hour with the primary antibody (see antibody list). 
Following the gel was washed in PBS (Phosphate-buffered saline) plus 0.1% Tween 20 and 
then incubated with the secondary fluorescent antibody for an additional 1 hour (see antibody 
list). β-Actin antibody was used as a loading control to confirm that samples were equally 
loaded and the effectiveness of the electrophoresis and imaged using a secondary fluorescent 
antibody. Gels were imaged with the ChemiDoc MP imager (Bio-Rad, Hercules, CA, USA) 
using specific protocols for the antibodies used based upon their excitation and emission 
specifications. Images were analysed using the ImageLab software version 6.0 (Bio-Rad). 
Background was subtracted from all lanes and the peak of intensity in densitometric analysis at 
the specific protein band compared between the groups.  
7.7.1.4 Immunohistochemical staining 
Immunohistochemistry was performed on parafin-embedded tissue sections of 4 μm thickness 
using the ImmPRESSTM Excel Staining kit (MP-7601 and MP-7602; Vector Laboratories, 
Burlingame, CA, USA). The sections were deparaffinized in 3 baths of xylene for 3 minutes 
and rehydrated in a similar series of ethanol. Microwaving antigen retrieval was performed in 
Tris-based solution (H-3301; Vector Laboratories), pH 9, for 25 min. The sections were washed 
using Dako wash buffer (S3006; Dako Agilent, Santa Clara, CA, USA). Quenching of 
endogenous peroxidase activity was done via incubation in BLOXALL™ Blocking Solution 
(SP-6000; Vector laboratories) for 10 minutes and blocked with 1x casein for 10 minutes (SP-
5020; Vector Laboratories). Sections were then incubated with the primary antibodies diluted 
in 1x casein (see antibody list for specific dilutions used) for 1 hour. After a second wash tissue 




IgG) ready-to-use (Vector laboratories) for 15 minutes. A new wash was performed, and the 
tissue sections incubated with ImmPRESSTM Excel reagent for 30 minutes. The positive 
immuno-reactivity was revealed by incubation with a mixture of ImmPACT™ DAB EqV 
Reagent 1 with Reagent 2 (Vector laboratories). Tissue sections were counterstained with 
Mayer’s haematoxylin. Finally, sections were dehydrated in a series of ethanol and xylene. No 
primary negative controls were obtained by replacing primary antibody for equal volume of 
goat serum and isotype negative controls by replacing the primary antibody for an isotype 
control antibody.  
All sections were wholly digitalized using the slide scanner Axio Scan.Z1 (Carl Zeiss, 
Oberkochen, Germany) and the images for the study selected using the ZEN image analysis 
software. 
7.7.1.5 Antibodies list 
7.7.1.5.1 Immunohistochemical staining 
• Anti-4-hydroxynonenal (4-HNE) antibody (ab46545; Abcam, Cambridge, MA, USA) 
rabbit polyclonal IgG at 1:200 dilution. 
• Anti-Cluster of differentiation 14 (CD14) antibody (ab36595; Abcam, Cambridge, MA, 
USA) mouse monoclonal at 1:500 dilution. 
• Anti-Cluster of differentiation 11b (CD11b) antibody (ab52478; Abcam, Cambridge, 
MA, USA) rabbit monoclonal at 1:200 dilution. 
• Rabbit IgG isotype control antibody (ab172730; Abcam, Cambridge, MA, USA) 
monoclonal at 1:200 dilution. 
• Mouse IgG isotype control antibody, clone MG3-35 (catalogue number 401302; 




7.7.1.5.2 Protein gel staining 
7.7.1.5.2.1 Primary antibodies 
• Anti-Acetyl CoA synthetase antibody (ab133664; Abcam, Cambridge, MA, USA) 
rabbit monoclonal IgG at 1:1,000 dilution. 
• Anti-ACOX1 antibody (ab184032; Abcam, Cambridge, MA, USA) rabbit monoclonal 
IgG at 1:1,000 dilution. 
• Anti-CPT1A antibody (ab83862; Abcam, Cambridge, MA, USA) rabbit polyclonal IgG 
at 1:1,000 dilution. 
• Anti-β-Actin antibody (A5441; Sigma-Aldrich, St. Louis, MO., USA) mouse 
monoclonal IgG at 1:1,000 dilution. 
7.7.1.5.2 Secondary antibodies 
• Sheep anti Rabbit IgG:DyLight®488 (STAR36D488GA; Bio-Rad, Hercules, CA, USA) 
polyclonal IgG at 1:1,000 dilution. 
• Goat anti Mouse IgG:DyLight®800 (STAR117D800GA; Bio-Rad, Hercules, CA, USA) 
polyclonal IgG at 1:1,000 dilution. 
7.7.1.6 Reagents list 
All drugs employed in the experiments were bought from Sigma-Aldrich, St. Louis, MO., USA. 
The corresponding catalogue numbers are: Forskolin-F6886; GW7647-G6793; Hypericin-
56690; Scoparone-254886; GW501516-SML1491; Visfatin-SRP4908; and, L-carnitine-







7.7.2 Supplementary Results 
7.7.2.1 Table S7.1: Normothermic machine perfusion fluid constitution. 
 
Table S7.1: Normothermic machine perfusion fluid constitution. 








3 units of group O Rhesus-negative donor packed red blood cells 
1000 mL of 5% w/v human albumin solution (Alburex 5, CSL Behring GmbH, Germany) 
10,000 IU heparin (Wockhardt, UK) 
30 mL sodium bicarbonate 8.4% (B. Braun Medical Limited, UK) 
10 mL calcium gluconate 10% 
500 mg vancomycin (Wockhardt, UK) 
60 mg gentamicin (Cidomycin, Sanofi, UK) 
50 mL of 10% v/v Aminoplasmal (B.Braun Medical Limited, UK) 
0.2 mL Cernevit (Baxter Healthcare Ltd., UK) 
0.1 mg phytomenadione (Konakion, Roche Products Ltd, UK) 





7.7.2.2 Table S7.2: Donor demographics, liver features and perfusion parameters. 
Liver number CONTROL 1 CONTROL 2 CONTROL 3 CONTROL 4 CONTROL 5 DEFAT 1 DEFAT 2 DEFAT 3 DEFAT 4 DEFAT 5 
Donor information 
Age 81 48 49 52 41 51 69 54 52 44 
Donor type DBD DCD DCD DBD DBD DBD DCD DBD DBD DCD 
Gender Male Male Male Female Female Male Male Male Female Female 
Height (cm) 173 170 203 172 165 174 193 175 169 155 
Body weight (kg) 76 95 115 75 95 81 101 98 86 70 
Body mass index (kg/m2) 25 33 28 25 35 37 27 32 30 29 
Donor risk index 2.08 2.00 2.09 1.99 1.67 2.00 3.02 1.83 2.04 2.58 
UK donor liver index 1.52 2.01 1.28 1.09 0.81 1.00 1.77 1.15 0.90 1.78 
ET donor risk index 2.02 2.01 2.59 2.41 1.96 1.76 3.41 1.85 1.75 2.82 
Peak ALT (IU/L) 39 74 177 104 335 76 67 110 30 65 
Peak GGT (IU/L) 31 -- 137 402 355 31 71 150 38 269 
Days on ventilator 1 5 4 3 2 2 2 3 2 4 
Co-morbidities and risk history Hypertension, 
light drinker 
Heavy drinker Light drinker Heavy drinker, 
depression 


























Liver weight (grams) 1699 1852 2139 2130 2317 1768 2330 2394 1874 1694 
Donor warm ischaemic time  
(minutes) 
-- 17 15 -- -- -- 13 -- -- 14 
Cold ischaemia time (minutes) 520 740 800 723 735 823 729 700 754 820 
Reason for clinical rejection Steatosis Steatosis Steatosis 
(severe on 
biopsy) 







Lactate (mmol/L)           
Highest 14.7 10.3 13.9 > 20.0 17.7 11.6 11.0 9.9 12.7 20.0 
Lowest 1.6 0.8 0.7 11.8 11.6 1.9 0.9 0.2 1.8 0.4 
Last 1.9 2.7 1.0 > 20.0 13.4 1.9 0.9 0.3 1.8 0.4 
Total Bile production (mL) 6.0 40.0 8.0 0 38.0 70 40.0 31.0 40.0 30.0 
Median Arterial flow (mL/min) 144 286 343 242 616 256 260 364 359 377 
Median Portal vein flow (mL/min) 871 1103 1283 902 1020 1185 1316 1454 1079 1454 
Median liver mass perfusion (mL/g/min) 0.60 0.75 0.76 0.54 1.05 0.81 0.68 0.76 0.77 1.08 
Total time (hours) of perfusion 12 24 18 18 24 24 24 12 18 18 
Viability achievement No Yes Yes No No Yes Yes Yes Yes Yes 





7.7.2.3 Table S7.3: Viability criteria achievement by the livers in each group. 
 
Table S7.3: Viability criteria achievement by the livers in each group. 



















Criteria Defatting (n = 5) Control (n = 5) 
Lactate clearance (≤ 2.5 mmol/L) 5 (100%) 2 (40%) 
pH > 7.3 perfusate 4 (80%) 2 (40%) 
Glucose metabolism 5 (100%) 4 (80%) 
HA flow (> 150 mL/min) 5 (100%) 4 (80%) 
PV flow (> 500 mL/min) 5 (100%) 5 (100%) 
Homogeneous perfusion/ soft parenchyma 5 (100%) 5 (100%) 
Bile production 5 (100%) 4 (80%) 




7.7.2.4 Figure S7.1: Lactate clearance dynamics and perfusion parameters in the context 





Figure S7.1: Lactate clearance dynamics and perfusion parameters in the context of defatting of human livers. Series 1: The graph shows the 
targets analysed for dynamic changes in the lactate metabolism over time. Series 2: for the assessment of dynamic changes in lactate concentration in the 
perfusate over time the area under the curve (AUC) was determined for each liver. Lactate AUC values from time 0 to 12 hours were compared with other 
perfusion parameters. There was a strong association between smaller values of lactate AUC with improvements in other metabolic parameters of the 
organ. Labels identify livers from different groups in the graph. Series 3: the time to achieve the lactate peak (in hours) was correlated with functional 
parameters and perfusion features. A shorter time to peak of lactate was associated with improvement in diverse parameters of metabolic function of the 
organ. Series 4: investigation of the correlation between time to lactate less than 2.5 mmol/L (in hours) and perfusion/ metabolic parameters. Data showed 





7.7.2.5. Figure S7.2: Biochemistry analysis of the perfusate.  
 
Panel A: Total proteins (TPROT) were measured in the perfusate and levels were comparable 
between groups. Panel B: Albumin presented a rising trend in the defatting group and it was stable 
in the control group. Panel C: Sodium levels measured in the perfusate were comparable between 
groups. Panel D: Potassium levels decreased quicker within 6 hours of perfusion in the defatting 
group and for the control levels decreased less and then were flat after initial 2–3 hours. Panel E: 
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AIM: To review the clinical impact of machine perfusion of the liver on biliary complications 
post-transplantation, particularly ischaemic-type biliary lesions (ITBL).  
METHODS: This systematic review was performed in accordance with the Preferred 
Reporting Systematic Reviews and Meta-Analysis (PRISMA) protocol. The following 
databases were searched: PubMed, MEDLINE, and Scopus. The keyword ‘liver 
transplantation’ was used in combination with the free term ‘machine perfusion’. Clinical 
studies reporting results of transplantation of donor human livers following ex situ or in situ 
machine perfusion were analysed. Details relating to donor characteristics, recipients, technique 
of machine perfusion performed, and postoperative biliary complications (ITBL, bile leak, and 
anastomotic strictures) were critically analysed. 
RESULTS: Fifteen articles were considered to fit the criteria for this review. Ex situ 
normothermic machine perfusion was used in six studies, ex situ hypothermic machine 
perfusion in five studies and the other four studies investigated in situ normothermic regional 
perfusion and controlled oxygenated rewarming. While studies on hypothermic machine 
perfusion and normothermic regional perfusion reported lower rates of ITBL, the interpretation 
of the results must be performed with caution. This is due to the lack of randomised controlled 
trials using biliary complications as a primary endpoint and the absence of standardisation for 
its assessment and reporting. Other biliary complications, such as biliary leak and anastomotic 
biliary strictures, are reported with similar incidences with all machine perfusion techniques. 
Restoration of organ to full metabolism during normothermic machine perfusion allows 
assessment of hepatobiliary function before transplantation, although universally accepted 




CONCLUSION: Machine perfusion of the liver may have potentially a positive impact on 
post-transplant biliary complications, specifically ITBL, although randomised controlled trials 
dedicated to assess this issue employing solid and standardised methodology are needed to 







8.2.1 Post-transplant biliary complications: the current scenario 
Post-transplant biliary complications often require laborious and costly interventions, placing a 
heavy burden on health resources and adversely affecting patient outcomes (1, 2). The incidence 
of these complications is increasing as a result of the growing utilisation of extended criteria 
donor (ECD) organs, mainly from donation after circulatory death (DCD). Biliary 
complications such as biliary leak and anastomotic strictures are primarily related to surgical 
technicalities and are usually successfully managed with endoscopic procedures (3). The most 
severe form of post-transplant biliary complication is non-anastomotic intrahepatic strictures 
(NAS). NAS is characterised by the occurrence of diffuse intrahepatic strictures in the biliary 
tree and it was initially associated with hepatic artery thrombosis (4). The ischaemic donor 
biliary tree was found to develop necrosis with fibrotic strictures, dilatations and potentially 




a patent hepatic artery without evidence of recurrence of biliary disease. This entity was 
subsequently classified as ischaemic-type biliary lesion (ITBL) (5). 
The reported incidence of ITBL is approximately 10–30% for controlled DCD and 1–3% for 
donation after brain death (DBD) organs (6–10). Patients generally present with elevated liver 
function tests suggesting cholestasis (bilirubin, alkaline phosphatase and gamma-
glutamyltransferase) within a few months of transplantation and may be asymptomatic initially. 
Initial work-up includes exclusion of hepatic artery thrombosis and anastomotic biliary 
strictures. Imaging investigations consist of non-invasive magnetic resonance 
cholangiopancreatography (MRCP) and computed tomographic cholangiography, or direct 
cholangiographic methods, such as endoscopic retrograde cholangiopancreatography and 
percutaneous transhepatic cholangiography. Due to the high reliability of current non-invasive 
imaging techniques in diagnosing biliary strictures, invasive procedures are currently reserved 
for scenarios where an intervention is planned, such as stricture dilatation, stenting or stone 
extraction (11, 12). With ITBL, imaging confirms the presence of fibrotic strictures, in most 
cases located around the bifurcation of the common bile duct leading to dilatation of the 
intrahepatic biliary system (1, 8). Figure 8.1 illustrates these typical imaging features of ITBL 
following liver transplantation. The obstructive strictures cause cholestasis with formation of 
sludge and casts that predispose to cholangitis, frequently requiring surgical or endoscopic 
intervention. Despite these measures, approximately 50% of patients with ITBL require re-




Figure 8.1: Magnetic resonance cholangiopancreatography (MRCP) images of 
ischaemic-type biliary lesions following liver transplantation.  
 
The images show two recipients of livers from donation after circulatory death donors 
that developed ischaemic-type biliary lesions within 60 days following transplantation. 
Hepatic artery thrombosis and anastomotic biliary strictures were ruled out. A: A typical 
lesion is seen affecting the bifurcation of the common hepatic bile duct with moderate 
dilatation of the intrahepatic biliary tree. B: The image shows strictures at the bifurcation 
of the common hepatic bile duct, diffuse intrahepatic strictures and a severe dilatation of 





Although the pathogenesis of ITBL is still not fully understood a growing body of evidence 
suggest that it is partially associated with ischaemia-reperfusion injury (IRI) (14, 15). Noack et 
al. in a well-designed in vitro study using rat-derived bile duct cells showed that they were more 
resistant to anoxia than hepatocytes, however during reoxygenation they produced higher 
amounts of reactive oxygen species (ROS). This was associated with increased rates of bile 
duct cell death when compared to hepatocytes (16). It has been shown that mitochondrial 
ischaemic induced injury leads to ROS production during reperfusion which in turn causes 
oxidative injury and activation of the inflammatory cascade (17, 18). Conversely, clinical series 
have reported severe injury to the biliary epithelium just after cold static storage (19, 20). 
Garcia-Valdecasas et al. using a porcine transplantation model suggested a direct relationship 
between prolonged ischaemic times and cell injury (15). Indeed, other clinical series have 
confirmed the association of longer cold ischaemia time and higher rates of ITBL (21–24). A 
similar relationship has been observed with warm ischaemia time in DCD liver transplantation 
(15, 25). A large clinical series of donor bile duct biopsies before liver transplantation showed 
similar injury to the biliary epithelium after static cold storage (SCS), and that it was 
exacerbated after reperfusion; however, this did not correlate with the development of ITBL 
(26). Nevertheless, the authors reported a strong association between ITBL and damage to the 
peribiliary vascular plexus and peribiliary glands. As progenitor biliary cells are known to 
reside in the peribiliary glands, the former finding suggests an association between ITBL and 
an attenuated regenerative capacity of the biliary epithelium (26, 27).   
Ischaemic injury is likely to play a major role in ITBL pathogenesis, although other factors 
have also been shown to be implicated. Immunological mediated injury to the biliary epithelium 
has been associated with ITBL (28). It may be the result of direct immunological damage to the 




arteriopathy (29, 30). This cross reactivity is described in scenarios of cytomegalovirus 
infection (30), ABO incompatibility (31) and transplantation for primary sclerosing cholangitis 
(1). Bile salt toxicity has also been investigated as a potential cause for ITBL by having a direct 
detergent effect on phospholipid cellular membranes of the biliary epithelium (28). Flushing of 
the biliary tree during organ procurement is necessary in order to remove all bile salts that could 
damage cholangiocytes (5, 28). Furthermore, an imbalance in the post-transplant bile 
composition, with a higher bile salt/ phospholipid ratio, due to inefficient ATP-dependent 
biliary transporters has been suggested as a predictive factor for ITBL (32). While detail of the 
pathogenesis of ITBL is beyond the scope of this review, information on the implicated 
mechanisms can be found in a number of published reviews (9, 28). 
8.2.2 Machine perfusion of donor livers 
The utilisation of DCD livers is increasing. In 2017, in the United Kingdom, they constituted 
28% of the livers transplanted (33). Furthermore, the rising prevalence of donor obesity (body 
mass index greater than 30 kg/m2) and an ageing population continue to compound the risks to 
those livers (33). These high-risk ECD organs are associated not only with a higher risk of graft 
dysfunction post-transplantation but also increased rates of ITBL (34). Despite these 
disadvantages, their utilisation is required to tackle the ever-growing discrepancy between 
organ donor supply and demand. Machine perfusion (MP) of the liver is being developed as a 
means of assessment and reconditioning of ECD donors, potentially allowing for safer 
transplantation of these high-risk livers (34, 35). Different techniques of MP have been 
developed; it can be performed in situ during organ procurement or ex situ after the procedure. 
With regards to livers, the only technique of in situ MP described so far is normothermic 
regional perfusion (8). Ex situ MP protocols vary in terms of oxygenation (active or pre-charged 




normothermic), timing of perfusion (preservation or end-ischaemic) and via of organ perfusion 
(portal vein alone or dual portal vein and hepatic artery perfusion) (34, 36). 
Hypothermic machine perfusion (HMP) has been performed around 10 C in most studies (37, 
38). At this temperature liver metabolism is reduced; and, passive oxygen delivery by diffusion 
in an oxygen carrier-free perfusate is enough to support the organ (39). The first published 
clinical series employed pre-charged oxygen delivery to the organs (37), technique that was 
later followed by active oxygenation of the perfusate (40). Hypothermic oxygenated MP can be 
performed via portal vein alone (HOPE) or via portal vein and hepatic artery (dual hypothermic 
oxygenated perfusion – D-HOPE) (41–43). Both techniques have shown the capacity of 
improve mitochondrial oxidative function prior to rewarming, resulting in increased adenosine 
triphosphate (ATP) synthesis and a reduction in ROS production, oxidative tissue injury and 
activation of the inflammatory cascade (42, 43).  
Normothermic machine perfusion (NMP) maintains the organ at physiological temperatures 
(37 C) and therefore restores full metabolic activity. This enables the possibility of functional 
or viability assessment prior to transplantation (44, 45). It also opens up a window of 
opportunity for ex situ therapeutic interventions (34). Furthermore, previous studies have 
reported on the safety of extended normothermic perfusion of organs, which may facilitate 
transportation and logistical management of busy transplant units (46). However, potential 
drawbacks of NMP is that it requires obligatorily the inclusion of an oxygen carrier in the 
perfusate, and NMP inevitably induces reperfusion injury to some extent. 
Subnormothermic machine perfusion (SMP) has been performed at around 20 C in most 
studies. It encompasses purely SMP and the controlled oxygenated rewarming (COR) from 10 




to increase liver metabolism to an extent that it would allow assessment of organ function 
without inducing the detrimental changes associated with organ reperfusion at normothermic 
temperatures (48). Evidence for the clinical benefits is available for COR perfusions, it was 
associated with lower markers of hepatocellular injury after transplantation and enhanced graft 
function through the avoidance of subtle changes in organ temperature (47).      
For DCD livers, there are encouraging reports of in situ oxygenated normothermic regional 
perfusion (NRP). It has been successfully applied to controlled DCD donors (withdrawal of life 
support in patients with irreversible clinical conditions) and uncontrolled DCD (witnessed 
cardiac arrest without response to resuscitative measures) (8, 49, 50). NRP limits ischaemia and 
prevents depletion of energy stores prior to SCS and this is suggested to be essential for 
uncontrolled DCD donors and beneficial for controlled DCD (8).     
More recently, combinations of MP techniques have been suggested to merge the advantages 
of individual protocols, enhancing the rescue of liver function what may potentially improve 
graft function after transplantation (51, 52). Despite differences between techniques, MP has 
the potential to limit ischaemic injury to the organ, thus offering a safer preservation 
environment and an opportunity for organ reconditioning which could mitigate IRI. 
As discussed herein, the current evidence shows that cholangiocytes are more vulnerable to IRI 
than hepatocytes and that the pathogenesis for biliary injury goes beyond IRI. Therefore, 
investigation of the impact of MP on biliary function specifically, and not only on 
hepatocellular function, is fundamental. The aim of this review was to investigate the current 
clinical evidence available regarding the effect of MP on post-transplant biliary complications, 





This systematic review was performed in accordance with the Preferred Reporting Systematic 
Reviews and Meta-Analysis (PRISMA) protocol (53).  
The following databases were searched for the development of this review: PubMed, 
MEDLINE and Scopus. The keyword ‘liver transplantation’ was used in combination with the 
free term ‘machine perfusion’. The literature review was performed until June 20, 2018 and 
there were no limits on the date for inclusion of publications. The literature search strategy used 
for one database is presented in the supplementary Table S8.1. 
The screening and selection of articles were independently performed by two authors (YLB and 
APCSB). There was no disagreement in study selection between authors. Manuscript titles that 
were not related to the main scope of the review were excluded. Full abstracts were then read 
and excluded if found not to be relevant to the review. Finally, full papers were assessed for 
eligibility and included in this review. The flow diagram for the literature selection process is 
shown in Figure 8.2. 
Inclusion criteria were: (1) clinical studies reporting results of transplantation of donor human 
livers following ex situ or in situ MP; (2) articles written in English and published. Exclusion 
criteria were: (1) absence of transplantation following MP; (2) exclusively animal models; (3) 
single case report; (4) review articles; and, (5) articles not written in English. 
Details relating to donor characteristics (type, age, donor risk index [DRI], warm ischaemic 
time [WIT], cold ischaemia time [CIT]), recipients (age, model for end-stage liver disease 
[MELD]), perfusion (type of perfusion, oxygenation, timings) and postoperative biliary 
complications (ITBL, leak and anastomotic strictures) were retrieved from each manuscript and 




review protocol was registered before this review was started. No simplifications or 




Figure 8.2: Study flow diagram for systematic review of the literature on the impact of 
machine perfusion of the liver and post-transplant biliary complications. 
 
Following literature search duplicate articles were excluded and the titles screened. The selected 






Fifteen articles were considered to fit the criteria for this review. A diagrammatic summary of 
the screening process is provided in Figure 8.2. 
8.4.1 Machine perfusion and ischaemic-type biliary lesions (ITBL) 
Eight out of fifteen clinical studies utilised an end-ischaemic model of MP (MP commenced 
after a variable period of SCS), four studies utilised preservation MP (MP from organ 
procurement up to transplantation) and three employed NRP. NMP was used in six studies, 
HMP in five studies and the other four studies investigated NRP and COR. HMP with active 
perfusate oxygenation (HOPE and D-HOPE) studies were seen to be currently focused on DCD 
organs and HMP with pre-charged oxygenation on DBD organs. NMP studies used both donor 
types, however preservation studies explored a higher proportion of DBD compared to DCD 
organs. The contrary was seen for end-ischaemic NMP.  
Donor and recipient characteristics, of the cases included in individual studies, are presented in 
Table 8.1. It also reports the rates of ITBL. Table 8.2 describes the incidence of bile leak and 
anastomotic biliary stricture within the different studies. Studies characteristics were described 









Table 8.1: Comparison between donor, recipient, perfusion characteristics and the reported rates of ischaemic-type biliary 
lesions. 



























Ex situ Normothermic Machine Perfusion 
Nasralla et al.(46) 2018 NMP Preserv. 121 56 (16–
84) 
1.7€ 55 13 (6–35) 87 34 7.4% 11.1% 126 21 3 
Selzner et al.(54) 2016 NMP Preserv.. 10 48 (17–
75) 
1.9 57 21 (8–40) 8 2 0% 0% 103 NA 0 




53 (28–67) 13 (9–32) 6 3 0% 0% 167 (95–
293) 
22 0 
Ravikumar et al.(55) 2016 NMP Preserv. 20 58 (21–
85) 
NA NA 12 (7–27) 16 4 0% 0% NA 21 0 
Watson et al.(58) 2018 NMP End-Isc. 22 57 2.3 NA NA 6 16 0% 25.0% 386 12 3 
Mergental et al.(57) 2016 NMP End-Isc. 5 49 (29–
54) 
2.3 56 (47–66) 8 (8–13) 1 4 0% 0% 422 28 0 
Ex situ Hypothermic Non-Oxygenated Machine Perfusion 
Guarrera et al.(59) 2015 HMP End-Isc. 31 57 (+/–
18)* 
1.9 (±0.5)* 57 (±8.0)* 19 (±5.9)* 31 0 9.7% NA 558 NA 0 
Guarrera et al.(37) 2010 HMP End-Isc. 20 39 (+/–
2.5)* 
NA 55 (±6.2)* 17 (±7.4)* 20 0 5.0% NA 306 26 0 
Ex situ Hypothermic Oxygenated Machine Perfusion 
van Rijn et al.(43) 2017 DHOP
E 




57 (54–62) 16 (15–22) 0 10 NA 10.0% 331 15 0 
Dutkowski et al.(38) 2015 HOPE End-Isc. 25 54 (36–
63) 
NA 60 (57–64) 13 (9–15) 0 25 NA 0% 188 (141–
264) 
31 (26–36) 0 
Dutkowski et al.(40) 2014 HOPE End-Isc. 8 54 (NA) 2.2 (NA) 60 (NA) 12 (NA) 0 8 NA 0% 141 (NA) 31 (22–41) 0 
In situ Normothermic Regional Perfusion 
De Carlis et al.(60)¥ 2017 NRP NRP 7 48* NA 54* 10.6* 0 7 NA 0% 414* 33 0 
Oniscu et al.(49) 2014 NRP NRP 11 46 (16–
74) 
NA 68 (43–74) NA 0 11 NA 0% 389 (169–
450) 
26 (13–48) 0 
Minambres et al.(50) 2017 NRP NRP 11 58 (50–
67) 
NA 55 (±13)* NA 0 11 NA 0% 266 
(±82.7)* 
12 (11–16) 0 
Controlled Oxygenated Rewarming 




52 (43–65) 18 (11–23) 6 0 0% NA 508 (369–
870) 
NA 0 
*Data presented as median or median (±Standard deviation), if available. Otherwise, all data presented as median (Interquartile range). ¥Combined hypothermic oxygenated machine perfusion 
after normothermic regional perfusion. Six uncontrolled DCD were included in this study. € Eurotransplant DRI. Abbreviations: MP- Machine perfusion; MELD- Model for end stage liver 
disease; DBD- Donation after brain death; DCD- Donation after circulatory death; ITBL- Ischaemic-type biliary lesions; CIT- Cold ischaemic time; Func. WIT- Functional warm ischaemic 
time; Re-Tx- Re-transplantation; NA- Not applicable or not available; Preserv.- Preservation; End-Isc.- End ischaemic; NMP- Normothermic machine perfusion; HMP- Hypothermic machine 





Table 8.2: Prevalence of bile leak and anastomotic biliary strictures between clinical studies using different techniques of 
machine perfusion of donor livers. 
Author Year Study 
design 





Ex situ Normothermic Machine Perfusion 
Nasralla et al.(46) 2018 RCT NMP Preservation 121 87 34 0 0 
Selzner et al.(54) 2016 PS NMP Preservation 10 8 2 0 0 
Bral et al.(56) 2017 PS NMP Preservation 9 6 3 0 0 
Ravikumar et al.(55) 2016 PS NMP Preservation 20 16 4 0 4 (DBD) 
Watson et al.(58) 2018 DS NMP End-Ischaemic 22 6 16 0 0 
Mergental et al.(57) 2016 DS NMP End-Ischaemic 5 1 4 0 0 
Ex situ Hypothermic Non-Oxygenated Machine Perfusion 
Guarrera et al.(59) 2015 PS HMP End-Ischaemic 31 31 0 1 0 
Guarrera et al.(37) 2010 NCS HMP End-Ischaemic 20 20 0 1 1 
Ex situ Hypothermic Oxygenated Machine Perfusion 
van Rijn et al.(43) 2017 PS DHOPE End-Ischaemic 10 0 10 0 2 
Dutkowski et al.(38) 2015 PS HOPE End-Ischaemic 25 0 25 5 (in total) 
Dutkowski et al.(40) 2014 PS HOPE End-Ischaemic 8 0 8 1 1 
In situ Normothermic Regional Perfusion 
De Carlis et al.(60)¥ 2017 DS NRP NRP 7 0 7* 0 1 
Oniscu et al.(49) 2014 DS NRP NRP 11 0 11 1 1 
Minambres et al.(50) 2017 DS NRP NRP 11 0 11 NA NA 
Controlled Oxygenated Rewarming 
Hoyer et al.(47) 2016 PS COR End-Ischaemic 6 6 0 NA NA 
¥Combined hypothermic oxygenated machine perfusion after normothermic regional perfusion. Six uncontrolled DCD were included in this study. Abbreviations: RCT- Randomised 
controlled trial; PS- Single-arm non-randomised pilot study; DS- Descriptive study; NCS- Non-randomised cohort studies; DBD- Donation after brain death; DCD- Donation after 
circulatory death; NA- Not applicable or not available; NMP- Normothermic machine perfusion; HMP- Hypothermic machine perfusion; DHOPE- Dual vessel hypothermic 




8.4.2 Normothermic machine perfusion and post-transplant biliary complications 
The largest randomised controlled clinical trial involving NMP as a preservation strategy was 
recently published by Nasralla et al. (46). Following procurement, transplantable livers were 
randomised and allocated to the intervention group that had NMP up to the point of 
transplantation or a control group that had conventional SCS. From the 121 livers perfused, 87 
were from DBD donors and 34 from DCD donors. Results did not show statistically significant 
differences in bile duct complications between groups, with one patient in each arm developing 
ITBL within the first year, both requiring re-transplantation. On MRCP, the rate of NAS was 
not significantly different between groups for DBD (NMP 7.4% vs. SCS 5.4%; p = 0.678) and 
DCD (NMP 11.1% vs. SCS 26.3%; p = 0.180). The incidence of anastomotic strictures was 
also similar for DBD or DCD organs (NMP 40.7% vs. SCS 41.8%; p = 0.909; and, NMP 48.1% 
vs. SCS 57.9%; p = 0.515, respectively) (46).  
Other clinical studies investigating NMP using a preservation approach (54–56) involved 
smaller patient numbers, the majority of which were from DBD donors, and did not specifically 
report the incidence of ITBL (Table 8.1). Ravikumar et al. published the first phase 1 clinical 
trial demonstrating the safety and feasibility of NMP in a preservation approach, as an 
alternative to SCS (55). In all, 20 donor livers (16 DBD and 4 DCD) were transplanted 
following NMP. The 30-day graft survival was similar to static cold stored livers and the median 
peak aspartate aminotransferase within the first 7 postoperative days was lower. In terms of 
biliary complications, the authors reported the occurrence of four cases of anastomotic biliary 
strictures in the NMP group (55). 
The two studies of NMP after a period of SCS (end-ischaemic model) involved organs that 




livers and applied predefined viability criteria prior to transplantation. Mergental et al. did not 
observe any biliary complications at 7 months of follow up post-transplantation (57). Watson 
et al. reported the occurrence of 4 cases of ITBL in 16 DCD liver transplants, of which 3 needed 
re-transplantation (58). The authors of the latter study suggested that NMP per se does not 
prevent ITBL but may provide biomarkers to identify livers that are high risk, such as maximum 
bile pH > 7.5 and bile glucose ≤ 3 mmol/L or ≥ 10 mmol less than perfusate glucose (58).     
8.4.3 Hypothermic machine perfusion and post-transplant biliary complications 
The first clinical study using HMP prior to transplantation was performed by Guarrera et al. 
(37). Twenty DBD livers were perfused after a period of SCS in a non-actively oxygenated 
model of HMP. ITBL rate was reported as 5%, half of the incidence of the control matched 
cohort that was subjected to SCS. In addition, there was one case of bile leak and one report of 
anastomotic biliary stricture (37). The same approach was repeated later in a study of DBD 
livers declined by the United Network for Organ Sharing region for transplantation (59). The 
authors found a significant decrease in the rate of biliary stricture in comparison with SCS (10% 
vs. 33%, p = 0.031). One report of bile leak was noted in the HMP group and three in SCS 
respectively (Table 8.2). 
Following these initial studies, the Zurich group developed the concept of HOPE, with active 
oxygenation of the perfusate, and applied this MP strategy to DCD donors (38, 40). Their first 
clinical trial was published in 2015, reporting the results of transplantation of 25 DCD livers 
(38). The authors reported no cases of ITBL at 1-year follow-up of patients who received 
perfused DCD livers, whereas control livers subjected to SCS developed a significantly higher 




extrahepatic biliary complications, as the reported rates of leaks and anastomotic strictures were 
similar (HOPE 5/25 vs. Control 12/50) (38). 
The Groningen group published the first clinical series using D-HOPE in 2017 (43). Ten DCD 
livers were transplanted following 2 hours of D-HOPE, one patient in the perfusion group 
developed ITBL compared to 7 out of 20 in the control group. The case in the D-HOPE group 
was described as NAS in segments II and III of the liver and was managed with endoscopic 
stenting. Three control livers which developed ITBL required re-transplantation. The rate of 
anastomotic biliary strictures was comparable between groups (D-HOPE 2 vs. Control 3, p = 
1.000) as was the reported rate of biliary cast formation (D-HOPE 3 vs. Control 3, p = 0.372) 
(43).         
8.4.4 Normothermic reginal perfusion and post-transplant biliary complications 
The first series reporting the results for transplantation of livers following NRP was published 
in 2014 by Oniscu et al. (49) The authors reported the results of transplantation of 11 controlled 
DCD livers, with a minimum follow-up of three months, with no clinical or radiological 
evidence of ITBL. One patient developed an anastomotic stricture, treated endoscopically by 
cholangio-pancreatography (exact intervention performed is not described), and one patient had 
a bile leak (49). Minambres et al. 2017, studying controlled DCD transplantation after NRP, 
reported no cases of ITBL after 1-year follow-up (50). De Carlis et al. 2017 performed NRP on 
one controlled DCD liver and six uncontrolled DCD (60). On arrival at the transplant centre, 
the livers were subjected to D-HOPE until transplantation. No cases of ITBL were observed 
and one patient had an anastomotic biliary stricture 45 days after transplantation, which was 




In terms of SMP, Hoyer et al. reported transplantation of six DBD livers following COR 
perfusion (47). No biliary complications were reported within a follow-up period of six months. 
8.5 Discussion 
Post-transplant biliary complications are associated with high rates of morbidity and re-
transplantation and are a major obstacle to the wider clinical utilisation of ECD livers. Although 
there is a growing body of evidence suggesting that MP can offer safer organ preservation when 
compared to SCS, and also offer an opportunity for organ assessment and/ or reconditioning 
prior to transplantation, properly designed randomised controlled trials using biliary 
complications as a primary endpoint are still missing (38, 43, 46, 49, 58). In this review, the 
available literature investigating the impact of MP on post-transplant biliary complications, 
with special reference to ITBL has been assessed. MP techniques suggested to have the 
potential to alleviate IRI, such as HMP and NRP, have also reported lower rates of ITBL, 
however, these results should be considered in face of the limitations of study designs, restricted 
sample size of pilot studies and inconsistencies in the definition of ITBL. Other biliary 
complications, such as biliary leak and anastomotic biliary strictures, are reported with similar 
incidences with MP techniques.  
Liver IRI is thought to be a major driver of biliary injury and, therefore, it is associated with 
complications following transplantation. More specifically, during ischaemia, without oxygen 
as a terminal acceptor of electrons in the electron transport chain, succinate accumulates and 
acts as a store for electrons. Succinate oxidation during the early stage of reperfusion, blocks 
mitochondrial complex II of the electron transport chain resulting in a reverse flow of electrons 
towards mitochondrial complex I leading to accentuated leakage of electrons, and generation 




at hypothermic temperatures is able to promote mitochondrial metabolism of succinate prior to 
reperfusion (36, 42, 62). By re-establishing adequate mitochondrial oxidative function, HOPE 
is able to recover ATP stores, since during hypothermia mitochondria have lower energy 
requirements due to a minimum activation of the organ metabolism. Therefore, mechanistically, 
HOPE can in theory prevent the reverse flow of electrons during reperfusion, ROS generation 
and activation of the inflammatory cascade (36). These factors may mitigate IRI, which would 
be beneficial not only for hepatocellular function but also for the prevention of further biliary 
injury.  
Extensive research focussing on the effect of oxygenated HMP on post-transplant biliary 
complications has been performed by the Groningen group. In a recent publication exploring 
the effects of D-HOPE on bile duct biopsies from a previous published series of cases, they 
showed less injury to deep and periluminal peribiliary glands after reperfusion during 
transplantation in the perfused group in comparison with SCS control livers (43, 63). Peribiliary 
glands have been described as stores for biliary progenitor cells, therefore injury to them would 
potentially decrease the regenerative capacity of the biliary system (64, 65). The authors 
acknowledge that definitive evidence to support this would require a clinical randomized trial 
that has since been initiated at their centre (63). 
Preservation NMP shortens ischaemic injury and offers a more physiological environment for 
the organ before transplantation. Nevertheless, as previously discussed, the injury to biliary 
cells might not be restricted to an ischaemic mechanism but may also be worsened during 
reperfusion. NMP restores the full metabolism of the organ, inevitably resulting in the 
production and circulation of ROS and potential activation of the inflammatory response 
leading to tissue injury (66). On the other hand, restoration of the organ to full metabolism 




accepted criteria have yet to be validated (35). Watson et al. suggested bile pH and glucose 
content as markers of bile duct injury and associated those with the development of ITBL (58).     
Promisingly, in situ NRP has shown excellent biliary outcomes after transplantation of DCD 
livers (49, 50, 60). NRP may potentially prevent ischaemic injury and deterioration of ATP 
stores during organ procurement. In addition, NRP allows assessment of the liver metabolism 
even before SCS (8). Despite these points, there is no mechanistic evidence available to 
demonstrate any alleviation in IRI after reperfusion.  
The present body of work has several limitations; thus, interpretation of the results must be 
performed with caution. First, thus far, there is no randomised controlled trial using biliary 
complications post-transplantation as a primary endpoint. Few clinical studies from each MP 
technique are available and most are pilot studies with small sample size, which limits definitive 
interpretation of the data. Second, there is lack of standardisation in the methods to assess these 
complications or to define ITBL radiologically. For example, MRCP was not performed in all 
studies evaluated. Moreover, MRCP is not routinely requested for patients after transplantation 
unless clinically indicated. In addition, there is no widely accepted criteria to report the findings 
on the MRCP, findings in which the significance without clinical correlation is not clear. 
Furthermore, donor livers and recipient characteristics, as well as machine perfusion technique 
protocols, exhibit a high degree of variability between studies. Thus far, there has been no 
standardisation in terms of methodology and reporting of results. Some studies further neglect 
to report important data variables, such as donor risk index, recipient age, and recipient MELD 
and CIT. All these features are presented in Table 8.1 to allow an unbiased assessment of the 
retrieved information by the reader. All together, these factors require attention before making 





Up to now, most of clinical series studying MP have focussed on the evaluation of 
hepatocellular function rather than biliary function and injury. Despite the subject of this review 
being a relevant topic with important clinical implications, the direct effects of MP on biliary 
tree integrity are still relatively under-researched. More clinical randomised trials must be 
reported in the field over the next few years. 
Higher rates of ITBL following transplantation of ECD livers, mainly DCD, place a major 
restraint on the wider use of these marginal livers. Each technique of MP may offer different 
advantages and they all have the potential to tackle this problem. A preclinical study has shown 
that a combination of HOPE and NMP increased the rescue of metabolic parameters of high-
risk ECD organs (52). This approach may derive benefits from the individual methods, thus 
possibly optimising gains also in terms of biliary function. Pharmacological interventions 
during NMP may potentially alleviate IRI, positively affecting biliary cells (67), and may have 
a direct effect on post-transplant biliary complications. Supplementation of the perfusate with 
substances that may induce proliferation and maturation of progenitor cells from peribiliary 
glands may be a feasible option to be considered (9). We hypothesize that therapies promoting 
increase in secretion of phospholipids and cholesterol in the bile would equilibrate the 
phospholipids/ bile salts balance mitigating further injury to the biliary tree. Although 
promising, these are options that still need to be explored in future studies. A diagrammatic 




Figure 8.3: Diagrammatic summary of the current evidence for the impact of machine perfusion of the liver on post-transplant 
ischaemic-type biliary lesions and future perspectives.  
 
The current evidence suggests that ischaemic-type biliary lesions have a multifactorial pathogenesis. These diverse factors lead to injury to 
the biliary epithelium, peribiliary glands and peribiliary vascular plexus. Currently, there is evidence proposing potential benefits of machine 
perfusion on post-transplant ischaemic-type biliary lesions. The figure summarises those and possible future interventions that could enhance 





The high incidence of post-transplant biliary complications, specifically ITBL, is a major 
constraint to wider utilisation of ECD livers. While MP is currently considered a promising tool 
to increase ECD utilisation, definitive clinical evidence for a positive impact of MP on post-
transplant biliary complications is still pending. Despite some clinical series suggesting a 
potentially beneficial effect of MP on ITBL rates, randomised controlled trials powered for its 
occurrence as a primary endpoint are needed to confirm this data. In addition, further efforts 
should be taken by the scientific community to promote standardisation in the assessment and 






8.7.1 Table S8.1: Literature search strategy example 
Database Strategy 
PubMed ‘liver transplantation’ (MeSH) AND ‘machine perfusion’ (text) 
Abbreviations: MeSH: Medical subject heading; text: Text word 
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GENERAL DISCUSSION AND CONCLUSION: LIMITATIONS 







This thesis examined how to develop ex situ normothermic machine perfusion of the liver to 
improve the reconditioning of high-risk extended criteria donor organs. Two possible 
alternatives were investigated (Figure 9.1): (1) The use of hypothermic oxygenated machine 
perfusion as a therapeutic intervention preceding normothermic machine perfusion; and (2) the 
delivery of a pharmacological combination of drugs targeting the hepatic lipid metabolism 
during normothermic perfusion to enhance the metabolic support to donor organs. 
In detail, this thesis studied: 
• The feasibility of developing a unified protocol of machine perfusion combining 
hypothermic and normothermic machine perfusions; and whether the combined 
protocol would derive specific benefits of the individual techniques. 
• The feasibility of using a single acellular haemoglobin-based oxygen carrier 
perfusate for an uninterrupted combined protocol of hypothermic and 
normothermic machine perfusions, the Cold-to-Warm machine perfusion of the 
liver. 
• The cytotoxicity in vitro of a combination of drugs targeting the enhancement of 
hepatic lipid metabolism towards primary human cells of the liver: hepatocytes, 
cholangiocytes and intrahepatic endothelial cells. In addition, the effectiveness of 
the drugs in decreasing the intracellular lipid content of primary human 
hepatocytes loaded with fat was examined. 
• The feasibility of using normothermic machine perfusion as a tool for the delivery 
of a pharmacological intervention targeting the hepatic lipid metabolism of human 
livers; and the effectiveness of this treatment in enhancing the hepatic lipid 
metabolism of a whole human organ, decreasing the intracellular lipid content and 




Figure 9.1: Diagrammatic summary of the strategies examined in this thesis for developing 
normothermic machine perfusion of the liver for improvement of marginal donor graft 
quality. 
 
High-risk extended criteria donor (ECD) livers are more vulnerable to the cellular damage caused 
by ischaemia followed by the insult of warm blood during the revascularisation. The significant 
cellular damage impairs the metabolic function of the organs and thus leads to a high risk of 
delayed graft function or even graft loss postoperatively. End-ischaemic normothermic machine 
perfusion (NMP) alleviates the damage associated with ischaemia-reperfusion injury (IRI) 
because it limits the period of cold ischaemia and delivers nutrients and oxygen to support the full 
metabolism of the organs. Whilst limitation of the ischaemic insult is beneficial, it does not 
prevent the amplification of the inflammatory immune response associated with reperfusion and, 
therefore, approximately 40% of the high-risk ECD livers fail to recover metabolic function 
sufficiently to be deemed transplantable. In Chapters 3 and 4 the use of hypothermic oxygenated 
machine perfusion (HMP) as a therapeutic intervention targeting resuscitation of mitochondrial 
bioenergetic and oxidative status prior to NMP, in a combined protocol, was explored. This 
combination successfully enhanced the return of metabolic functions to parameters considered 
adequate for transplantation. Alternatively, the delivery of a pharmacological intervention aiming 
to increase the hepatic lipid metabolism was investigated. The boosted lipid metabolism enhanced 
the metabolic support to other cellular and mitochondrial processes. This effect also mitigated 
oxidative tissue damage and the propagation of the inflammatory response with lower tissue 




9.1 The development of the Cold-to-Warm protocol of machine perfusion of the liver 
Clinical evidence of benefits of hypothermic and normothermic machine perfusion (MP) of 
donor livers individually was reviewed in Chapters 1 and 2. The proposition and stepwise 
development of the Cold-to-Warm protocol of ex situ MP was presented in Chapters 3 and 4. 
The combined protocol of hypothermic and normothermic MP, in the two studies performed, 
was shown to optimise mitochondrial oxidative function replenishing cellular adenosine 
triphosphate (ATP) stores during the hypothermic phase; and to mitigate the expression of 
markers of oxidative tissue damage, reactive oxygen species’ production and activation of 
inflammatory cells. Ultimately, organs submitted to the combined protocol were more likely to 
recover sufficient metabolic function to be considered transplantable. Therefore, considering 
that the ultimate goal of MP technology is to increase reconditioning and utilisation of high-
risk extended criteria donor (ECD) organs, the combination of hypothermic and normothermic 
perfusions needs to be considered as a plausible alternative for future clinical studies. 
Although this combined perfusion protocol seems promising, it has some limitations. Whilst 
the use of human donor organs for research eliminates issues with animal studies, imposed by 
the inherent variability in response between species, their scarcity limits sample size and the 
intrinsic heterogeneity compromises an exact match between experimental groups. 
Nevertheless, admittedly, animal studies offer some other advantages, such as the possibility of 
large numbers of animals which can be studied, superior comparability between experimental 
groups and easier implementation of interventional studies. Therefore, whilst missing, data 
from animals may potentially provide important information on the benefits of the proposed 
strategy. The developed combined protocol of hypothermic and normothermic MP is suggested 




viability criteria previously used for clinical transplantation; however, final viability assessment 
for organ function would be transplantation, not performed in these preclinical studies (1). 
9.2 Future research questions—The Cold-to-Warm liver machine perfusion protocol 
After the development of the Cold-to-Warm MP protocol in Chapters 3 and 4, there are key 
topics to be possibly investigated in future studies. 
 
9.2.1 The development of a clinical protocol of Cold-to-Warm MP of the liver 
The results from the preclinical studies involving the combined protocol of hypothermic and 
normothermic MP showed that it potentially improves the reconditioning of ECD livers. 
However, whether all the potential advantageous effects seen for donor organs during the 
experiments are going to translate into clinical benefits to patients still need to be investigated. 
The first clinical series using an end-ischaemic combined protocol of hypothermic and 
normothermic MP was recently published (2). This pilot study demonstrated clinically the 
safety and feasibility of this combined protocol using a single haemoglobin-based oxygen 
carrier (HBOC)-based perfusate throughout the entire perfusion. The 3-month survival rate was 
100% for the five transplants performed (2). However, the absence of a control group limits 
further assessment of the clinical benefits of the combined protocol over isolated MP 
techniques. In addition, the assessment of post-transplant biliary complications was 
compromised by the non-realisation of imaging exams. 
Therefore, the results from the two preclinical studies included in this thesis allied to those from 
the first clinical series demonstrating the safety and feasibility of a combined protocol of 




future approach to increase ECD liver utilisation. Nevertheless, future randomised controlled 
trials using biliary complications as a primary endpoint and comparing the combined protocol 
with each technique independently are required to prove its superiority over isolated protocols. 
 
9.2.2 Determining the safety of advancing ECD liver reconditioning during MP one step 
further 
The suggested improved reconditioning of ECD livers in an end-ischaemic combined protocol 
of MP may push the limits one step further for utilisation of donor organs with either 
unfavourable features (advanced age, steatosis, poor in situ flush) or damaged by prolonged 
periods of ischaemia, that would otherwise potentially fail to achieve transplantability criteria 
during normothermic machine perfusion (NMP). An interesting question is to determine 
whether there will be limits for utilisation of these ‘reconditioned’ organs. For example, future 
studies need to show the safety of transplanting ECD livers damaged by periods of ischaemia 
exceeding current acceptable standards prior to initiation of MP. Concisely, the benefits of 
transplanting these organs should exceed the associated risks, such as post-transplant biliary 
complications and graft dysfunction. To date, even though donation after circulatory death 
donor livers with prolonged warm ischaemia time were included in clinical studies, cold 
ischaemia time has been preserved within relatively acceptable limits prior to initiation of MP. 
In conclusion, the development of therapeutic interventions during MP, pharmacological or not, 
aiming to improve the reconditioning of the highest risk ECD livers is a new proposition 





9.2.3 The utilisation of HBOC as an oxygen carrier replacing red blood cells in the 
perfusate for ex situ machine perfusion of donor livers 
Successful tissue oxygenation during NMP is based on the deployment of a perfusion fluid 
containing some sort of oxygen carrier. The commonest oxygen carrier used in this scenario, 
so far, is red blood cells (RBC). Whilst, due to their nature, RBC are safe, widely used and 
effective, their utilisation for this purpose requires caution. This is because RBC are a precious 
and scarce resource whose availability depends on voluntary donation and they are irreplaceable 
in the treatment of some life-threatening conditions, such as acute anaemia caused by surgical 
bleeding or in the context of trauma. In addition, RBC are associated with an increased risk of 
adverse immune reactions and infections (2–4). Considering the combination of hypothermic 
and normothermic MP, an RBC-based perfusate may not be used at hypothermic temperatures 
because of the risk of sludging (5) and haemolysis due to lower deformability of erythrocyte 
membranes at low temperatures (2). 
Alternative oxygen carriers to replace RBC have been extensively investigated; a thorough 
examination of these molecules is beyond the scope of this thesis and can be found elsewhere 
(6, 7). In the context of MP of the liver, the polymerised bovine HBOC Hemopure® 
(hemoglobin glutamer-250 [bovine]; HBOC-201, Hemoglobin® Oxygen Therapeutics LLC, 
Cambridge, USA) was used in previous experimental studies (3, 8). Fontes et al. (2015) 
reported for the first time the use of an HBOC-based perfusate for subnormothermic machine 
perfusion (SMP) in a porcine liver transplant model (8). Six livers submitted to SMP were 
compared with static cold storage (SCS) preserved organs. The authors reported that SMP-
treated organs presented higher 5-day survival (100% vs. 30%), higher bile production and 




HBOC-based perfusate offered adequate tissue oxygenation during SMP without evidence of 
oxidative damage to the organs (8). 
More recently, two other studies reported the feasibility of using an HBOC-based perfusate for 
NMP of human donor livers (3, 9). In Birmingham, our machine perfusion group first tested in 
vitro the cytotoxicity of Hemopure® towards primary human hepatocytes and then perfused five 
human donor livers using an HBOC-based perfusate. Compared with an RBC-based perfusate, 
HBOC perfused livers extracted more oxygen without any evidence of tissue damage (3). Those 
findings were confirmed later by Matton et al., who reported even higher ATP synthesis, 
cumulative bile production and vascular flows in liver perfused with an HBOC-based perfusate 
(9). 
In Chapter 4, a new study was designed to test the feasibility of using an HBOC-based 
perfusate uninterruptedly from the hypothermic until the normothermic phase of the combined 
protocol of MP. This approach initially provided logistical advantages, such as avoidance of 
interruption of the perfusion to change the perfusate, which may increase its clinical 
applicability. To explore fully the advantages of having a perfusion fluid that could be used at 
variable temperatures, the organs were slowly rewarmed employing the Controlled Oxygenated 
Rewarming (COR) technique (10). COR avoids subtle temperature changes to the organs and 
has been shown to improve mitochondrial function with superior post-transplant outcomes 
compared with SCS (11). 
This study tested the safety and stability of an HBOC-based perfusate for hypothermic 
oxygenated machine perfusion (HMP) of the liver. Although the HBOC-based perfusate was 
shown to be as effective as an oxygen-carrier-free perfusate at hypothermia, it facilitates the 




similar protocol was tested recently in a clinical series of five transplants, as described above, 
and the authors concluded that the use of an HBOC-based perfusate for MP of donor livers is 
apparently a safe alternative for RBC as an oxygen carrier in this scenario (2). 
Therefore, mounting evidence suggests that HBOC may be a safe option to replace RBC as an 
oxygen carrier in the perfusate for ex situ MP of donor livers providing effective tissue 
oxygenation under variable temperatures. It may prevent the concerns associated with the use 
of RBC described above, and also offer other advantages, such as a long shelf life at room 
temperature, without the need for specific storage conditions and increase consistency between 
batches. 
Whilst deployment of an HBOC-based perfusate confers several advantages, some potential 
limitations deserve further investigation. Previous clinical studies reported minor increases in 
methaemoglobin (MetHb) levels after transfusion of Hemopure® in humans (12, 13). MetHb is 
an oxidized form of haemoglobin that cannot bind oxygen and has a reduced ability to release 
oxygen to tissues (14). Physiologically, the erythrocytes’ enzyme methaemoglobin reductase 
reduces the MetHb formed, keeping levels lower than 2% (15). Clinically, levels under 15% 
are only associated with greyish skin without further complications (14, 15). In the context of 
MP, a previous report on a porcine model showed stable MetHb levels of around 2% during 
SMP (8). We have found similar stable levels during HMP and rewarming, nevertheless, during 
NMP MetHb levels increased steadily, reaching median levels of around 7% at the end of three 
hours of NMP. Despite this increase, there was no suggestion of any ischaemic injury to the 





In addition, the visual aspect of the bile during MP varies accordingly with the use of an HBOC- 
or an RBC-based perfusate. Grossly, the bile formed during MP using an HBOC-based 
perfusate is darker and more fluid. Further investigations on bile composition may clarify the 
reason for this difference and suggest whether it may have any clinical significance. 
 
9.3 The ex situ manipulation of the hepatic lipid metabolism during normothermic 
machine perfusion 
The studies presented in Chapters 5 and 6 showed that pharmacological modulation of the 
hepatic lipid metabolism during NMP can promote defatting of whole human livers within six 
hours. More importantly than reducing the lipid content, the enhanced lipid metabolism 
improved the metabolic status of the organs, optimised their functional recovery, decreased 
vascular resistance and reduced the expression of markers of ischaemia-reperfusion injury 
(IRI). These findings are promising and may guarantee future clinical investigation, opening a 
window of opportunity to improve the reconditioning of steatotic donor organs. Moreover, 
equally importantly, this study exemplifies the possible potential advantages of delivering 
therapeutic interventions during NMP and together with other strategies under investigation, 
such as stem cells treatment and immunological modification of the organs, defatting may 
potentially help to increase ECD liver utilisation (16). 
All the exciting findings described above must be interpreted in the face of the limitations of 
the study. In the United Kingdom, histological assessment of donor liver steatosis is not 
performed routinely, and livers are discarded solely based on a surgical macroscopic assessment 
of steatosis. As a consequence, livers presenting with various grades of steatosis, assessed at 




between groups. Another factor to be taken into consideration is the scarcity and heterogeneity 
amongst discarded human livers, which does not facilitate a perfect matching between 
experimental groups and limits sample size. In addition, this preclinical study is not a transplant 
model, yet transplantability was assessed using the clinically tested viability criteria (1). In 
accordance, development in the future of animal transplant models may provide additional 
evidence of the continuity of the benefits of the treatment after transplantation. 
9.4 Future research questions—Effect of defatting therapies on donor liver functional 
recovery 
After this thorough stepwise investigation for the delivery of a cocktail of defatting agents to 
human donor livers undergoing NMP in Chapters 5–7, numerous research questions may arise 
for future studies. 
 
9.4.1 The practical applicability of the defatting protocol in clinical transplantation 
The pharmacological enhancement of intracellular lipid metabolism during NMP not only 
decreased the lipid content of human donor livers but it also improved the intracellular 
metabolic support to the organs. All the organs that received the treatment reached the 
previously published viability criteria from Birmingham and, therefore, would potentially be 
deemed transplantable (1). Treated organs would meet similarly the viability criteria published 
recently by the Cambridge group, which considers also other additional factors (perfusate 
transaminases, bile production and bile quality) (17). Thus, this first preclinical study forms 





However, some questions may deserve discussion prior to its clinical application. Whilst the 
cytotoxicity of the defatting cocktail to primary human cells of the liver was tested prior to the 
delivery to human donor livers during NMP, the effect of the individual components of the 
cocktail in isolation was not evaluated. Therefore, future studies may determine whether all the 
drugs are necessary, or a refined combination provides a similar effect. In addition, the 
beneficial effects of the treatment were achieved predominantly within the initial six hours of 
perfusion, thereafter they seem to be maintained. It was hypothesised that the drugs have been 
already metabolised by the liver at this time point, whereas measurement of the drug 
concentration would be required to confirm this hypothesis. This former observation raises the 
question as to whether an additional bolus of drugs should be given to enhance the benefits to 
the organs, or the aim is considered achieved and the organ allocated for transplantation. In 
either case, assessment of the concentration of the drugs in the cold flush after perfusion, 
immediately before transplantation, must inform us about the risk of delivering the drugs to 
recipients. A negligible concentration must reassure the safety of the procedure and possibly 
hasten its clinical application. 
 
9.4.2 The potential beneficial impact of the defatting cocktail on post-transplant biliary 
complications 
A remarkable finding of this study was the positive impact of the treatment on biliary function. 
Watson et al. (2018) described that bile-pH < 7.5 during NMP is suggestive of biliary tree 
necrosis and can increase the risk of ischaemic-type biliary lesions (17). Contrary to this, treated 
livers demonstrated bile-pH levels higher than 7.5 whilst the converse was seen in control livers. 




cholesterol levels in the perfusate. Altogether, it is suggested that the treatment had a beneficial 
effect on the biliary system by itself, although further investigation is needed to understand the 
mechanisms involved. The protective role of defatting therapies mitigating IRI, as represented 
by the lower oxidative tissue damage and alleviated activation of the inflammatory response 
may be potentially correlated. Furthermore, an increase in the secretion of phospholipids and 
cholesterol in the bile may equilibrate the phospholipids/bile salts balance, preventing further 
injury to the biliary tree. Thus, these observations may guarantee future studies investigating 
the delivery of pharmacological agents during NMP, which may potentially prevent the 
development of ischaemic-type biliary lesions post-transplantation. 
 
9.4.3 Mitigation of IRI is likely to be a key factor to increase safely the utilisation of 
steatotic donor livers 
Mitigation of IRI seems to be a key factor to improve the reconditioning of steatotic livers. 
Recently, He et al. published the first case of ischaemia-free organ transplantation (IFOT) for 
a severely steatotic donor liver (18). The authors reported that the recipient did not have post-
reperfusion syndrome, and the organ demonstrated minimal signs of hepatobiliary injury and 
reduced pro-inflammatory response (18). These findings suggest that IFOT might be a 
promising approach to increase ECD livers’ utilisation and reduce postoperative complications, 
whereas it should be highlighted that this technique is limited to donation after brainstem death 
donors and might be logistically challenging in a multivisceral retrieval setting. 
Kron et al. (2017) in a transplant rat model of severely steatotic livers submitted to 12 hours of 
SCS showed that short-term hypothermic oxygenated perfusion (HOPE) prior to implantation 




endothelial cell activation, without changing the steatosis grading of the organs (19). The same 
study reported results of six moderately steatotic human livers that had HOPE prior to 
transplantation suggesting achievement of similar benefits. However, some observations 
deserve attention, such as the perfusion period was variable (1.8–4.8 hours), the livers had short 
cold ischaemia time (median 4.1 hours) and macrovesicular steatosis rates differ slightly from 
controls (HOPE 20–40% vs. controls 25–60%). Interestingly, the prolonged perfusion interval 
in comparison with the standard 1–2 hours of HOPE may indicate that the authors considered 
it necessary to downregulate mitochondrial respiration and potentially replenish cellular energy 
stores prior to transplantation. 
These studies, in combination with the findings from this thesis, suggest that strategies to 
mitigate IRI might possibly drive the setting of a new benchmark for steatotic liver preservation. 
 
9.5 Conclusion 
Chapters 1 and 2 discussed the need to increase ECD organs’ utilisation to address the liver 
transplant waiting list mortality; and how the use of these marginal organs impacts negatively 
on postoperative outcomes. The current clinical evidence supporting machine perfusion of the 
liver as an alternative to recondition these risky organs was reviewed, and the advantages and 
limitations of different modalities of machine perfusion were described. Chapter 3 presented 
a newly developed protocol of ex situ end-ischaemic machine perfusion of the liver, which 
combines HOPE and NMP. This unified protocol derived benefits of the individual techniques 
and increased the rate of donor organs recovering adequate metabolic parameters to be deemed 
transplantable. Chapter 4 showed that it is feasible to use an acellular HBOC-based perfusate 




facilitates the logistics of combining these protocols in an uninterrupted fashion from cold to 
warm, the Cold-to-Warm MP. Chapter 5 reviewed the problematic features of fatty livers in 
the context of liver transplantation and the possible role of MP techniques. The concept of 
steatosis reversal or defatting was introduced, and the pharmacodynamics of the drugs utilised 
so far were discussed. Chapter 6 first tested the cytotoxicity in vitro of a combination of 
defatting agents on primary human hepatocytes, cholangiocytes and intrahepatic endothelial 
cells. It was shown that the drugs are safe for those cells, and they were effective in reducing 
the lipid content of fat-laden primary human hepatocytes via upregulation of fatty acids’ β-
oxidation. Chapter 7 described the first study designed to deliver the defatting drugs to donor 
human livers undergoing NMP. It was shown that the pharmacological modulation of the 
hepatic lipid metabolism during normothermic perfusion can promote defatting of whole human 
livers within six hours. The enhancement in the lipid metabolism improved the metabolic 
support to other cellular processes, improving the rescue of appropriate functional parameters 
of the organs and mitigating IRI-associated tissue damage. Treated livers exhibited improved 
biliary function, as represented by higher production of good quality bile; whilst 
mechanistically this is most likely to be associated with the alleviated IRI, other hypotheses are 
reviewed in Chapter 8. Chapter 9 discussed future directions for studies in the field and 
revised key points of the two proposals investigated to improve the reconditioning of high-risk 
ECD organs in this thesis: (1) The use of hypothermic oxygenated machine perfusion as a 
therapeutic intervention preceding NMP; and (2) the delivery of a pharmacological combination 
of drugs targeting the hepatic lipid metabolism during NMP to enhance the metabolic support 
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